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Chapter 1
General introduction and outline of the thesis
Henk-Jan Boiten
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Despite major advances in diagnostics and therapy, coronary artery disease (CAD) re-
mains the major cause of mortality worldwide.1 Due to optimized medical therapy and 
advanced percutaneous and surgical coronary revascularization procedures, life expec-
tancy of patients with CAD has increased.2 Coronary heart disease prevalence in the 
Netherlands in January 2011 was 604.500 habitants (Figure 1). Due to the ageing pop-
ulation, more patients are referred for diagnosis and the assessment of prognosis of 
CAD. Several invasive and noninvasive modalities are available to detect CAD, including 
functional imaging (myocardial perfusion imaging [MPI] and stress echocardiography) 
and anatomical imaging (computed tomography [CT]). The gold standard for detecting 
significant CAD is invasive coronary angiography. Due to the invasive aspect only pa-
tients with a high-pretest likelihood of CAD are referred for this procedure. Noninvasive 
testing is preferred in patients with a lower pretest likelihood of CAD. Cardiac stress 
testing is central to the evaluation of patients with known or suspected CAD. The most 
widely available stress testing modalities combined with imaging are exercise or phar-
macologic stress echocardiography and stress radionuclide MPI using single-photon 
emission computed tomography (SPECT). 
Figure 1. Coronary heart disease prevalence in men (bold) and women (light), per 1000 habitants, 
in the Netherlands in 2011 according to strata of age (www.volksgezondheidenzorg.info).3 
From atherosclerosis and myocardial ischemia to imaging
CAD is characterized by atherosclerotic plaques in the coronary arteries. Due to the im-
balance between oxygen demand and oxygen supply atherosclerosis can lead to re-
duced coronary artery blood flow resulting in myocardial ischemia that proceeds from 
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subclinical to clinical manifestations (Figure 2). After the onset of ischemia there is a 
temporal sequence of events that occurs, called the ‘ischemic cascade’.4 The earliest ab-
normality in the ischemic cascade is hypoperfusion, which can be detected by SPECT 
MPI (Figure 2). This hypoperfusion is then followed by diastolic dysfunction and regional 
systolic dysfunction. This myocardial dysfunction leads to wall motion abnormalities, 
which can be evaluated by stress echocardiography. Finally, changes on electrocardiog-
raphy (ECG) and angina pectoris will occur. Overall, SPECT MPI has a slightly higher sen-
sitivity (84%) as compared to stress echocardiography (80%). Specificity is higher for 
stress echocardiography (86%) compared to SPECT MPI (77%). These findings are in line 
with the ischemic cascade (Figure 2), since perfusion abnormalities (detected by SPECT 
MPI) proceed systolic dysfunction (detected by stress echocardiography).5 
 
Figure 2. The ischemic cascade. Coronary stenoses will lead to perfusion abnormalities (detected 
by SPECT), diastolic dysfunction, systolic dysfunction with wall motion abnormalities (detected 
by echocardiography), ECG changes and angina pectoris (Gaemperli et al.)6.
Cardiac stress testing
Cardiac stress testing is used to provoke ischemic changes that may not be apparent 
at rest. Symptom-limited treadmill or bicycle exercise is still the preferred method of 
stress testing, because it can evaluate the reproducibility of the patient’s symptoms.7 
During stress testing, blood pressure, heart rate, and electrocardiographic leads are 
13671_HJBoiten_BW.indd   13 01-08-16   10:27
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continuously monitored, which allows the evaluation of exercise capacity and the blood 
pressure response during exercise, providing additional diagnostic and prognostic in-
formation.8 However, patients are frequently unable to exercise due to a weak general 
physical condition or the presence of comorbidities such as neuropathy, peripheral 
vascular disease or chronic obstructive pulmonary disease (COPD). In these patients, 
exercise-independent pharmacological stress testing represents an alternative. Impor-
tantly, the reported sensitivities and specificities of exercise and pharmacological stress 
testing are similar.9 Pharmacological stress is of interest because pharmacological stress 
is used in half of the myocardial perfusion studies performed in the USA.10 
 
Table 1. Exercise versus pharmacologic stress testing (Zoghbi et al. [11])
Exercise stress Pharmacologic stress (major agents)
Dipyridamole Adenosine Dobutamine 
Mechanism Physical exercise 
(bicycle or treadmill)
Inhibits uptake of 
adenosine
Activation of A2A- 
receptors
Activation of 
α-1, ß-1 and ß-2 
receptors
Hemodynamic effects Increase in HR, CO. 
Vasoconstriction
Coronary vasodi-
latation
Coronary vasodila-
tation
Increase in HR, CO 
and contractility
Contraindications Myocarditis
2nd or 3rd degree AV 
block
Acute MI
Obstructive lung 
disease
2nd or 3rd degree 
AV block
Acute MI
Obstructive lung 
disease
2nd or 3rd degree 
AV block
Acute MI
ACS
Severe aortic 
stenosis
Uncontrolled 
hypertension
HR = heart rate. CO = cardiac output. MI = myocardial infarction. AV = atrio-ventricular. ACS = acute coronary syn-
drome.
Table 1 shows the comparisons between exercise stress and some frequently used phar-
macologic stress agents.11 Usually, dipyridamole or adenosine is used in case of pharma-
cologic stress. In patients who have contraindications to these vasodilators dobutamine 
is recommended.12 Dobutamine is a synthetic catecholamine with a half-life of 2 min-
utes. It has alpha-1 (mild), beta-1 (strong) and beta-2 (mild) agonist activity resulting in 
an increase of myocardial oxygen demand, thereby mimicking the exercise stress by in-
creasing the blood flow.13 Previous data showed that increased blood flow (hyperemia) 
induced by dobutamine stress testing is of equal magnitude to hyperemia induced by 
vasodilator stress agents.14 
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SPECT MPI
MPI using SPECT is useful in identifying regional abnormalities in coronary artery blood 
flow. It is able to determine the physiological relevance of this blood flow to cardiac 
function and myocardial viability (myocardium which does not contract at rest but has 
the potential to recover). Stress MPI is also useful in detecting myocardial perfusion 
defects which are not detectable in rest. Advantages of SPECT include assessment of 
myocardial perfusion and regional function at rest and stress and its widely established 
prognostic information.15 The use of MPI requires the intravenous injection of a radio-
active blood flow marker (tracer) followed by imaging of regional myocardial uptake 
in contrast to stress echocardiography.16,17 Free 99mTechnetium, due to diffusion in total 
body water, is not extracted in the myocardium. So, for 99mTechnetium to be indicative 
of coronary blood flow, it must be coupled to a compound that selectively accumulates 
in the myocardium. 99mTechnetium-labeled sestamibi and tetrofosmin are useful radio-
pharmaceuticals and provide a lower radiation burden than thallium. These tracers are 
currently the most frequently used radiotracers for assessing myocardial perfusion.17 
Figure 3. Example of 99mTc-sestamibi stress-rest SPECT myocardial perfusion imaging. 
A. Normal SPECT study. B. Abnormal SPECT study: perfusion defects anterior and septal.
After injection of the radiopharmaceutical, MPI using SPECT is performed. It reveals the 
distribution of the concerning radioactive tracers, and therefore the relative blood flow 
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to the different regions of the myocardium. The gamma rays emitted (hence ‘emission’) 
by the radiotracers are detected by the gamma camera from the SPECT system. The 
basis for SPECT imaging is that severe myocardial ischemia or myocardial infarction can 
destroy cells in a way that they will not take up the radiopharmaceutical (perfusion de-
fect). The presence of a perfusion defect is defined as an abnormal study (Figure 3).
Figure 4A.
Normal dobutamine stress echocardiogram. Normal left ventricle wall motion and thickening at baseline, and further 
improvement of wall motion and thickening (hyperkinesia) during low- and high-dose dobutamine infusion, and 
recovery phase. 
SPECT MPI interpretation includes the type (reversible, fixed, both), the site, and the 
extent and severity of the perfusion defect. For the interpretation of a SPECT MPI study 
a segmental model of the left ventricle is used. Each myocardial segment is assigned 
a score from 0 to 3 (0 = normal; 1 = slightly reduced; 2 = moderately reduced; and 3 
= severely reduced or absent uptake of the radiotracer). Summation of the scores of 
the myocardial segments generate the summed stress score (SSS) and the summed rest 
score (SRS). The difference between stress and rest scores is defined as the summed 
difference score (SDS). This scores provide quantitative information on the extent and 
severity of a myocardial perfusion defect.
13671_HJBoiten_BW.indd   16 01-08-16   10:27
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Figure 4B. 
Abnormal dobutamine stress echocardiogram The interventricular septum is hypokinetic at baseline, becomes 
normokinetic during low-dose dobutamine infusion, and becomes akinetic during high-dose dobutamine infusion 
and during the recovery phase. This biphasic response during DSE is indicative of significant CAD, probably in the left 
anterior descending artery.
Echocardiographic imaging 
Another frequently used noninvasive stress modality in evaluating patients for known 
or suspected CAD is stress echocardiography. This cardiac stress method consists of 
two-dimensional imaging of left ventricular wall motion and thickening using dobuta-
mine as a stressor (dobutamine stress echocardiography [DSE]). Advantages of DSE in-
clude its availability, relatively low cost and lack of radiation exposure.15 
Imaging is acquired at rest and continuously during the stress test and the recovery 
phase. The Wall Motion Score Index (WMSI) can be determined at rest and peak stress 
as the sum of the segmental scores of the left ventricular segments divided by the total 
number of segments. Each segment is scored using a 5-point scale as follows: 1 = nor-
mal, 2 = mild hypokinesis, 3 = severe hypokinesis, 4 = akinesis, and 5 = dyskinesis. Is-
chemia on echocardiography is defined as new or worsened wall motion abnormalities 
(WMAs) during stress, which is indicated by an increase of wall motion score. Ischemia 
13671_HJBoiten_BW.indd   17 01-08-16   10:27
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was not considered to be present when akinetic segments at rest became dyskinetic 
during stress. DSE results are defined as abnormal if there was ischemia during stress 
or fixed WMAs. 
Cardiac imaging in Rotterdam
From approximately January 1990, numerous patients underwent cardiac stress im-
aging at the Thoraxcenter of the Erasmus Medical Center in Rotterdam (Erasmus MC, 
formerly known as Dijkzigt Ziekenhuis). SPECT MPI or DSE was performed in patients 
with known or suspected CAD for evaluating various aspects of ischemic heart disease, 
including diagnosis, risk assessment and stratification, assessment of myocardial via-
bility and evaluation of left ventricular function. Clinical data (i.e. cardiac risk factors) 
including age, gender, diabetes mellitus, smoking, hypertension, hypercholesterolemia, 
heart failure, cardiac history (previous myocardial infarction, previous revascularization) 
and medication use were collected before the stress test. Then, all obtained data, in-
cluding stress test results and imaging data, were collected in an electronic registry that 
accumulated in the course of daily clinical care. Patients were then followed during the 
subsequent years. Follow-up data were obtained by a questionnaire, reviewing hospital 
records contacting the patient’s general practitioner, and/or review of civil registries. 
Follow-up events were all-cause mortality, cardiac mortality, non-fatal myocardial in-
farction and/or coronary revascularization. The cause of death was retrieved at Statis-
tics Netherlands (www.cbs.nl). Prior to contacting the patient, the online municipal civil 
registry was used to determine the patient’s present survival status. The collection of all 
these data (follow-up included) forms the basis of this thesis. 
Previous researchers of the Thoraxcenter18 reported the outcomes of DSE and/or 
stress SPECT MPI for short- and medium term follow-up. These reports examine data 
of various patient cohorts (patients with versus without angina pectoris, after coronary 
revascularization etc.), multiple clinical scenarios (hypertension, obesity, diabetes melli-
tus, heart transplant patients, assessment of known or suspected CAD, etc.), and differ-
ent types of stress (exercise or pharmacologic stress) and different types of tracers (ses-
tamibi or tetrofosmin). From a clinical point of view, these studies provides information 
in risk stratifying patients and optimal clinical management. 
Gaps in knowledge about cardiac stress imaging
SPECT MPI and DSE are safe non-invasive imaging techniques to identify and risk stratify 
patients with known or suspected CAD. Both techniques have been implemented in in-
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ternational guidelines.1,7,9 Stress testing is still the most common noninvasive technique 
to assess patients with known or suspected CAD.19 In the last decades, stress testing 
has been used for both detecting CAD and providing prognostic information.20 Stress 
testing for the assessment of prognosis is recommended in patients with intermediate 
or high pretest probability of CAD.7,17 The prognostic value of SPECT MPI and DSE is 
well established for the short- and medium term follow-up. SPECT parameters and DSE 
results have incremental prognostic value to clinical and stress test variables in separat-
ing low- and high-risk patients according to risk of mortality and future cardiac events. 
This information is used to guide further evaluation and therapy. However, over time, 
patients may develop hemodynamically significant CAD that was not present at time of 
the stress test. Several studies have examined the ‘warranty period’ of a normal stress 
test.21,22 A warranty period is defined as the duration of time whereby the patient’s risk 
alters significantly from that observed during the early portion of follow-up.23 Several 
clinical characteristics may affect the risk of cardiac events over time, including the 
existence of hypertension, a previous myocardial infarction and the presence of dia-
betes mellitus. Also the inability to perform an exercise test, a history of CAD, gender, 
and increasing age are significant predictors of adverse outcome. Moreover, in heart 
transplant recipients progression of cardiac allograft vasculopathy (CAV) may occur.24 
These patients considered at increased risk of cardiac events may have an accelerated 
progression of CAD. From a clinical point of view, it is important to determine the war-
ranty period; patients with a normal stress test have a favorable prognosis. Hence, with 
no changes in symptoms these patients could be spared further (invasive) evaluation. 
However, no data are available regarding the long-term prognostic value of SPECT MPI 
and DSE. This creates uncertainties in the clinical management of these patients. For 
clinicians it is important to know for what time-period they can rely on the results of the 
stress test. 
Aim and outline of the thesis
The primary aim of this thesis was to evaluate the long-term outcome of both SPECT 
MPI and stress echocardiography, either with exercise stress or pharmacologic stress 
(dobutamine). As radionuclide tracers 99mTc-tetrofosmin and 99mTc-sestamibi were used. 
All-cause mortality, cardiac mortality, nonfatal MI and/or late coronary revascularization 
were primary endpoints of interest during long-term follow-up. The large electronic 
registry (the CLINT system, developed and maintained by Dr. Ron T. van Domburg,)25 
that accumulated in the course of daily clinical care during the last decades was the 
basis of this thesis. 
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In Part A the long-term prognostic value of a normal cardiac stress test is described. 
Patients with normal SPECT MPI are considered at low risk of cardiac events. The very 
long-term outcome after normal exercise stress SPECT MPI is described in Chapter 2. 
Exercise electrocardiography (ECG) is useful in evaluating patients with known or sus-
pected CAD, but exercise ECG may be false negative. Therefore, Chapter 3 focused on 
the long-term outcome after exercise stress SPECT MPI in patients with known or sus-
pected CAD while exercise ECG testing was normal. 
In Part B the long-term outcome after cardiac stress testing is studied in several pa-
tients groups considered at increased risk of adverse events. The duration of a low risk 
status after a normal stress test is unclear. Importantly, during a long follow-up period, 
several competing risks may affect the warranty period. In Chapter 4, the long-term 
prognostic value of exercise SPECT MPI using 99mTc-tetrofosmin as a tracer is determined 
in patients with known or suspected CAD. Pharmacologic stress (like dobutamine) is 
employed in patients unable to perform exercise testing because of disease complica-
tions like diabetes mellitus and obesity. Such patients consitute a high-risk group due to 
the underlying cardiovascular risk profile. Also, the inability to perform an exercise test 
is a strong predictor of adverse outcome in itself. In Chapter 5, the long-term prognos-
tic value of exercise and dobutamine stress SPECT MPI is evaluated in obese patients. 
Another specific group of high-risk patients are heart transplant recipients. To date, 
long-term data of SPECT MPI in heart transplant recipients are lacking. Accordingly, in 
Chapter 6 the long-term prognostic value of SPECT MPI in this patient group is eval-
uated. In patients with limited exercise capacity due to disease complications such as 
stroke, neuropathy, or peripheral vascular disease, dobutamine stress testing represents 
an achievable alternative to vasodilator stress (like adenosine). The prognostic value of 
dobutamine stress 99mTc-sestamibi SPECT in patients with limited exercise capacity is 
studied in Chapter 7. In addition, elderly patients have a high cardiovascular risk sta-
tus. The long-term value of noninvasive imaging modalities for prognostic stratification 
is also important in these patients, especially due to the ageing population. As a con-
sequence, in Chapter 8, the long-term cardiovascular outcomes of dobutamine stress 
SPECT MPI is studied in elderly patients (defined as ≥65 years).
The surface ECG is probably the most commonly used test in cardiology, it is simple, 
low-cost, and widely available. QRS duration as assessed on the surface ECG has prog-
nostic value in several patients groups, for example in patients with heart failure and 
left ventricular systolic dysfunction.26,27 In Chapter 9, the long-term prognostic value of 
QRS duration in patients undergoing dobutamine stress SPECT MPI is discussed. Then, 
the long-term prognostic value of dobutamine stress SPECT MPI (Chapter 10) and DSE 
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(Chapter 11) is described in patients with diabetes mellitus unable to perform an ex-
ercise test. Currently, it is not known whether the prognostic value of DSE is preserved 
at long-term outcome in high-risk patients. Accordingly, the long-term outcome of DSE 
in high-risk patients unable to perform exercise testing, is assessed in Chapter 12. In 
Chapter 13 the fourteen year outcome after stress SPECT MPI compared to DSE is stud-
ied. 
In patients presenting with an ACS coronary revascularization reduces the incidence 
of all-cause mortality and nonfatal MI.28 Optimal medical therapy, percutaneous coro-
nary intervention (PCI) and coronary artery bypass graft surgery (CABG) are treatment 
options in these patients. However, information about the impact of coronary revascu-
larization in patients with stable CAD is controversial. The ‘jury is still out’ regarding the 
benefit of revascularization in patients with stable CAD.29 In Part C the impact of early 
coronary revascularization is studied in patients with myocardial ischemia at DSE and 
myocardial ischemia at stress SPECT in Chapter 14 and 15, respectively.
Finally, in Part D, we summarize the main findings and discuss the results described 
in this thesis in a broader perspective. In addition, future challenges according to SPECT 
MPI and echocardiography are addressed (Chapter 16). 
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ABSTRACT
Objective. The goal of this study was to evaluate the very long-term outcome after 
normal exercise 99mTc-sestamibi myocardial perfusion single-photon emission computed 
tomography (SPECT). Exercise 99mTc-sestamibi SPECT is widely used for risk stratification, 
but data on very long-term outcome after a normal test are scarce.
Methods. A consecutive group of 233 patients (122 men, mean age 54 ± 12 years) with 
known or suspected coronary artery disease (CAD) underwent exercise 99mTc-sestamibi 
SPECT and had normal myocardial perfusion at exercise and at rest. Follow-up endpoints 
were all-cause mortality, cardiac mortality, nonfatal myocardial infarction, and coronary 
revascularization. Predictors of outcome were identified by Cox proportional hazard 
regression models using clinical and exercise testing variables.
Results. During a mean follow-up of 15.5 ± 4.9 years, 41 (18%) patients died, of which 
13 were cardiac deaths. A total of 18 (8%) patients had a nonfatal myocardial infarction, 
and 47 (20%) had coronary revascularization. The annualized event rates for all-cause 
mortality, cardiac mortality, cardiac mortality/nonfatal infarction, and major adverse 
cardiac events were, respectively, 1.1%, 0.3%, 0.7%, and 1.8%. Multivariate analysis 
demonstrated that the variables age, male gender, diabetes, diastolic blood pressure 
at rest, rate pressure product at rest, peak exercise heart rate, and ST-segment changes 
were independent predictors of major adverse cardiac events. 
Conclusion. Patients with suspected or known CAD and normal exercise 99mTc-sestamibi 
myocardial perfusion SPECT have a favorable 15-year prognosis. Follow-up should be 
closer in patients with known CAD, and/or having clinical and exercise parameters 
indicating higher risk status.
Key Words: Coronary disease, prognosis, follow-up studies, radioisotopes. 
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INTRODUCTION
Exercise 99mTc-sestamibi myocardial perfusion single-photon emission computed to-
mography (SPECT) provides clinically useful information for diagnosis and risk stratifi-
cation of patients with known or suspected coronary artery disease (CAD). Accurate risk 
stratification of these patients is required to optimize patient management. A recent 
meta-analysis of the literature demonstrated that normal myocardial perfusion SPECT 
has a high negative predictive value for cardiac  events.1,2 Patients with normal myocar-
dial perfusion SPECT are considered at low risk of cardiac events, the annualized event 
rate is generally <1% during the first few years after testing. Accordingly, in these low 
risk patients, further (invasive) diagnostic and therapeutic strategies and associated 
medical care costs can be avoided.1-3 
However, over time, a significant change in risk may occur after a normal myocardial 
perfusion SPECT. The underlying clinical risk and history of CAD significantly influence 
the event rate after a normal myocardial perfusion SPECT. Moreover, a temporal compo-
nent of risk has been identified, which may increase the annualized cardiac event rate to 
2%, even in the presence of a normal myocardial perfusion SPECT.4 These observations 
have led to the perception that a ‘‘warranty period’’ exists after a normal myocardial per-
fusion SPECT. In the currently available literature, mean follow-up after myocardial per-
fusion SPECT was approximately 3 years.1-3 Data of very long-term outcome after normal 
myocardial perfusion SPECT are lacking, and consequently, the duration of the low-risk 
status after a normal test is not clear. This creates uncertainties in patient management 
recommendations. The goals of the current study were as follows: 
1) To assess very long-term outcome after normal myocardial perfusion SPECT. 
2) To define a low-risk period after normal myocardial perfusion SPECT. 
3) To identify predictors of increased risk.
METHODS
Study Design
The study population consisted of 242 consecutive patients with known or suspected 
CAD who underwent exercise 99mTc-sestamibi myocardial perfusion SPECT and had nor-
mal myocardial perfusion at exercise and at stress. The majority of the study population 
has been described in a previous study from our center.5 The local medical ethics com-
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mittee approved the protocol, and all the patients gave informed consent. A structured 
interview and clinical history were obtained, including assessment of cardiac risk fac-
tors, and the symptoms before the exercise test.
Exercise Testing Protocol
All the patients performed a symptom-limited upright bicycle ergometry test with step-
wise increment of 20 W every minute. Cuff blood pressure measurement and standard 
12-lead surface electrocardiograms were obtained at rest and every minute during ex-
ercise, until the end of the recovery phase. The electrocardiograms were digitally stored 
and analyzed by an experienced observer. Test endpoints included the following: severe 
angina, decrease in systolic blood pressure fall >40 mm Hg, blood pressure >240/120 
mm Hg, or significant cardiac arrhythmia. An ischemic response was defined as ≥1 mm 
horizontal or downsloping ST-segment depression at 80ms after the J point. 
Myocardial Perfusion SPECT
Approximately 1 minute before the termination of the exercise test, an intravenous 
dose of 370 MBq of 99mTc-sestamibi was administered as previously described.5 For rest-
ing studies, 370 MBq of the same tracer was administered at least 24 h after the exercise 
test. Image acquisition was performed using a SPECT camera system (Orbiter camera; 
Siemens, Iselin, NJ; or Picker Prism 3000XP camera; Picker, Cleveland, OH). Thirty-two 
projections were obtained, from the left posterior oblique to the right anterior oblique 
over 180⁰. The semiquantitative interpretation of the scan was performed by visual anal-
ysis assisted by the circumferential profiles analysis. Stress and rest tomographic views 
were reviewed side-by-side by two experienced observers who were unaware of the 
patients’ clinical data. In case of disagreement, a majority decision was achieved by a 
third observer. A normal study was defined as the absence of perfusion abnormalities. 
Patient Follow-Up
Follow-up data were collected in the year 2011 and were completed in respect of 233 
patients (96%). Outcome data were obtained by evaluation of hospital records, contact-
ing the patient’s general practitioner, and/or review of civil registries. The date of the last 
review or consultation was used to calculate follow-up time. Endpoints were all-cause 
mortality, cardiac death, nonfatal myocardial infarction, and coronary revascularization. 
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Nonfatal myocardial infarction was defined as new symptoms of ischemia, and/or ECG 
changes indicative of new ischemia, and/or imaging evidence of myocardial infarction, 
accompanied by detection of a rise and fall of cardiac biomarkers.6 Major adverse car-
diac events (MACE) were defined as the occurrence of cardiac death, nonfatal myocar-
dial infarction, or revascularization. 
Statistical Analysis
Values were expressed as mean ± SD or number, and compared using the Student’s t 
test or chi-squared test. Univariate and multivariate Cox proportional hazard regression 
models (SPSS statistical software version 15.0, SPSS, Chicago, IL) were used to identify 
independent predictors of outcome.7 Variables were selected in a stepwise forward se-
lection manner with entry and retention set at a significance level of .05. The risk of a 
variable was expressed as a hazard ratio with a corresponding 95% confidence interval. 
The probability of survival was calculated using the Kaplan-Meier method, and survival 
curves were compared using the log-rank test. P value <.05 was considered statistically 
significant.
Table 1. Patient characteristics
Age (years) 54 ± 12
Men 122 (52%)
Height (cm) 170 ± 10
Weight (kg) 74 ± 13
Hypertension 78 (33%)
Smoking 61 (26%)
Hypercholesterolemia 63 (27%)
Diabetes mellitus 16 (7%)
ACE-inhibitor 29 (12%)
Beta-blocker 78 (33%)
Known coronary artery disease 57 (24%)
Prior coronary revascularization 55 (24%)
Prior myocardial infarction 19 (8%)
Typical angina 58 (25%)
Atypical angina 120 (52%)
Nonspecific symptoms 14 (6%)
No symptoms 41 (18%)
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RESULTS
Clinical Characteristics
Clinical characteristics of the 233 patients are summarized in Table 1. A total of 222 
(95%) patients had an interpretable ECG at baseline. There were no major side effects 
or complications as result of the test. There was a significant increase in heart rate (78 
± 15 to 147 ± 24 beats/minute, P<.001), and systolic blood pressure (138 ± 22 to 188 
± 25 mm Hg, P<.001) from rest to peak exercise. The mean workload was 143 ± 43 W, 
corresponding with an exercise duration of 7 minutes. The target heart rate (85% of 
the maximal predicted heart rate) was reached in 173 patients (74%). Exercise-induced 
angina occurred in 29 (12%) patients, and 19 (8%) had ST segment depression during 
the exercise test.
Outcome
Kaplan-Meier survival curves and cumulative event rate are presented in Figures 1, 2, 3, 
4, and 5. During a mean follow-up of 15.5 ± 4.9 years, 41 (18%) patients died, of which 
13 were cardiac deaths. A total of 18 (8%) patients had a nonfatal myocardial infarction. 
Coronary revascularization procedures were performed in 47 patients (20%). Seventeen 
patients (7%) underwent coronary artery bypass surgery, and 30 (13%) underwent per-
cutaneous coronary intervention. The annualized event rates for all-cause mortality, car-
diac mortality, cardiac mortality/nonfatal infarction, and major adverse cardiac events 
were respectively 1.1%, 0.3%, 0.7%, and 1.8%. All-cause mortality was significantly 
higher in patients with known CAD (Figure 5).
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Figure 1. Kaplan-Meier event-free survival for the endpoint
of all-cause mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT.
Figure 2. Kaplan-Meier event-free survival for the endpoint
of cardiac mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT.
Figure 3. Kaplan-Meier event-free survival for the endpoint
of cardiac mortality and nonfatal myocardial infarction in
patients with normal exercise 99mTc-sestamibi myocardial
perfusion SPECT.
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Fig re 1. Kaplan-Meier event-free survival for the endpoint of all-cause mortality in patients with 
normal exercise 99mTc-sestamibi myocardial perfusion SPECT.
13671_HJBoiten_BW.indd   32 01-08-16   10:27
15-year outcome after normal exercise 99mTc sestamibi myocardial perfusion imaging. | 33
(138 ± 22 to 188 ± 25 mm Hg,P\ .001 from rest to peak
exercise. The mean workload was 143 ± 43 W, corre-
spondingwith an exercise duration of 7 minutes.The target
heart rate (85% of the maximal predicted heart rate) was
reached in 173 patients (74%). Exercise-induced angina
occurred in 29 (12%) patients, and 19 (8%) hadST segment
depression during the exercise test.
Outcome
Kaplan-Meier survival curves and cumulative event
rate are presented in Figures 1, 2, 3, 4, and 5. During a
mean follow-up of 15.5 ± 4.9 years, 41 (18%) patients
died, of which 13 were cardiac deaths. A total of 18
(8%) patients had a nonfatal myocardial infarction.
Coronary revascularization procedures were performed
in 47 patients (20%). Seventeen patients (7%) under-
went coronary artery bypass surgery, and 30 (13%)
underwent percutaneous coronary intervention. The
annualized event rates for all-cause mortality, cardiac
mortality, cardiac mortality/nonfatal infarction, and
major adverse cardiac events were respectively 1.1%,
0.3%, 0.7%, and 1.8%. All-cause mortality was signif-
icantly higher in patients with known CAD (Figure 5).
Risk Stratification
Univariate analysis demonstrated that age, diabetes
mellitus, diastolic blood pressure at rest, and heart rate
during exercise was predictors of all-cause mortality
(Table 2). Diastolic blood pressures at rest and peak
exercise heart rate were predictors of cardiac mortality.
Beta-blocker use, and peak exercise heart rate were
predictors of cardiac mortality/nonfatal infarction. Age,
male gender, diastolic blood pressure at rest and peak
exercise heart rate were predictors of major adverse
cardiac events.
Multivariate models demonstrated that age, male
gender, diabetes, heart rate at rest and peak exercise
heart rate were independent predictors of all-cause
Table 1. Patient characteristics
Age (years) 54 ± 12
Men 122 (52%)
Height (cm) 170 ± 10
Weight (kg) 74 ± 13
Hypertension 78 (33%)
Smoking 61 (26%)
Hypercholesterolemia 63 (27%)
Diabetes mellitus 16 (7%)
ACE-inhibitor 29 (12%)
Beta-blocker 78 (33%)
Known coronary artery disease 57 (24%)
Prior coronary revascularization 55 (24%)
Prior myocardial infarction 19 (8%)
Typical angina 58 (25%)
Atypical angina 120 (52%)
Nonspecific symptoms 14 (6%)
No symptoms 41 (18%)
Figure 1. Kaplan-Meier event-free survival for the endpoint
of all-cause mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT.
Figure 2. Kaplan-Meier event-free survival for the endpoint
of cardiac mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT.
Figure 3. Kaplan-Meier event-free survival for the endpoint
of cardiac mortality and nonfatal myocardial infarction in
patients with normal exercise 99mTc-sestamibi myocardial
perfusion SPECT.
Journal of Nuclear Cardiology Schinkel et al 903
Volume 19, Number 5;901–6 15-year outcome normal SPECT
Figure 2. Kaplan-Meier event-free survival for the endpoint of cardiac mortality in patients with 
normal exercise 99mTc-sestamibi myocardial perfusion SPECT.
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Figure 3. Kaplan-Meier event-free survival for the endpoint of cardiac mortality and nonfatal myo-
cardial infarction in patients with normal exercise 99mTc-sestamibi myocardial perfusion SPECT.
Figure 4. Kaplan-Meier event-free survival for the endpoint of major adverse cardiac events in 
patients with normal exercise 99mTc-sestamibi myocardial perfusion SPECT.
mortality (Table 3). Heart rate at rest and peak exercise
heart rate were predictors of cardiac mortality (Table 4).
Male gender, diabetes, and peak exercise heart rate were
predictors of cardiac mortality/nonfatal infarction
(Table 5). Age, male gender, diabetes, diastolic blood
pressure at rest, rate pressure product at rest, peak
exercise heart rate, and ST segment changes were
independent predictors of major adverse cardiac events
(Table 6).
DISCUSSION
In this study, very long-term outcome after normal
exercise 99mTc-sestamibi myocardial perfusion SPECT
was assessed in respect of 233 patients with known or
suspected CAD. The 15.5 ± 4.9-year follow-up demon-
strated that the overall outcome of these patients was
favorable. Annualized event rates were relatively low
during the entire follow-up period. Particularly, in the
first 5 years after normal exercise 99mTc-sestamibi
myocardial perfusion SPECT, annualized event rates
were very low. Predictors of increased risk were
identified by multivariate analyses of clinical and
exercise test data. Clinical predictors of adverse out-
come were age, male gender, and diabetes. Exercise
testing variables associated with an increased risk were
heart rate at rest, peak exercise heart rate, diastolic blood
pressure at rest, rate pressure product at rest, and ST
segment changes.
Currently, there are no studies providing very long-
term outcome data, and consequently the duration of the
low-risk status after a normal test is not clear.1-4 Several
previous studies have reported on the medium-term
prognosis after a normal myocardial perfusion SPECT.
In these previous studies, the number of included
patients ranged from 88 to 273, and mean follow-up
ranged from 10 months to 7.4 years.1-3 In the available
literature, mean follow-up after myocardial perfusion
SPECT was approximately 3 years.1-3 The previous
studies have demonstrated that the medium-term prog-
nosis of patients with suspected or known CAD and
normal myocardial perfusion SPECT is favorable.
Moreover, several large observational series have stud-
ied medium-term prognosis in patients with normal or
low-risk thallium-201, 99mTc-sestamibi, and 99mTc-te-
trofosmin. Meta-analyses of these series revealed that
the annualized cardiac mortality rate was approximately
0.5%.1,2 The Dutch Heart Foundation data8 indicate that
all-cause mortality in men aged 55-64 years, during the
period 1986-1998 was (min-max) 2808-3175, and car-
diac mortality was 206-422/100.000. In women aged
55-64 years, in the period 1985-1996, all-cause mortality
was (min-max) 476-771, and cardiac mortality was 64.9-
106/100.000. Hence, the event rates in the general
population appear to be lower than in the study
population. The study patients were referred to exercise
myocardial perfusion SPECT by their treating physi-
cians, and the risk profile of the patients was different
from that of the general population. In the present study
with 15-year follow-up annualized cardiac mortality rate
was 0.3% using exercise 99mTc-sestamibi myocardial
perfusion SPECT.
The present study demonstrates that patients with a
normal exercise 99mTc-sestamibi myocardial perfusion
SPECT have a favorable prognosis even at 15-year
follow-up. In these patients a watchful waiting approach
to care is justified, and additional diagnostic strategies
including invasive coronary angiography can be avoi-
ded. Previous studies have shown that this type of
management strategy may be both clinically effective
and cost-effective.9,10 Clearly, clinical judgment
remains important in deciding patient management
decisions, also in patients with a normal exercise
99mTc-sestamibi myocardial perfusion SPECT. The
duration of the low-risk status depends on several
factors that influence the natural progression of
Figure 4. Kaplan-Meier event-free survival for the endpoint
of majo adverse cardiac events in patients with normal
exercise 99mTc-sestamibi myocardial perfusion SPECT.
Figure 5. Kaplan-Meier event-free survival for the endpoint
of all-cause mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT, with or without a
history of CAD.
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mortality (Table 3). Heart rate at rest and peak exercise
heart rate were predictors of cardiac mortality (Table 4).
Male gender, diabetes, and peak exercise heart rate were
predictors of cardiac mortality/nonfatal infarction
(Table 5). Age, male gender, diabetes, diastolic blood
pressure at rest, rate pressure product at rest, peak
exercise heart rate, and ST segment changes were
independent predictors of major adverse cardiac events
(Table 6).
DISCUSSION
In this study, very long-term outcome after normal
exercise 99mTc-sestamibi myocardial perfusion SPECT
was assessed in respect of 233 patients with known or
suspected CAD. The 15.5 ± 4.9-year follow-up demon-
strated that the overall outcome of these patients was
favorable. Annualized event rates were relatively low
during the entire follow-up period. Particularly, in the
first 5 years after normal exercise 99mTc-sestamibi
myocardial perfusion SPECT, annualized event rates
were very low. Predictors of increased risk were
identified by multivariate analyses of clinical and
exercise test data. Clinical predictors of adverse out-
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testing variables associated with an increased risk were
heart rate at rest, peak exercise heart rate, diastolic blood
pressure at rest, rate pressure product at rest, and ST
segment changes.
Currently, there are no studies providing very long-
term outcome data, and consequently the duration of the
low-risk status after a normal test is not clear.1-4 Several
previous studies have reported on the medium-term
prognosis after a normal myocardial perfusion SPECT.
In these previous studies, the number of included
patients ranged from 88 to 273, and mean follow-up
ranged from 10 months to 7.4 years.1-3 In the available
literature, mean follow-up after myocardial perfusion
SPECT was approximately 3 years.1-3 The previous
studies have demonstrated that the medium-term prog-
nosis of patients with suspected or known CAD and
normal myocardial perfusion SPECT is favorable.
Moreover, several large observational series have stud-
ied medium-term prognosis in patients with normal or
low-risk thallium-201, 99mTc-sestamibi, and 99mTc-te-
trofosmin. Meta-analyses of these series revealed that
the annualized cardiac mortality rate was approximately
0.5%.1,2 The Dutch Heart Foundation data8 indicate that
all-cause mortality in men aged 55-64 years, during the
period 1986-1998 was (min-max) 2808-3175, and car-
diac mortality was 206-422/100.000. In women aged
55-64 years, in the period 1985-1996, all-cause mortality
was (min-max) 476-771, and cardiac mortality was 64.9-
106/100.000. Hence, the event rates in the general
population appear to be lower than in the study
population. The study patients were referred to exercise
myocardial perfusion SPECT by their treating physi-
cians, and the risk profile of the patients was different
from that of the general population. In the present study
with 15-year follow-up annualized cardiac mortality rate
was 0.3% using exercise 99mTc-sestamibi myocardial
perfusion SPECT.
The present study demonstrates that patients with a
normal exercise 99mTc-sestamibi myocardial perfusion
SPECT have a favorable prognosis even at 15-year
follow-up. In these patients a watchful waiting approach
to care is justified, and additional diagnostic strategies
including invasive coronary angiography can be avoi-
ded. Previous studies have shown that this type of
management strategy may be both clinically effective
and cost-effective.9,10 Clearly, clinical judgment
remains important in deciding patient management
decisions, also in patients with a normal exercise
99mTc-sestamibi myocardial perfusion SPECT. The
duration of the low-risk status depends on several
factors that influence the natural progression of
Figure 4. Kaplan-Meier event-free survival for the endpoint
of major adverse cardiac events in patients with normal
exercise 99mTc-sestamibi myocardial perfusion SPECT.
Figure 5. Kaplan-Meier event-free survival for the endpoint
of all-cause mortality in patients with normal exercise 99mTc-
sestamibi myocardial perfusion SPECT, with or without a
history of CAD.
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Figure 5. Kaplan-Meier event-free survival for he endpoint o  all-cause m rtality in patients with 
normal exercise 99mTc-sestamibi myocardial p rfusion SPECT, with or without a history of CAD.
Table 2. Univariate predictors of outcome
All-cause
mortality
Cardiac
mortality
Cardiac mortality/
nonfatal infarction
Maj r adverse
cardiac events
Clinical features
Age >70 years 7.46 (2.84–19.51) 2.52 (0.51–12.56) 1.39 (0.38–5.10) 3.59 (1.37–9.38)
Male gender 1.53 (0.77–3.05) 2.53 (0.65–9.78) 1.96 (0.84–4.57) 2.44 (1.41–4.24)
Hypertension 0.79 (0.38–1.65) 0.43 (0.09–2.03) 1.43 (0.63–3.24) 1.43 (0.82–2.49)
Smoking 0.76 (0.34–1.69) 1.06 (0.27–4.13) 0.78 (0.30–2.05) 0.65 (0.34–1.21)
Hypercholesterolemia 0.60 (0.26–1.39) 0.26 (0.03–2.06) 1.16 (0.48–2.79) 1.19 (0.66–2.15)
Diabetes mellitus 3.12 (1.07–9.14) 1.38 (0.17–11.52) 2.81 (0.84–9.44) 2.35 (0.84–6.57)
ACE–inhibitor 1.97 (0.81–4.84) 0.69 (0.09–5.62) 0.53 (0.12–2.37) 1.25 (0.57–2.76)
Beta-blocker 0.91 (0.44–1.87) 1.70 (0.50–5.76) 2.39 (1.06–5.38) 1.62 (0.93–2.83)
Prior myocardial
infarction
1.77 (0.60–5.21) 1.13 (0.14–9.37) 2.21 (0.68–7.24) 2.57 (0.99–6.66)
Stress test results
Heart rate at rest 0.99 (0.89–1.18) 0.92 (0.61–1.40) 0.84 (0.64–1.11) 0.91 (0.79–1.04)
Peak exercise
heart rate
0.80 (0.71–0.90) 0.60 (0.46–0.86) 0.72 (0.60–0.86) 0.82 (0.75–0.90)
Diastolic blood
pressure rest
0.75 (0.58–0.97) 0.55 (0.31–0.98) 0.70 (0.46–1.05) 0.77 (0.63–0.95)
Rate pressure
product at rest
1.03 (0.93–1.14) 0.96 (0.75–1.22) 0.94 (0.80–1.10) 0.97 (0.90–1.05)
Typical angina 0.72 (0.24–2.20) 0.69 (0.09–5.62) 1.26 (0.40–3.94) 2.02 (0.92–4.43)
ST segment changes 0.53 (0.12–2.38) 0.00 (0.00–4.18) 0.89 (0.19–4.08) 1.28 (0.49–3.31)
Values are expressed as Cox proportional hazard ratio and 95% confidence interval
Risk Stratification
Univariate analysis demonstrated that age, diabetes mellitus, diastolic blood pressure 
at rest, and heart rate during exercise was predictors of all-cause mortality (Table 2). 
Diastolic blood pressures at rest and peak exercise heart rate were predictors of cardiac 
mortality. Beta-blocker use, and peak exercise heart rate were predictors of cardiac mor-
All-c us
mortality
Cardiac
mortality
Cardi c mortality/
nonfatal infarction
Major adverse
cardiac events
Clinical features
Age >70 years 7.46 (2.84–19.51) 2.52 (0.51–12.56) 1.39 (0.38–5.10) 3.59 (1.37–9.38)
Male gender 1.53 (0. 7–3.05) 2.53 (0.65–9.78) 1.96 (0.84–4.57) 2. 4 (1.41–4.24)
Hypertension 0.79 (0.38–1.65) 0.43 ( .09–2.03) 1.43 (0.63–3.24) 1.43 (0.82–2.49)
Smoking 0.76 (0.34–1.69) 1.06 (0.27–4.13) 0.78 (0.30–2.05) 0.65 (0.34–1.21)
Hypercholesterolemia 0.60 (0.26–1.39) 0.26 ( .03–2.06) .16 (0.48–2.79) .19 (0. 6–2.15)
Diab tes mellitus 3.12 (1.07–9.14) 1.38 (0.17– 1.52) 2.81 (0.84–9. 4) 2.35 (0.84–6.57)
ACE–inhibitor 1.97 (0.81–4.84) 0.69 ( .09–5.62) 0.53 (0.12–2.37) 1.25 (0.57–2.76)
Beta-blocker 0.91 (0. 4–1.87) 1.70 (0.50–5.76) 2.39 (1.06–5.38) 1.62 (0.93–2.83)
Prior myocardial
infarction
1. 7 (0.60–5.21) .13 (0.14–9.37) .21 (0.68–7.24) 2.57 (0. 9– . 6)
Stress test results
Heart rate at rest 0. 9 (0.89– .18) 0.92 (0.61–1.40) 0.84 (0.64– . 1) 0.91 (0.79–1.04)
Peak exercise
heart rate
0.80 (0.71–0.90) 0.60 (0.46–0.86) 0.72 (0.60–0.86) 0.82 (0.75–0.90)
Diastolic bl od
pressure rest
0.75 (0.58–0.97) 0. 5 (0.31–0.98) 0.70 (0.46–1.05) 0. 7 (0.63–0.95)
Rate pressure
product at rest
1.03 (0.93– .14) 0.96 (0.75–1. 2) 0.94 (0.80– .10) 0.97 (0.90–1.05)
Typical angina 0.72 (0.24– .20) 0.69 ( .09–5.62) 1.26 (0.40–3.94) 2.02 (0.92– .43)
ST segment changes 0.53 (0.12–2.38) . 0 ( . 0–4.18) 0.89 (0.19–4.08) 1.28 (0.49– .31)
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ypertension 0.79 (0.38–1.65) 0.43 (0.09–2.03) 1.43 (0.63– .24) 1.43 (0.82– .49)
S oking 0.76 (0.34–1.69) 1.06 (0.27–4.13) 0.78 (0.30–2.05) 0.65 (0.34– .21)
ypercholesterole ia 0.60 ( .26–1.39) 0.26 (0.03–2.06) 1.16 (0.48–2.79) 1.19 (0.66–2.15)
iabetes el itus 3.12 (1.07–9.14) 1.38 (0.17–11.52) 2.81 (0.84–9.44) 2.35 (0.84–6.57)
ACE–inhibitor 1.97 (0.81–4.84) 0.69 (0.09–5.62) 0.53 (0.12– .37) 1.25 (0.57–2.76)
Beta-blocker 0.91 (0.44–1.87) 1.70 ( .50–5.76) 2.39 (1.06–5.38) 1.62 (0.93–2.83)
Prior yocardial
infarction
1.77 (0.60–5.21) 1.13 (0.14–9.37) 2.21 (0.68–7.24) 2.57 (0.99–6.66)
Stress test results
eart ate at rest 0.99 (0.89–1.18) 0.92 (0.61– .40) 0.84 (0.64–1.11) 0.91 (0.79–1.04)
Peak ex rcise
heart ate
0.80 ( .71–0.90) 0.60 ( .46–0.86) 0.72 (0.60– .86) 0.82 (0.75–0.90)
iastolic blood
pressure r st
0.75 (0.58–0.97) 0.55 (0.31–0.98) 0.70 ( .46–1.05) 0.77 (0.63–0.95)
Rate pressure
product at rest
1.03 (0.93–1.14) 0.96 (0.75–1.22) 0.94 (0.80–1.10) 0.97 (0.90–1.05)
Typical ngina 0.72 (0.24–2.20) 0.69 (0.09–5.62) 1.26 (0.40–3.94) 2.02 (0.92–4.43)
ST seg ent changes 0.53 (0.12– .38) 0.00 ( .00–4.18) 0.89 (0.19–4.08) 1.28 (0.49–3.31)
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tality/nonfatal infarction. Age, male gender, diastolic blood pressure at rest and peak 
exercise heart rate were predictors of major adverse cardiac events. Multivariate models 
demonstrated that age, male gender, diabetes, heart rate at rest and peak exercise heart 
rate were independent predictors of all-cause mortality (Table 3). Heart rate at rest and 
peak exercise heart rate were predictors of cardiac mortality (Table 4). Male gender, dia-
betes, and peak exercise heart rate were predictors of cardiac mortality/nonfatal infarc-
tion (Table 5). Age, male gender, diabetes, diastolic blood pressure at rest, rate pressure 
product at rest, peak exercise heart rate, and ST segment changes were independent 
predictors of major adverse cardiac events (Table 6).
Table 3. Multivariate predictors of all-cause mortality
HR (95% CI)  P value
Age* 1.06 (1.04–1.09) <.001
Male gender 2.70 (1.45–5.03) .002
Diabetes 3.06 (1.22–7.65) .02
Heart rate at rest 1.30 (1.07–1.58) .01
Peak exercise heart rate 0.80 (0.69–0.92) .03
Values are expressed as Cox proportional hazard ratio and 95% confidence interval.
* Per 1 unit increment.
Table 4. Multivariate predictors of cardiac mortality
HR (95% CI)  P value
Heart rate at rest 1.73 (1.02–2.94) .04
Peak exercise heart rate 0.50 (0.35–0.69) <.001
Values are expressed as Cox proportional hazard ratio and 95% confidence interval.
DISCUSSION
In this study, very long-term outcome after normal exercise 99mTc-sestamibi myocardial 
perfusion SPECT was assessed in respect of 233 patients with known or suspected CAD. 
The 15.5 ± 4.9-year follow-up demonstrated that the overall outcome of these patients 
was favorable. Annualized event rates were relatively low during the entire follow-up 
period. Particularly, in the first 5 years after normal exercise 99mTc-sestamibi myocardial 
perfusion SPECT, annualized event rates were very low. Predictors of increased risk were 
identified by multivariate analyses of clinical and exercise test data. Clinical predictors 
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of adverse outcome were age, male gender, and diabetes. Exercise testing variables as-
sociated with an increased risk were heart rate at rest, peak exercise heart rate, diastolic 
blood pressure at rest, rate pressure product at rest, and ST segment changes.
 Currently, there are no studies providing very long term outcome data, and con-
sequently the duration of the low-risk status after a normal test is not clear.1-4 Several 
previous studies have reported on the medium-term prognosis after a normal myocar-
dial perfusion SPECT. In these previous studies, the number of included patients ranged 
from 88 to 273, and mean follow-up ranged from 10 months to 7.4 years.1-3 In the avail-
able literature, mean follow-up after myocardial perfusion SPECT was approximately 3 
years.1-3 The previous studies have demonstrated that the medium-term prognosis of 
patients with suspected or known CAD and normal myocardial perfusion SPECT is favor-
able. Moreover, several large observational series have studied medium-term prognosis 
in patients with normal or low-risk thallium-201, 99mTc-sestamibi, and 99mTc-tetrofosmin. 
Meta-analyses of these series revealed that the annualized cardiac mortality rate was 
approximately 0.5%.1,2 The Dutch Heart Foundation data8 indicate that all-cause mor-
tality in men aged 55-64 years, during the period 1986-1998 was (min-max) 2808-3175, 
and cardiac mortality was 206-422/100.000. In women age 55-64 years, in the period 
1985-1996, all-cause mortality was (min-max) 476-771, and cardiac mortality was 64.9-
106/100.000. Hence, the event rates in the general population appear to be lower than 
in the study population. The study patients were referred to exercise myocardial perfu-
sion SPECT by their treating physicians, and the risk profile of the patients was different 
from that of the general population. In the present study with 15-year follow-up annual-
ized cardiac mortality rate was 0.3% using exercise 99mTc-sestamibi myocardial perfusion 
SPECT.
 The present study demonstrates that patients with a normal exercise 99mTc-sestamibi 
myocardial perfusion SPECT have a favorable prognosis even at 15-year follow-up. In 
these patients a watchful waiting approach to care is justified, and additional diagnostic 
strategies including invasive coronary angiography can be avoided. Previous studies 
have shown that this type of management strategy may be both clinically effective and 
cost-effective.9,10 Clearly, clinical judgment remains important in deciding patient man-
agement decisions, also in patients with a normal exercise 99mTc-sestamibi myocardial 
perfusion SPECT. The duration of the low-risk status depends on several factors that 
influence the natural progression of (subclinical) CAD. The present study demonstrates 
that several clinical and exercise test parameters can be used to identify patients at 
increased risk for adverse outcome. Prognosis was worse in patients with a history of 
CAD. Additionally multivariate analysis demonstrated that several clinical and exercise 
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testing parameters influence very long-term outcome. Therefore, follow-up should be 
closer in patients with known CAD, and/or clinical and exercise parameters indicating 
higher risk status. Repeated testing should be considered in patients with a change in 
symptoms or worsening clinical status.
Table 5. Multivariate predictors of cardiac mortality/nonfatal myocardial infarction
HR (95% CI)  P value
Male gender 2.61 (1.11–6.14) <.03
Diabetes 6.93 (2.18–22.04) <.01
Peak exercise heart rate 0.70 (0.58–0.84) <.001
Values are expressed as Cox proportional hazard ratio and 95% confidence interval.
Table 6. Multivariate predictors of major adverse cardiac events
HR (95% CI)  P value
Age* 1.03 (1.01-1.06) <.01
Male gender 2.82 (1.75-4.53) <.001
Diabetes 3.95 (1.88-8.30) <.001
Diastolic blood pressure at rest 0.79 (0.64-0.97) <.03
Rate-pressure product at rest 1.14 (1.04-1.25) <.01
Peak exercise heart rate 0.80 (0.71-0.89) <.001
ST segment changes 2.94 (1.44-5.99) <.01
Values are expressed as Cox proportional hazard ratio and 95% confidence interval.
* Per 1 unit increment.
Study limitations
This study has some limitations. The study population and the number of adverse events 
were relatively small. Information on changes in medical therapy during follow-up was 
not available. During the period when the SPECT studies were performed, electrocar-
diogram gated acquisition was not routinely performed in our laboratory. Gated SPECT 
provides information on regional and global left ventricular function, which is an im-
portant predictor of long-term prognosis. Future studies are needed to clarify the value 
of gated SPECT for the assessment of very long-term prognosis in patients with normal 
myocardial perfusion.  Finally, in the present study attenuation correction was not ap-
plied. Recent data indicate that attenuation correction may further improve diagnostic 
accuracy of myocardial perfusion SPECT.11,12
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CONCLUSION
Patients with suspected or known CAD and normal exercise 99mTc-sestamibi myocardial 
perfusion SPECT have a favorable 15-year prognosis. Prognosis is particularly favorable 
during the initial 5 years after testing. Follow-up should be closer after this initial 5-year 
period and in patients with known CAD, and/or having clinical and exercise parameters 
indicating higher risk status.
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ABSTRACT
Aims. Exercise myocardial perfusion imaging (MPI) is widely used, but the long-term 
prognostic value of this test in patients with normal exercise electrocardiographic test-
ing is not defined.
Methods and results. A consecutive group of 650 patients (428 men, mean age: 56±11 
years) with known or suspected coronary artery disease underwent exercise electro-
cardiographic testing and MPI. Follow-up endpoints were mortality and major adverse 
cardiac events (MACE). Predictors of outcome were identified by multivariate logistic re-
gression analysis using clinical, exercise electrocardiographic testing and single-photon 
emission computed tomography (SPECT) variables. A total of 324 (50%) patients had 
an abnormal SPECT, and 131 (20%) had completely or partially reversible perfusion de-
fects. During a mean follow-up of 9.0±2.0 years, 107 (23%) patients died, 69 (11%) had 
a non-fatal myocardial infarction, 90 (14%) underwent coronary artery bypass surgery, 
and 142 (22%) percutaneous coronary intervention. Multivariate analysis demonstrated 
that the summed rest score was an independent predictor of mortality [hazard ratio 
(HR): 1.15, 95% confidence interval (CI): (1.08–1.22), P<0.001]. The summed stress score 
was an independent predictor of MACE [HR: 1.09, 95% CI: (1.04–1.13), P<0.001]. The 
addition of SPECT variables to clinical and exercise electrocardiographic testing data 
provided incremental prognostic information for the prediction of mortality and MACE 
(both P<0.001).
Conclusion. Approximately 20% of patients with known or suspected coronary artery 
disease and normal exercise electrocardiographic testing have completely or partially 
reversible myocardial perfusion defects. MPI provides additional information for the 
prediction of 9-year cardiovascular outcomes in these patients.
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INTRODUCTION
Both exercise electrocardiography and exercise myocardial perfusion imaging (MPI) 
have proved to be clinically useful non-invasive tests for the evaluation of patients with 
known or suspected coronary artery disease.1,2 Exercise MPI with single-photon emis-
sion computed tomography (SPECT) is a well-validated modality to detect coronary 
artery disease and provides clinically useful prognostic information.3-5 Due to basic dif-
ferences between the two tests, exercise MPI is a more sensitive test for the detection 
of myocardial ischaemia as compared with exercise electrocardiographic testing.6 In this 
context, the impact of MPI on the prediction of long-term outcome in patients with 
normal exercise electrocardiographic testing has not been evaluated. The aim of this 
study was to assess the use of exercise MPI for the prediction of long-term cardiovascu-
lar outcomes in patients with known or suspected coronary artery disease and normal 
exercise electrocardiographic testing.
METHODS
Patients
The study population consisted of 650 consecutive patients (428 men, mean age: 56±11 
years) referred for exercise myocardial perfusion SPECT for the evaluation of known or 
suspected coronary artery disease, who demonstrated normal exercise electrocardio-
graphic testing. All patients were referred by their treating physician to exercise stress 
myocardial perfusion SPECT. The indication for this test was typical angina in 184 (28%) 
patients, typical angina in 220 (34%), non-specific symptoms in 51 (8%), and risk strati-
fication in 195 (30%). Patients with uninterpretable exercise electrographic testing due 
to the following resting ECG abnormalities were not included: pre-excitation (Wolff–
Parkinson–White) syndrome, electronically paced ventricular rhythm, complete left 
bundle-branch block, or any intraventicular conduction defect with a QRS duration 
>120 ms, left ventricular hypertrophy. The local hospital ethics committee approved 
the study protocol and all patients gave informed consent. A structured interview and 
clinical history were obtained including the assessment of cardiac risk factors and symp-
toms.
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Exercise protocol
All patients performed a symptom-limited upright bicycle ergometry test with stepwise 
increment of 20W every minute. Cuff blood pressure measurement and standard 12-
lead surface electrocardiograms were obtained at rest and every minute during exer-
cise, until the end of the recovery phase. The electrocardiograms were digitally stored 
and analysed by an experienced observer. Normal exercise electrocardiographic test-
ing was defined according to the practice guidelines for exercise testing.1,2 Test end-
points included the following: severe angina, decrease in systolic blood pressure fall 
>40 mmHg, blood pressure >240/120 mmHg, or significant cardiac arrhythmia. An is-
chaemic response was defined as ≥1 mm horizontal or downsloping ST-segment de-
pression at 80ms after the J point.
MPI protocol
Approximately 1 min before the termination of the exercise test, an intravenous dose 
of 370 MBq of technetium-99m (99mTc)-tetrofosmin (in 477 patients) or 99mTc-sestamibi (in 
173 patients) was administered as previously described.7 For resting studies, 370 MBq 
of the same tracer was administered at least 24 h after the exercise test. Image acquisi-
tion was performed using a SPECT camera system (Orbiter camera; Siemens, Iselin, NJ, 
USA; or Picker Prism 3000 × P camera;Picker, Cleveland, OH, USA). Thirty-two projections 
were obtained over a 180° arc, from left posterior oblique to right anterior oblique, with 
an acquisition time of 45s per projection. Data were collected in a 64 × 64 matrix (word 
mode), and images were reconstructed using a filtered back projection algorithm and 
a ramp reconstruction filter. Transaxial tomograms were reconstructed using the SPETS 
software package (Nuclear Diagnostics AB, Hägersten, Sweden). From the three-dimen-
sional data, oblique (short axis) and sagittal (vertical long axis), perpendicular and par-
allel to the long axis, respectively, were reconstructed. The interpretation of the scan 
was semi-quantitatively performed by visual analysis assisted by circumferential profile 
analysis. Profile curves of 2.5 standard deviation (SDs) below normal perfusion were 
considered abnormal. Each of the left ventricular segments was scored using a four-
point scoring system (0=normal, 1=slightly reduced, 2=moderately reduced, and 3=se-
verely reduced, or absent uptake). Stress and rest tomographic views were reviewed 
side-by-side by two experienced observers who were unaware of the patients’ clinical 
data. In the case of disagreement, a majority decision was achieved by a third observer. 
An abnormal study was considered in the presence of a fixed and/or reversible perfu-
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sion defect. The perfusion defect scores were derived by the summation of the score 
of the six myocardial segments at rest [summed rest score (SRS) and at stress (summed 
stress score (SSS)]. The difference was expressed as the summed difference score (SDS). 
These indices were expressed as the percent of the total myocardium (% myocardium) 
as described previously.8
Outcomes evaluation
Outcome data were obtained by review of hospital records and/or contacting the pa-
tient’s general practitioner. The date of the last review or consultation was used to cal-
culate the follow-up time. In patients who suffered from multiple events during the 
follow-up, the first event was used to calculate the event-free survival. Endpoints were 
mortality and major adverse cardiac events (MACE; i.e. death, non-fatal myocardial in-
farction and coronary revascularization). Nonfatal myocardial infarction was defined as 
new symptoms of ischaemia, and/or ECG changes indicative of new ischaemia, and/or 
imaging evidence of myocardial infarction, accompanied by the detection of a rise and 
fall of cardiac biomarkers.9
Statistical analysis
Values were expressed as the mean value ± SD or number, and compared using Stu-
dent’s t-test or X2 test. Univariate and multivariate Cox proportional hazard regression 
models (SPSS statistical software version 15.0, SPSS, Chicago, IL, USA) were used to iden-
tify the independent predictors of late cardiac events.10 All clinical features, stress test 
variables, and SPECT variables were analysed to identify the independent predictors 
of adverse events. For the multivariate analysis, variables were selected in a stepwise 
forward selection manner with the entry and retention set at a significance level of 
0.05. The risk of a variable was expressed as a hazard ratio (HR) with a corresponding 
95% confidence interval (CI). The probability of survival was calculated using the Ka-
plan–Meier method, and survival curves were compared using the log-rank test. P-value 
<0.05 was considered statistically significant.
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RESULTS
Patient characteristics
Baseline data of the 650 patients are summarized in Table 1. There were no major side 
effects or complications as the result of the tests. The haemodynamic changes during 
exercise electrocardiography are summarized in Table 2. The mean exercise time was 
7.2±2.1 min, the mean maximum workload was 144±42W. SPECT demonstrated normal 
myocardial perfusion in 326 (50%) patients. Completely reversible perfusion defects 
were detected in 52 (8%) patients, 79 (12%) had partially reversible perfusion defects, 
and 193 (30%) had fixed perfusion defects. The median SSS (expressed as % of myocar-
dium) was 16.7±15.3, the median SRS was 8.3±13.9, and the median SDS was 2.8±7.0.
Table 1. Clinical characteristics
Age (years) 56±11
Men 428 (66%)
Length (cm) 172±9
Weight (kg) 77±14
Hypertension 284 (44%)
Smoking 165 (25%)
Hypercholesterolemia 256 (39%)
Diabetes mellitus 56 (9%)
Chronic obstructive pulmonary disease 36 (6%)
Angiotensin-converting enzyme inhibitor 144 (22%)
Beta blockers 250 (38%)
Calcium channel blockers 277 (43%)
Diuretics 89 (14%)
Nitrates 164 (25%)
Prior coronary revascularization 195 (30%)
Prior percutaneous coronary intervention 83 (13%)
Prior coronary artery bypass surgery 141 (22%)
Prior myocardial infarction 172 (26%)
Typical angina 184 (28%)
Atypical angina 220 (34%)
Non-specific symptoms 51 (8%)
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Table 2. Exercise testing data
Rest Peak P-value
Heart rate (bpm) 80 ± 18 140 ± 24 <0.001
Systolic blood pressure (mmHg) 137 ± 20 181 ± 30 <0.001
Diastolic blood pressure (mmHg) 87 ± 11 92 ± 14 <0.005
Rate – pressure product (x103 mmHg bpm) 11.0 ± 3.2 25.9 ± 8.2 <0.001
Outcomes
During a mean follow-up of 9.2±2.0 years, 107 (16%) patients died. Mortality was sig-
nificantly higher in patients with an abnormal SPECT study than that in patients with 
normal SPECT results (Figure 1). A total of 69 (11%) patients had a non-fatal myocardial 
infarction, 90 (14%) underwent coronary artery bypass surgery, and 142 (22%) under-
went percutaneous coronary intervention. Patients with an abnormal SPECT study had 
a significantly increased MACE rate as compared with patients with normal SPECT re-
sults (Figure 2).
Figure 1. Mortality curves in patients with normal versus abnormal myocardial perfusion SPECT.
Figure 2. Major adverse cardiac events in patients with normal versus abnormal myocardial per-
fusion SPECT. 
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Univariate analysis
Clinical, exercise testing, and SPECT variables associated with mortality and MACE are 
summarized in Table 3. Univariate predictors of mortality were age >70 years, prior 
myocardial infarction, peak rate-pressure product (RPP), abnormal SPECT scan, SRS, and 
SSS. Univariate predictors of MACE were age >70 years, male gender, hypercholestero-
laemia, use of beta blockers, use of calcium channel blockers, prior coronary revascu-
larization, prior myocardial infarction, peak RPP, typical angina, abnormal SPECT scan, 
SRS, and SSS.
Table 3. Univariate predictors of mortality and major cardiac events
Mortality Major adverse cardiac events
HR (95 CI) P-value HR (95% CI) P-value
Clinical features
   Age >70 years 3.84 (2.19-6.74) <0.001 2.66 (1.54–4.58) 0.0003
   Male gender 1.48 (0.94-2.35) 0.09 1.95 (1.39–2.74) <0.0001
   Hypertension 1.16 (0.76-1.76) 0.49 1.03 (0.75–1.41) 0.86
   Smoking 1.54 (0.99-2.42) 0.06 1.08 (0.75–1.53) 0.69
   Hypercholesterolaemia 1.31 (0.86–1.99) 0.21 1.49 (1.08–2.04) 0.01
   Diabetes mellitus 1.27 (0.63–2.54) 0.50 1.26 (0.73–2.19) 0.40
   Beta blockers 1.25 (0.82–1.91) 0.29 1.64 (1.19–2.26) 0.002
   Calcium channel blockers 1.28 (0.84–1.94) 0.25 1.40 (1.02–1.92) 0.04
   Prior coronary revascularization 0.94 (0.60–1.49) 0.80 2.47 (1.76–3.49) <0.0001
   Prior myocardial infarction 1.86 (1.20–2.88) 0.005 2.17 (1.52–3.10) <0.0001
Stress test results
   Peak RPP 0.88 (0.82–0.95) <0.001 0.91 (0.86–0.96) <0.001
   Typical angina 0.89 (0.47–1.67) 0.72 2.20 (1.62–2.99) <0.001
SPECT scan parameters
   Abnormal scan 1.72 (1.12–2.63) 0.01 2.08 (1.51–2.85) <0.0001
   SRSa 1.19 (1.12–1.26) <0.001 1.09 (1.04–1.14) <0.001
   SSSa 1.16 (1.10–1.23) <0.001 1.12 (1.08–1.17) <0.001
   SDSa 0.97 (0.83–1.14) 0.70 1.24 (1.14–1.34) <0.001
aper 5.6% of the total myocardium increment. Values are expressed as the Cox proportional HR and 95% CI.
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Multivariate analysis
Multivariate analysis demonstrated that SPECT variables provided incremental prog-
nostic information over clinical data and exercise electrocardiographic test variables for 
the prediction of mortality and MACE. Exercise electrocardiographic variables provided 
no incremental information over clinical data for the prediction of outcome. The SRS 
was an independent predictor of mortality, and provided incremental prognostic in-
formation over clinical data and exercise electrocardiographic test variables (P<0.001, 
Table 4). The SSS was an independent predictor of MACE (P<0.001, Table 5).
Table 4. Multivariate predictors of mortality
HR (95% CI) P-value
Agea 1.05 (1.03–1.07) <0.001
Smoking 1.94 (1.26–2.97) <0.002
SRSb 1.15 (1.08–1.22) <0.001
a per 1 unit increment
b per 5.6% of the total myocardium increment. Values are expressed as the Cox proportional HR and 95% CI.
Table 5. Multivariate predictors of major adverse cardiac events
HR (95% CI) P-value
Agea 1.03 (1.02–1.04) <0.001
Male gender 1.47 (1.12-1.93) 0.006
Prior myocardial infarction 1.53 (1.19–1.96) <0.001
SSSb 1.09 (1.04–1.13) <0.001
a per 1 unit increment
b per 5.6% of the total myocardium increment. Values are expressed as the Cox proportional HR and 95% CI.
DISCUSSION
This study assessed the use of exercise MPI for the prediction of outcome in patients 
with known or suspected coronary artery disease and no electrocardiographic abnor-
malities during exercise electrocardiographic testing. Approximately 50% of patients 
with normal exercise electrocardiographic testing had an abnormal myocardial perfu-
sion study, and 20% had completely or partially reversible perfusion defects. Exercise 
myocardial perfusion SPECT provided significant prognostic information for the pre-
diction of outcome in these patients. Patients with an abnormal SPECT study had a sig-
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nificantly increased mortality rate and had significantly more MACE as compared with 
patients with a normal SPECT.
Despite of its recognized limitations, exercise electrocardiographic testing is fre-
quently used for prognostic stratification of patient with known or suspected coronary 
artery disease. Current clinical practice guidelines recommend exercise electrocardio-
graphic testing for the initial evaluation and risk stratification of these patients.1–3 The 
present results demonstrate that even in patients without electrocardiographic abnor-
malities during electrocardiographic testing, superior risk stratification can be obtained 
using myocardial perfusion SPECT. The discrepancy between exercise electrocardio-
graphic testing and SPECT results is probably related to basic differences between these 
two tests. Angina and electrocardiographic changes (detected by exercise electrocar-
diographic testing) occur late in the ischaemic cascade, whereas perfusion abnormali-
ties (detected by SPECT) are an early ischaemic phenomenon.6 These differences result 
in a higher sensitivity of myocardial perfusion SPECT for the detection of myocardial 
ischaemia leading to better risk stratification.
In the present study, patients were referred to exercise SPECT for the evaluation of 
known or suspected coronary artery disease by their treating physicians. Clearly, clini-
cal judgement and application of the appropriateness criteria should be used to select 
the optimal test for a particular patient.11 Risk stratification using myocardial perfusion 
SPECT has disadvantages as radiation exposure to the patient and higher costs. Radia-
tion exposure is an increasingly relevant topic as myocardial perfusion SPECT studies 
are an important source of medical radiation exposure and patients frequently have 
multiple procedures performed over time. New cadmium zinc telluride SPECT camera 
technology may substantially reduce radiation exposure while maintaining image qual-
ity.12 Moreover, an individualized imaging protocol may further reduce study time and 
radiation exposure. The current study demonstrated that 50% of the patients had nor-
mal stress myocardial perfusion images. In these patients resting images are not nec-
essary and a further reduction in the radiation dose can be achieved by using a stress-
only imaging protocol.13 Cost is another factor limiting routine risk stratification using 
myocardial perfusion SPECT as compared with exercise electrocardiographic testing. 
Further studies are needed to evaluate whether the initial lower cost of exercise elec-
trocardiographic testing results in lower overall cost of clinical care. The suboptimal ac-
curacy of exercise electrocardiographic testing may result in potential misdiagnosis of 
obstructive coronary artery disease, which may hinder appropriate patient care. Addi-
tionally, myocardial perfusion SPECT has a high negative predicting value, which may 
avoid the use of unnecessary (invasive) diagnostic procedures.
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This study has limitations. First, in this study myocardial perfusion SPECT was per-
formed for risk stratification of patients with known or suspected coronary artery dis-
ease. Myocardial perfusion SPECT has a good sensitivity and specificity for the evalua-
tion of coronary artery disease. Still, coronary angiography is considered the reference 
methods for the assessment of coronary artery disease, and coronary angiography was 
not routinely performed in these patients. Second, no attenuation correction was used 
during exercise myocardial perfusion SPECT. Application of attenuation correction may 
have improved the accuracy of the SPECT studies. Recent data indicate that attenuation 
correction may further improve risk stratification.14,15
In conclusion, ~20% of patients with known or suspected coronary artery disease 
and normal exercise electrocardiographic testing have completely or partially reversible 
myocardial perfusion defects. MPI provides additional information for the prediction of 
9-year cardiovascular outcomes in these patients.
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PART B
Prediction of long-term outcome in patients 
considered at increased risk of adverse events
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ABSTRACT
Background. Exercise 99mTc-tetrofosmin single-photon emission computed tomogra-
phy (SPECT) is a useful tool for short- and medium-term risk stratifications. Currently, 
the long-term prognostic application of this technique has not been evaluated. 
Methods and Results. Exercise 99mTc-tetrofosmin was performed in 655 consecutive 
patients. Ten patients who underwent revascularization <60 days after nuclear testing 
were excluded from the analysis. The present data are based on 638 patients with com-
plete follow-up. An abnormal SPECT study was defined as the presence of fixed and/or 
reversible perfusion defects. End points were cardiac death, nonfatal infarction, and late 
coronary revascularization. A total of 344 (54%) patients had an abnormal SPECT study. 
Perfusion defects included fixed defects alone in 186 patients (29%) and reversible de-
fects in 158 (25%) patients. During a mean follow-up of 11±3.3 years, 174 (27%) patients 
died (all-cause mortality). Nonfatal myocardial infarction occurred in 76 (12%) patients, 
and late coronary revascularization was performed in 194 (30%) patients. Univariable 
and multivariable Cox proportional hazard regression analyses showed that exercise 
99mTc-tetrofosmin SPECT provided prognostic information incremental to clinical data 
and exercise test data. Patients with a normal SPECT had a relatively favorable long-
term prognosis, in contrast to patients with an abnormal study who had a significantly 
increased risk of cardiac events. The SPECT parameters abnormal scan, reversible defect, 
and summed rest score were strong predictors of long-term outcome. 
Conclusion. Exercise 99mTc-tetrofosmin myocardial perfusion SPECT has an incremental 
long-term prognostic value over clinical and stress test parameters for the prediction of 
major adverse cardiac events.
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INTRODUCTION
Technetium-99m (99mTc)-labeled agents are currently the most frequently used radio-
nuclide tracers for the assessment of myocardial perfusion. Historically, 99mTc-labeled 
agents were developed to overcome some limitations of thallium.1,2 These agents have 
a higher photon energy and shorter physical half-life, resulting in improved images 
quality and longer myocardial retention as compared to thallium.3 Multiple studies 
have demonstrated the value of 99mTc-labeled tracers in conjunction with single-photon 
emission computed tomography (SPECT) for the diagnosis of coronary artery disease, 
and the estimation of medium-term prognosis.3-10 Several studies have demonstrated ef-
fective risk stratification with 99mTc-tetrofosmin myocardial perfusion SPECT. Long-term 
outcome data after exercise 99mTc-tetrofosmin myocardial perfusion SPECT are currently 
not available. Therefore, the aim of this study was to evaluate the long-term prognostic 
value of exercise 99mTc-tetrofosmin SPECT for the prediction of major adverse cardiac 
events in patients with known or suspected coronary artery disease.
METHODS
Study Design
The study population consisted of 655 consecutive patients, who underwent exercise 
99mTc-tetrofosmin SPECT imaging for the evaluation of known or suspected coronary 
artery disease. The current report details the results of a repeat follow-up from a prior 
study from our center.6 The reason to perform this repeat follow-up study was to assess 
the very long-term prognostic value of exercise 99mTc-tetrofosmin myocardial perfusion 
SPECT. Diamond and Forrester clinical score was used to stratify patients with suspected 
coronary artery disease into groups with low, intermediate, or high probability of cor-
onary artery disease. All patients gave informed consent before the test. The protocol 
was approved by the Hospital Ethics Committee. Ten patients who underwent revascu-
larization <60 days after nuclear testing were excluded from the analysis. This exclusion 
was based on the previously published data indicating that referral to coronary revas-
cularization in the first 60 days after nuclear testing tends to be based on the results of 
the scan and that referral to revascularization >60 days after nuclear testing tends to be 
based on the worsening of the patient’s clinical status.11 In December 2010, follow-up 
was performed. The present data are based on 638 patients with complete follow-up.
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Clinical Data
A structured interview and clinical history were obtained, and cardiac risk factors were 
assessed before nuclear testing. A blood pressure ≥140/90 mm Hg, or treatment with 
antihypertensive medication was considered as hypertension. A fasting glucose level 
≥7.8 mmol/L or the need for insulin or oral hypoglycemic agents was considered as di-
abetes mellitus. A total cholesterol ≥6.4 mmol/L, or treatment with lipid-lowering med-
ication was considered as hypercholesterolemia. 
Exercise Testing
All patients fulfilled a symptom-limited upright bicycle ergometry test with a stepwise 
increment of 20 W every minute and with three electrocardiographic leads continuously 
monitored. Cuff blood pressure measurements and twelve-lead electrocardiograms 
were recorded at rest and every minute during exercise and recovery. The Schiller sys-
tem Cardiovit CSG/12 (Schiller Inc., Baar, Switzerland) was used for computer averaging 
of the electrocardiographic complexes.Significant ST-segment depression was defined 
as a >1-mm horizontal or downsloping ST-segment depression occurring at 80 ms after 
the J point.6 The target heart rate was defined as 85% of the maximum heart rate pre-
dicted for age and gender.
99mTc-Tetrofosmin SPECT Imaging 
An intravenous dose of 370 MBq of 99mTc-tetrofosmin (Myoview, Amersham, Bucking-
hamshire, United Kingdom) was injected approximately 1 minute before the cessation 
of exercise. In rest studies, 370 MBq of tetrofosmin was administered at least 24 hours af-
ter the exercise study. Myocardial images were acquired with a triple-head gammacam-
era system (Picker Prism 3000 XP, Cleveland, Ohio, USA). For each study, six oblique 
(short axis) slices from the apex to the base and three sagittal (vertical long axis) slices 
were defined. Each of the six short-axis slices was divided into eight equal segments. 
Owing to corresponding of the septal part of the two basal slices to the fibrous portion 
of the interventricular septum and normally exhibits reduced uptake, this region was 
excluded from analysis. As a consequence, 47 segments were indentified (3 long axis 
and 44 short axis). The interpretation of the scan was semiquantitatively performed by 
visual analysis and aided by circumferential profiles analysis. Exercise and rest tomo-
graphic views were reviewed side by side by an experienced observer who was blind 
to the patients’ clinical information. A reversible perfusion defect was defined as a per-
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fusion defect on the exercise images that partially or completely resolved at rest in ≥2 
contiguous segments or slices. A fixed perfusion defect was defined as a perfusion de-
fect on exercise images in two or more contiguous segments or slices, which persists on 
rest images. The presence of a fixed and/or reversible perfusion defect was considered 
as an abnormal study. Each myocardial segment was assigned a score from 0 to 3 (0 
= normal; 1 = slightly reduced; 2 = moderately reduced; and 3 = severely reduced or 
absent uptake). Summed stress score (SSS) and summed rest score (SRS) were calcu-
lated by the summation of the scores of the myocardial segments at stress and at rest, 
respectively. The difference between stress and rest scores, summed difference score 
(SDS), was considered representative of the extent and severity of myocardial ischemia. 
Standard 17-segment-based scores were calculated and converted into percent of the 
total myocardium (% myocardium) by dividing the summed scores by the maximum 
potential score, and multiplying by 100.12
Follow-Up
Collection of follow-up data was performed by contacting the patient, the patient’s 
general practitioner, civil registries, and review of hospital records. Outcome events 
were overall mortality, cardiac death, nonfatal myocardial infarction, and late (>60 days) 
coronary revascularization. A death caused by acute myocardial infarction, significant 
arrhythmias, or refractory congestive heart failure was defined as cardiac death. Sudden 
death occurring without another explanation was included as cardiac death. Nonfatal 
myocardial infarction was described by cardiac biomarker levels and ECG-changes. Ma-
jor adverse cardiac events were the combined endpoint of cardiac death, nonfatal myo-
cardial infarction, or coronary revascularization.
Statistical Analysis
Continuous variables were expressed as the mean ± SD and analyzed using the Student’s 
t test. The chi-squared test was used to compare categorical variables. Univariable and 
multivariable Cox proportional hazard regression models were performed to determine 
those variables which were independent predictors of late cardiac events. Variables 
were selected in a stepwise forward selection manner with entry and retention set of 
a significance level of 0.05. The risk of a variable was expressed as a hazard ratio (HR) 
with a corresponding 95% confidence interval. The assumption of the proportional haz-
ards was evaluated by performing the log-minus-log survival plot. The assumption was 
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met. Interaction terms were used to investigate collinearity; no interactions were found. 
The incremental value of myocardial perfusion SPECT over the clinical variables in the 
prediction of major adverse cardiac events was evaluated using a multivariate analysis 
including one pre-imaging model and three post-imaging models. Survival curves were 
generated using the Kaplan-Meier method to assess the probability of survival and 
were compared using the log-rank test. P <.05 was considered statistically significant.
RESULTS
Clinical Characteristics and Exercise Test Results
The characteristics of the 638 patients are presented in Table 1. Diamond and Forrester 
pre-test probability of coronary artery disease was low in 51 (8%), intermediate in 364 
(57%) and high in 223 (35%) patients. During the exercise test, typical angina was ob-
served in 106 patients, and 124 patients showed significant ST-segment depression. 
Side effects were short ventricular tachycardia (<10 complexes) in, seven patients (1%), 
and atrial fibrillation in 8 (1%) patients. Minor side effects included dizziness in 40 (6%) 
patients, headache in 18 (3%) patients, and nausea in 12 (2%). Patients experienced no 
myocardial infarction or ventricular fibrillation.
Table 1. Baseline characteristics.
n=638 Number (%)
Age (years) 56 ± 11
Women 210 (33)
Congestive heart failure 70 (11)
Diabetes mellitus 58 (9)
Hypercholesterolemia 268 (42)
Hypertension 275 (43)
Previous myocardial infarction 171 (27)
Previous coronary artery bypass graft 91 (14)
Previous percutaneous coronary intervention 124 (19)
Known coronary artery disease 294 (46)
Smoking 153 (24)
Beta blockers 261 (41)
Calcium antagonists 269 (42)
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SPECT results and prognosis
A total of 344 (54%) patients had an abnormal SPECT study. Perfusion defects included 
fixed defects alone in 186 patients (29%) and reversible defects in 158 (25%) patients. Of 
these reversible defects, 56 were completely reversible and 102 were partially reversible. 
The means (SD) of the SPECT parameters SSS, SRS, and SDS were 3.68 (2.86), 2.43 
(2.55), and 1.25 (1.30), respectively. During a mean follow-up of 11±3.3 years, 174 (27%) 
patients died (all-cause mortality). Nonfatal myocardial infarction occurred in 76 (12%) 
patients, and late coronary revascularization was performed in 194 (30%) patients. The 
Kaplan-Meier survival curves are presented in Figures 1, 2, 3, 4, and 5. The survival curves 
show that a normal 99mTc-tetrofosmin myocardial perfusion SPECT was associated with 
relatively low risk for major adverse cardiac events. Conversely, patients with an abnor-
mal study had a significantly increased risk of major adverse cardiac events. Figure 5 
demonstrates survival curves for allcause mortality and nonfatal myocardial infarction 
according to strata of coronary revascularization.
Figure 1. Kaplan Meier survival curves for major ad-
verse cardiac events (cardiac death, nonfatal infarction, 
and coronary revascularization). Event-free survival was 
significantly different in patients with a normal and pa-
tients with abnormal exercise 99mTc-tetrofosmin myocar-
dial perfusion SPECT. y = years.
Figure 2. Kaplan Meier survival curves for all-cause 
mortality. Event-free survival was significantly different 
in patients with a normal and patients with abnormal 
exercise 99mTc-tetrofosmin myocardial perfusion SPECT. 
y = years.
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Figure 3. Kaplan Meier survival curves for all-cause 
mortality and non-fatal myocardial infarction. Event-
free survival was significantly different in patients with a 
normal and patients with abnormal exercise 99mTc-tetro-
fosmin myocardial perfusion SPECT. y = years.
Figure 4. Kaplan Meier survival curves for revasculari-
zation. Event-free survival was significantly different 
in patients with a normal and patients with abnormal 
exercise 99mTc-tetrofosmin myocardial perfusion SPECT. 
y = years.
Predictors of Outcome
Predictors of major adverse cardiac events are demonstrated in Table 2. Univariable pre-
dictors of major adverse cardiac events were age, male gender, hypercholesterolemia, 
previous myocardial infarction, revascularization, peak heart rate, rate-pressure prod-
uct, typical angina and all analyzed scan parameters. A multivariable model revealed 
that myocardial perfusion SPECT had an incremental prognostic value over clinical vari-
ables and stress test parameters. The post-imaging models demonstrated that an ab-
normal scan was a powerful predictor of outcome; there was a direct relation between 
an abnormal scan and the risk of major adverse cardiac events
Figure 5. Kaplan Meier survival curves for the combined endpoint of all-cause mortality or non-fatal myocardial in-
farction according to strata of coronary revascularization. Event-free survival was not significantly different between 
patients with and without revascularization during follow-up. y = years. 
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Table 2. Predictors of major adverse cardiac events (cardiac death, nonfatal infarction or revascu-
larization) at univariable and multivariable analysis. 
Univariable
analysis
Multivariable analysis
Pre-imaging Post-imaging I Post-imaging II Post-imaging III
   Age* 1.02 (1.01-1.03) 1.05 (1.03-1.06) 1.03 (1.01-1.04) 1.02 (1.01-1.03) 1.05 (1.03-1.08)
   Male gender 1.89 (1.50-2.39) 1.80 (1.29-2.51) p=0.11 1.40 (1.09-1.79) 1.97 (1.25-3.10)
   Congestive heart failure p=0.69 p=0.62 p=0.65 p=0.78 p=0.15
   Diabetes mellitus p=0.22 1.96 (1.26-3.08) 1.74 (1.13-2.69) p=0.13 2.36 (1.35-4.14)
   History of angina p=0.26 p=0.63 p=0.93 p=0.66 p=0.52
   Hypercholesterolemia 1.30 (1.06-1.60) p=0.79 p=0.89 p=0.17 p=0.92
   Hypertension p=0.58 p=0.82 p=0.87 p=0.10 p=0.80
   Previous infarction 1.58 (1.26-1.97) 1.71 (1.15-2.55) 1.51 (1.10-2.08) 1.33 (1.06-1.68) p=0.06
   Revascularization 4.54 (3.63-5.68) 1.93 (1.43-2.60) 3.23 (2.43-4.30) 3.64 (2.93-4.53) 3.11 (2.32-4.16)
   Smoking p=0.16 2.25 (1.50-3.38) 1.42 (1.03-1.94) p=0.18 2.41 (1.60-3.64)
Exercise test results
   Peak heart rate 0.87 (0.83-0.91) p=0.16 p=0.31 0.98 (0.97-0.99) p=0.21
   Peak systolic BP p=0.91 p=0.29 p=0.16 p=0.86 p=0.11
   Peak RPP 0.96 (0.95-0.98) p=0.70 p=0.94 p=0.56 p=0.93
   Typical angina 1.68 (1.30-2.18) p=0.40 p=0.53 p=0.94 p=0.60
   ST-segment changes p=0.12 p=0.10 p=0.33 p=0.20 p=0.41
Scan parameters
   Abnormal scan 1.68 (1.36-2.08) - 1.57 (1.12-2.20) - -
   Reversible defect 1.94 (1.55-2.44) - - 1.62 (1.20-2.20) -
   Fixed defect 1.28 (1.03-1.58) - - p=0.47
   SRS** 1.02 (1.01-1.02) - - - 1.03 (1.01-1.04)
   SDS** 1.05 (1.04-1.07) - - - p=0.49
   SSS** 1.27 (1.15-1.46) - - - -
Statistically significant predictors of outcome are presented as hazard ratio (confidence interval), of all other variables 
the p-value is presented.
 - = not included in the model, * = per unit increment, ** = per % myocardium increment, BP = blood pressure, RPP = 
rate pressure product, SSS = summed stress score, SRS = summed rest score, SDS = summed difference score.
DISCUSSION
The prognostic value of exercise 99mTc-tetrofosmin myocardial perfusion SPECT has been 
reported in previous studies with short-to-medium-term follow up.4-10 The long-term 
prognostic value of exercise 99mTc-tetrofosmin myocardial perfusion SPECT has not been 
defined. This study demonstrates that the prognostic value of exercise 99mTc-tetrofosmin 
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myocardial perfusion SPECT in predicting major adverse cardiac events, all-cause mor-
tality, and all-cause mortality and nonfatal myocardial infarction was maintained during 
a long-term follow-up of 11±3.3 years. Univariable and multivariable analyses showed 
that exercise 99mTc-tetrofosmin SPECT provided prognostic information incremental to 
clinical data and exercise test data. Patients with a normal SPECT had a relatively fa-
vorable long-term prognosis, in contrast to patients with an abnormal study who had 
a significantly increased risk of cardiac events. The SPECT parameters abnormal scan, 
reversible defect, and SRS were strong predictors of long-term outcome. 
Comparison to Previous Studies
Previous studies have demonstrated the prognostic value of exercise 99mTc-tetrofosmin 
myocardial perfusion SPECT for the prediction of cardiac events in patients with known 
or suspected coronary artery disease at short-medium term follow-up.4-10 Groutars et al.4 
studied 246 patients who had a normal exercise thallium/99mTc-tetrofosmin myocardial 
perfusion SPECT. The annualized cardiac event rate was 0.4%/year during a 25±3 month 
follow-up. Galassi et al.5 studied 459 patients with exercise 99mTc-tetrofosmin myocar-
dial perfusion SPECT. During a median follow-up of 38 months, the annualized event 
rate (cardiac death/nonfatal infarction) was 0.5%/year in patients with a normal study 
and 4.9%/year in those with an abnormal study. Shaw et al.7 reported the results from 
a multicenter registry and described an excellent prognosis for patients with a normal 
99mTc-tetrofosmin myocardial perfusion SPECT during a mean follow-up of 2.5 years 
(30 months). Borges-Neto et al.8 studied 473 patients with 99mTc-tetrofosmin and 518 
patients using 99mTc-sestamibi exercise myocardial perfusion SPECT. The study demon-
strated that the type of 99mTc-labeled myocardial perfusion agent did not affect inter-
pretation of results for risk stratification and prognostic assessment during the 1.5-year 
study period. Georgoulias et al.9 studied 246 asymptomatic patients after percutaneous 
coronary intervention with exercise 99mTc-tetrofosmin gated-SPECT. During 8.3±2.9-year 
follow-up of this selected population, myocardial perfusion SPECT provided incremen-
tal prognostic value. However, routine testing in asymptomatic patients is generally not 
recommended, and the clinical value and cost-effectiveness of routine SPECT after per-
cutaneous coronary intervention need further investigation. Recently, Jain et al.10 stud-
ied 371 patients with exercise or pharmacologic stress 99mTctetrofosmin gated-SPECT. 
During a mean follow-up of 3.9 years, SPECT findings significantly improved accuracy of 
cardiac event rate prediction compared to clinical information alone.
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Compared to these previous studies, our study included 638 patients who were fol-
lowed for 11±3.3 years. The findings of the current study extend the conclusions drawn 
from the previous medium-term prognostic studies. Previously, we have reported the 
4±1.3 year follow-up of these 655 patients who underwent exercise 99mTc-tetrofosmin 
myocardial perfusion SPECT.6 In the same previous study, patients with a normal study 
had an annualized event rate (cardiac death, nonfatal infarction, and coronary revas-
cularization) of 1.5%/year and those with an abnormal study of 5.0%/ year. In the cur-
rent long-term follow-up study, Kaplan-Meier survival curves continued to diverge over 
time. Patients with normal SPECT had a favorable event-free survival, indicating that the 
prognostic value of SPECT for the prediction of outcome was maintained during the 
long-term follow-up period. Hence, patients with normal SPECT scans can be excluded 
from coronary invasive procedures. In contrast, patients with an abnormal myocardial 
perfusion SPECT had significantly higher annualized event rates. A total of 294 (46%) 
patients had known coronary artery disease; this may have caused the relatively high 
event rate in this patient cohort. Future studies are needed to optimize risk modification 
to improve outcome in these patients. 
The 10 excluded patients who underwent revascularization <60 days after testing 
represent 1.6% of the overall cohort. This percentage is relatively low because in most 
of the patients with ischemia according to exercise 99mTc-tetrofosmin, medical therapy 
was probably optimized before a decision on referral to percutaneous coronary re-
vascularization or surgical coronary revascularization was made. Kaplan-Meier curves 
demonstrated that referral to coronary revascularization was relatively low in patients 
with normal scan results in the first 4 years after testing. Previous studies demonstrate 
that the timing of revascularization requires careful consideration.13 Patients with no 
or mild symptoms and little ischemia can safely be treated with medical treatment 
alone. Conversely, patients with moderate-to-severe symptoms and/or extensive ische-
mia should be strongly considered for revascularization therapy.13 The current analysis 
demonstrates that event-free survival from all-cause mortality and nonfatal myocardial 
infarction was not significantly different between patients with coronary revasculariza-
tion during follow-up and those without. This is in line with results from the COURAGE 
trial which demonstrated that clinical outcome was not significantly different between 
patients with stable angina who received an initial therapy of coronary revasculariza-
tion and optimal medical therapy compared with patients with optimal medical ther-
apy alone.14
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Limitations
This study has several limitations. First, no attenuation or scatter correction was used 
during exercise 99mTc-tetrofosmin myocardial perfusion SPECT. Application of attenu-
ation or scatter correction may have improved the accuracy of the SPECT studies. Re-
cent data indicate that attenuation correction may further improve risk stratification.15,16 
Second, previous studies have demonstrated that functional data derived from gated 
myocardial perfusion SPECT provides additional information to predict outcome. At 
the time of data collection, gated SPECT was not routinely performed. Therefore, in this 
study, the prognostic value of gated SPECT was not analyzed. Third, coronary angiogra-
phy was not routinely performed; therefore, the current analysis may be influenced by 
false-positive and false negative SPECT studies. Fourth, although the feasibility of the 
test was high, 72 (11%) patients had an inconclusive test (failure to achieve target heart 
rate and to demonstrate a perfusion abnormality). These 72 studies were considered 
normal. The feasibility and perhaps the prognostic value could have been higher if be-
ta-blocker therapy was routinely discontinued before the exercise test. Fifth, the results 
of exercise 99mTc-tetrofosmin myocardial perfusion SPECT were available to the treat-
ing physicians. Patient management decisions were made at discretion of the treating 
physicians. It cannot be excluded that patients with an abnormal study received more 
intensive medical therapy and were referred to coronary revascularization to favorably 
alter their prognosis. Therefore the prognostic power of exercise 99mTc-tetrofosmin myo-
cardial perfusion SPECT may have been underestimated in the present study. Sixth, the 
present results were obtained in patients who underwent exercise 99mTc-tetrofosmin 
imaging, and cannot be automatically be extrapolated to SPECT studies using other iso-
topes. Finally, clinical data upon which to adjust the multivariable model were relatively 
limited; this could have influenced the current analysis.
13671_HJBoiten_BW.indd   68 01-08-16   10:28
Long-term prognostic value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission | 69
CONCLUSION
Exercise 99mTc-tetrofosmin myocardial perfusion SPECT has an incremental long-term 
prognostic value over clinical and stress test parameters for the prediction of major ad-
verse cardiac events. Patients with a normal 99mTc-tetrofosmin SPECT have a relatively 
favorable long-term prognosis, in contrast to patients with an abnormal study who have 
a significantly increased risk of cardiac events.
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ABSTRACT
Objective. There are no data regarding the long-term prognostic value of single-pho-
ton emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in 
obese patients. The aim of this study was to examine the value of stress 99mTc-tetrofos-
min MPI findings for the prediction of very long-term outcome in obese patients.
Methods. The study population consisted of 261 patients with a body mass index ≥30 
kg/m2 who underwent exercise or pharmacological stress 99mTc-tetrofosmin MPI for the 
assessment of known or suspected coronary artery disease. Endpoints during follow-up 
were all-cause mortality, cardiac death, nonfatal infarction, and coronary revasculari-
zation. Kaplan-Meier survival cures were constructed and univariate and multivariate 
analyses were performed to identify predictors of very long-term outcome.
Results. The mean age was 59±10 years, 42% of the patients was male, and the body 
mass index was on average 37±7 kg/m2. MPI findings were normal in 109 patients (42%). 
Myocardial perfusion abnormalities were fixed in 62 patients (24%) and reversible in 90 
patients (34%). During a median 12-year follow-up, 91 (35%) patients died, and 27 (10%) 
had a nonfatal myocardial infarction. Survival curves were compared using the log-rank 
test at subsequent follow-up durations. Obese patients with a normal stress 99mTc-tetro-
fosmin study had a significantly better prognosis as compared with those with an ab-
normal study, up to 6 years after the test was performed.
Conclusion. Stress 99mTc-tetrofosmin MPI provides valuable prognostic information 
for the prediction of outcome in obese patients. Obese patients with a normal stress 
99mTc-tetrofosmin study have a significantly better prognosis as compared with those 
with an abnormal study, up to 6 years after the test is performed.
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INTRODUCTION
Obesity has reached global epidemic proportions in both adults and children and is asso-
ciated with numerous comorbidities.1,2 Obesity, defined as a body mass index (BMI)≥30, 
has a major impact on the risk of cardiovascular diseases. Obesity may cause premature 
coronary artery disease by its influence on known risk factors including diabetes, hy-
pertension, and sleep apnea. As a consequence, obese patients are at a significantly in-
creased risk of acute coronary syndromes, and have a reduced life expectancy.2-5 Multi-
ple studies have shown that stress myocardial perfusion imaging (MPI) yields additional 
diagnostic and prognostic information for the evaluation of coronary artery disease.6-8 
The extent and severity of abnormalities on MPI allow stratification of patients for future 
risk of adverse cardiac events. A previous study from our center showed that stress MPI 
is a useful tool in predicting mortality and cardiac events in obese patients.9
Currently, information on the very long-term prognostic value of stress 99mTc-tetro-
fosmin MPI in obese patients is not available. The very long-term prognostic value of 
MPI in these patients may be impaired because their increased underlying cardiovas-
cular risk and accelerated natural progression of coronary artery disease. This creates 
uncertainties in the clinical management of obese patients. The aim of this study was 
to assess the role of stress 99mTc-tetrofosmin MPI for risk stratification in obese patients 
and to determine the value of this test for the assessment of very long-term outcome.
METHODS
Study Design
The study population consisted of 267 consecutive obese patients who were referred 
for stress 99mTc-tetrofosmin SPECT between January 1995 and December 2002, because 
of known or suspected coronary artery disease. Follow-up was successful in 261 (98%) 
patients. Patients were considered obese if they had a body mass index ≥30 kg/m2, ac-
cording to the criterion of the National Institutes of Health and the World Health Orga-
nization. Body mass index was calculated as the body weight divided by the squared 
height. The study population was similar to that in a previous study from our center.9 
The local medical ethics committee approved the protocol and all patients gave in-
formed consent. A structured interview and clinical history were obtained, including 
assessment of cardiac risk factors, and the symptoms prior to the stress test.
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Stress Testing Protocol
The stress testing protocol has been described previously.9 In short, the choice of stress 
test was based on ability to exercise. Exercise stress testing was performed in 70 pa-
tients using a symptom-limited upright bicycle ergometer with a stepwise increment of 
20 W every minute. Dobutamine-atropine stress testing was performed in 191 patients. 
Computer averaging of the electrocardiographic complexes was performed for both 
stress tests. Significant ST-segment depression was defined as a horizontal or downslop-
ing ST-segment depression of more than 1 mm occurring 80 ms after the J point.
Myocardial Perfusion SPECT
Approximately 1 minute before the termination of the stress test an intravenous dose of 
370 MBq of 99mTc-tetrofosmin (Myoview; Amersham) was administered. For resting stud-
ies 370 MBq of the same tracer was administered at least 24 hours after the exercise test. 
Image acquisition was performed using a SPECT camera system (Picker Prism 3000XP 
camera; Picker, Cleveland, OH). A normal study was defined as absence of perfusion 
abnormalities. Summed stress score (SSS) and summed rest score (SRS) were calculated 
by the summation of the scores of the myocardial segments at stress and at rest, respec-
tively. Standard 17-segment-based scores were calculated and converted to percent of 
the total myocardium (% myocardium) by dividing the summed scores by the maxi-
mum potential score, and multiplying by 100.10
Patient Follow-Up
Outcome data were obtained by evaluation of hospital records, contacting the patient’s 
general practitioner, and/or review of civil registries. The date of the last review or con-
sultation was used to calculate follow-up time. Endpoints were all-cause mortality, car-
diac death, nonfatal myocardial infarction, and coronary revascularization. Nonfatal 
myocardial infarction was defined as new symptoms of ischemia, and/or ECG changes 
indicative of new ischemia, and/or imaging evidence of myocardial infarction, accom-
panied by detection of a rise and fall of cardiac biomarkers. Hard cardiac events were de-
fined as the occurrence of cardiac death or nonfatal myocardial infarction. Patients who 
underwent revascularization within 3 months of the stress test were censored, because 
previous studies have demonstrated that revascularization within 3 months is predom-
inantly based on the test results, whereas revascularization after this period reflects a 
worsening clinical status.
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Statistical Analysis
Values were expressed as mean value ± standard deviation or number. The Student’s t 
test was used to analyze continuous data. Differences between proportions were com-
pared using the Chi-squared test. Univariate and multivariate Cox proportional hazard 
regression models (SPSS statistical software version 15.0, SPSS, Chicago, IL) were used 
to identify independent predictors of outcome. Variables were selected in a stepwise 
forward selection manner with entry and retention set at a significance level of 0.05. The 
risk of a variable was expressed as a hazard ratio with a corresponding 95% confidence 
interval. The incremental value of SPECT MPI over the clinical variables in the prediction 
of events was performed according to 3 models. In model I, the only SPECT MPI vari-
able entered was the presence of abnormal perfusion. In model II, the variables entered 
were the presence of a fixed or reversible perfusion defect. In model III, the variables 
entered were SSS and SRS. The predictive value of each model was expressed using the 
Chi-squared statistic. The probability of survival was calculated using the Kaplan-Meier 
method, and survival curves were compared using the log-rank test. P value <.05 was 
considered statistically significant.
Table 1. Clinical characteristics.
Age (years) 59±10
Male gender 110 (42%)
Weight (kg) 101±16
Body mass index (kg/m2) 37±7
Diabetes mellitus 46 (17%)
Hypertension 156 (59%)
Hypercholesterolemia 109 (41%)
Smoking 60 (23%)
Angina 104 (39%)
Atypical chest pain 102 (38%)
Prior myocardial infarction 73 (28%)
Prior myocardial revascularization 77 (29%)
ACE-inhibitor 88 (33%)
Betablocker 145 (58%)
Calcium channel blocker 102 (38%)
Diuretic 67 (25%)
Data are presented as mean ± standard deviation or number of patients (percentages)
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RESULTS
Clinical characteristics
Baseline characteristics of the patients are presented in Table 1. The mean age was 
59±10 years and 42% of the patients were male. The body mass index was on average 
37±7 kg/m2. SPECT findings were normal in 109 patients (42%). Myocardial perfusion 
abnormalities were fixed in 62 patients (24%) and reversible in 90 patients (34%). A total 
of 34 patients had completely reversible perfusion defects, whereas 56 patients had 
partially reversible perfusion defects.
Patient Outcome
Kaplan-Meier survival curves and cumulative event rate are presented in Figures 1, 2, 3. 
Median follow-up duration was 12 years (range 9-16 years). During a mean follow-up of 
10.4±4.4 years, 91 (35%) patients died. Cardiac mortality occurred in 28 (11%) patients. 
Nonfatal myocardial infarction occurred in 27 (10%) patients, and 88 (34%) patients un-
derwent coronary revascularization. The annualized all-cause mortality rate after a nor-
mal study was 1.5%, 2.3%, and 1.9%, and after an abnormal study was 3.2%, 2.5%, and 
2.7% at, respectively, 5-, 10-, and 15-year follow-up. Annualized cardiac mortality rate 
after a normal study was 0.6%, 0.6%, and 0.5%, and after an abnormal study was 1.6%, 
1.0%, and 0.8% at, respectively, 5-, 10-, and 15-year follow-up. Annualized hard cardiac 
event rate after a normal study was 1.0%, 0.8%, and 2.3% and after an abnormal study 
was 2.0%, 1.2%, and 1.9% at respectively 5-, 10-, and 15-year follow-up. 
Figure 1. Kaplan-Meier event-free survival for 
the endpoint of all-cause mortality in patients 
with normal and abnormal stress 99mTc-tetro-
fosmin SPECT.
Figure 2. Kaplan-Meier event-free survival for 
the endpoint of cardiac mortality in patients 
with normal and abnormal stress 99mTc-tetro-
fosmin SPECT.
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Figure 3. Kaplan-Meier event-free survival for the endpoint of hard cardiac events (cardiac mor-
tality and nonfatal myocardial infarction) in patients with normal and abnormal stress99mTc-tetro-
fosmin SPECT.
To determine up to what time point during the follow-up the stress 99mTc-tetrofosmin 
SPECT study holds its prognostic value, the log-rank test was performed at subsequent 
follow-up durations (Figure 1). This analysis demonstrates that obese patients with a 
normal stress 99mTc-tetrofosmin study have a significantly better prognosis as compared 
with those with an abnormal study, up to 6 years after the test is performed. The per-
ishable date of stress 99mTc-tetrofosmin SPECT for the prediction of outcome in obese 
patients is approximately 6 years. 
Risk Stratification
Univariate analysis demonstrated that during the very long-term follow-up, age, prior 
heart failure, diabetes mellitus, prior myocardial infarction, and smoking were predic-
tors of all-cause mortality (Table 2). Age, prior heart failure, diabetes mellitus, prior myo-
cardial infarction were univariate predictors of cardiac mortality (Table 3). Age, prior 
heart failure, and prior myocardial infarction were significant univariate predictors of 
hard cardiac events (Table 4). Univariate analyses demonstrated that 99mTc-tetrofosmin 
SPECT parameters were not predictive of very long-term outcome. Multivariate analyses 
demonstrated that SPECT parameters had no incremental value over clinical variables 
for the prediction of all-cause mortality, cardiac mortality, and hard cardiac during the 
entire 12-year follow-up.
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Table 2. Univariate and multivariate predictors of all-cause mortality.
Multivariate
Parameter Univariate Model I Model II Model III
Age 1.07 (1.05–1.09) 1.08 (1.06–1.1) 1.07 (1.05–1.11) 1.08 (1.06–1.11)
Prior heart failure 2.5 (1.5–4.2) 2.0 (1.2–3.5) 2.0 (1.2–3.5) 2.0 (1.2–3.5)
Diabetes 2.1 (1.4–3.2) 2.3 (1.4–3.7) 2.3 (1.5–3.6) 2.3 (1.5–3.7)
Prior myocardial infarction 1.7 (1.1– 2.6) 2.1 (1.3–3.4) 2.2 (1.4–3.4) 2.1 (1.3–3.4)
Current smoking 1.5 (0.9–2.3) 1.5 (0.9–2.5) 1.6 (1.0–2.6) 1.6 (1.0–2.6)
Abnormal perfusion 1.5 (0.98–2.4) 1.1 (0.7–1.8) - -
Fixed 1.1 (0.7–1.8) - 0.9 (0.6-1.3) -
Reversible 1.3 (0.8-2.0) - 1.0 (0.6-1.5) -
SSS* 1.1 (0.9-1.2) - - 1.0 (0.9-1.2)
SRS* 1.1 (1.0-1.2) - - 0.99 (0.84-1.17)
Total Chi-square         - 75 72 72
Values are expressed as Cox proportional hazard ratio (95% confidence interval). In model I, the only SPECT MPI vari-
able entered was the presence of abnormal perfusion. In model II, the variables entered were the presence of a fixed 
or reversible perfusion defect. In model III, the variables entered were SSS and SRS.
* Per 5.6% of the total myocardium increment.
Table 3. Univariate and multivariate predictors of cardiac mortality.
Multivariate
Parameter Univariate Model I Model II Model III
Age 1.05 (1.02–1.09) 1.07 (1.02–1.11) 1.06 (1.02–1.11) 1.07 (1.02–1.12)
Prior heart failure 4.4 (2.0–9.7) 2.8 (1.2–6.4) 2.9 (1.3–6.9) 2.4 (1.1–5.7)
Diabetes 3.3 (1.5–6.9) 3.3 (1.5–7.3) 3.3 (1.5–7.3) 3.7 (1.7–8.0)
Prior myocardial infarction 3.3 (1.5–6.9) 3.7 (1.6–8.3) 4.0 (1.8–8.8) 2.9 (1.2–6.8)
Abnormal perfusion 2.0 (0.9–4.5) 1.2 (0.5–2.9) - -
Fixed 1.2 (0.6–2.6) - 0.9 (0.4–2.1) -
Reversible 1.3 (0.6–2.8) - 0.9 (0.4–2.0) -
SSS* 1.2 (1.1–1.4) - 1.1 (0.9–1.4)
SRS* 1.2 (1.1–1.4) - - 1.0 (0.8-1.3)
Total Chi-square - 42 43 45
Values are expressed as Cox proportional hazard ratio (95% confidence interval). In model I, the only SPECT MPI vari-
able entered was the presence of abnormal perfusion. In model II, the variables entered were the presence of a fixed 
or reversible perfusion defect. In model III, the variables entered were SSS and SRS.
* Per 5.6% of the total myocardium increment.
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DISCUSSION
The main finding of this study is that stress 99mTc-tetrofosmin MPI provides useful in-
formation for the prediction of outcome in obese patients. Obese patients with a nor-
mal stress 99mTc-tetrofosmin study have a significantly better prognosis as compared 
with those with an abnormal study, up to 6 years after the test is performed. After this 
6-year period, stress 99mTc-tetrofosmin MPI does not hold its value for the prediction 
of all-cause mortality, cardiac mortality, and hard cardiac events in obese patients. The 
perishable date of stress 99mTc-tetrofosmin SPECT for the prediction of outcome in obese 
patients is approximately 6 years. Although multiple studies have shown that stress MPI 
has an incremental prognostic value over clinical data for the prediction of mortality 
and cardiac events,6-8 no previous reports have assessed the very long-term prognostic 
value in obese patients.
Table 4. Univariate and multivariate predictors of hard cardiac events.
Multivariate
Parameter Univariate Model I Model II Model III
Age 1.05 (1.02-1.08) 1.06 (1.03-1.08) 1.06 (1.03-1.09) 1.05 (1.02-1.08)
Prior heart failure 2.8 (1.4-5.5) 2.4 (1.2-4.7) 2.5 (1.2-5.0) 2.3 (1.1-4.7)
Prior myocardial infarction 2.2 (1.3-3.8) 2.2 (1.3-4.0) 2.5 (1.4-4.5) 2.1 (1.1-3.8)
Abnormal perfusion 1.7 (1.0-3.0) 1.2 (0.6-2.1) - -
Fixed 1.0 (0.6-1.8) - 0.7 (0.4-1.2) -
Reversible 1.6 (0.9-2.8) - 1.1 (0.6-2.0) -
SSS* 1.1 (1.0-1.3) - - 1.1 (0.9-1.2)
SRS* 1.1 (1.0-1.3) - - 1.0 (0.8-1.2)
Total Chi-square - 30 33 28
Values are expressed as Cox proportional hazard ratio (95% confidence interval). In model I, the only SPECT MPI vari-
able entered was the presence of abnormal perfusion. In model II, the variables entered were the presence of a fixed 
or reversible perfusion defect. In model III, the variables entered were SSS and SRS.
* Per 5.6% of the total myocardium increment.
There is overwhelming evidence supporting the importance of obesity in the patho-
genesis and progression of coronary artery disease. Studies have shown that obesity is 
associated with more morbidity than smoking, alcoholism, and poverty.1-5 Obesity may 
have influence on insulin resistance, hypertension, hyperlipidemia, inflammatory mark-
ers, thromboembolism, and sleep apnea. These are established risk factors for coronary 
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artery disease. Conversely, other studies have reported on an obesity paradox, that is: 
lower mortality in obese patients.11,12 A recent study by Boiten et al13 described the very 
long-term outcome of 99mTc-tetrofosmin SPECT in 655 consecutive patients. During an 
11.0 ± 3.3-year follow-up, all-cause mortality was approximately 1%/year in patients 
with a normal study and 2%/year in those with an abnormal study. In this study, all-
cause mortality was 1.9%/year in obese patients with a normal study and 2.7%/year in 
those with an abnormal study. 
The evaluation of coronary artery disease in obese patients is challenging. The base-
line ECG in these patients is often influenced by the presence of obesity (false-positive 
for inferior myocardial infarction, microvoltages, and nonspecific repolarization abnor-
malities). Additionally, obese patients may have an impaired maximal exercise testing 
capacity (due to dyspnea, orthopedic limitations, left ventricular diastolic dysfunction). 
This is confirmed by this study in which 27% of the obese population was able to per-
form an exercise test, whereas the remaining 73% was unable to perform an exercise 
test and underwent a pharmacological stress study.
A few previous studies have reported on the short to medium-term prognostic value 
of SPECT MPI in obese patients. Duvall et al14 studied 433 obese patients with a mean 
body mass index of 47.3 ± 8 kg/m2. A total of 98 patients performed an exercise test 
and 335 underwent pharmacological stress testing in conjunction with 99mTc-SPECT. 
The patients had a mean follow-up of 24.9 ± 11.3 months, there was a statistically sig-
nificant difference in the Kaplan-Meier curves at 1-year follow-up; however, at 2-year 
follow-up there was no significant risk stratification. The authors stated that this lack of 
prognostic value at 2 years may have been the result of the retrospective nature of the 
study or the sample size and relative short follow-up length. Alternatively, obesity may 
have resulted in a more rapidly progression of the atherosclerotic process. Uretsky et 
al12 previously described the impact of weight on long-term survival in 3673 patients 
without known CAD and with normal stress SPECT MPI. During a 7.5±3-year follow-up, 
overweight and obese patients had a lower risk of all-cause mortality compared to nor-
mal weight patients. Hence, that study supported the obesity paradox (lower mortality 
in obese patients). In this study, event rates were substantially higher which was caused 
by the clinical profile of the patients (28% had previous myocardial infarction, 29% had 
previous myocardial revascularization) that was different from the patients studied by 
Uretsky et al.12 An earlier study from our center9 demonstrated that stress 99mTc-tetrofos-
min MPI was independently predictive of cardiac mortality and all-cause mortality in 
obese patients during a mean follow-up of 5.5±2 years. This study differs from previous 
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studies because the median follow-up duration was 12 years (range 9-16 years). This 
study extends the results from previous studies and demonstrates that the prognostic 
value is maintained up to 6 years after the date of the SPECT MPI.
Several factors may explain why the value of SPECT MPI has no incremental prog-
nostic value at 6-15-year follow-up. Hachamovitch et al15 have demonstrated previously 
that a warranty period after normal SPECT MPI exists. This warranty period is influenced 
by a temporal component of risk, which may increase the annualized cardiac event rate 
to 2%, even in the presence of a normal SPECT MPI. In that study of Hachamovitch et al,15 
overall, patients with a normal study had a favorable outcome. However, there were pa-
tients with a normal study that had an adverse outcome. Pharmacological stress testing, 
a history of coronary artery disease, diabetes, gender, and increasing age were signifi-
cant predictors of adverse outcome. Clinical characteristics, such as hypertension, dia-
betes, and the lesions from a previous myocardial infarction, might change and become 
worse in these years and can affect the risk on death and cardiac events. Moreover,this 
population of patients with obesity may have an accelerated progression of coronary 
artery disease as compared to patients without obesity. Because the prognostic value 
of SPECT MPI in obese patients is maintained up to 6 years after testing, more frequent 
monitoring of obese patients after this period may be justified. Repeated testing after 6 
years may be considered depending on the patient’s symptoms and clinical status. The 
appropriateness criteria for cardiac radionuclide imaging should be used to determine 
whether repeated testing is necessary.16
SPECT MPI provides clinically useful information for patients’ management and deci-
sions on further testing in obese patients. This study demonstrates that obese patients 
with a normal SPECT MPI have a favorable prognosis. In these patients, a watchful wait-
ing approach to care is justified, and additional diagnostic strategies including invasive 
coronary angiography can be avoided. Previous studies have demonstrated that this 
type of management strategy may be both clinically effective and cost-effective.17,18 In 
obese patients with an abnormal SPECT MPI study, medical therapy should be opti-
mized and further testing including invasive coronary angiography should be consid-
ered. Clearly, clinical judgment remains important in deciding patient management 
decisions, especially in obese patients.
This study has some limitations. First, the studied population was relatively small. 
Second, obesity may cause false positive SPECT MPI results because of attenuation. In 
this study, attenuation correction was not routinely performed. This may have influ-
enced the prognostic value of SPECT MPI in this study population.
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Recent data indicate that attenuation correction may further improve diagnostic accu-
racy of myocardial perfusion SPECT. Third, no information on medical therapy changes 
was available.
CONCLUSION
Stress 99mTc-tetrofosmin MPI provides valuable prognostic information for the predic-
tion of outcome in obese patients. Obese patients with a normal stress 99mTc-tetrofos-
min study have a significantly better prognosis as compared with those with an abnor-
mal study, up to 6 years after the test is performed.
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ABSTRACT
Background. Myocardial perfusion imaging (MPI) using single-photon emission com-
puted tomography (SPECT) is useful in the evaluation of cardiac allograft vasculopathy 
(CAV) in heart transplant (HTx) recipients. The current study evaluated the long-term 
prognostic value of stress SPECT MPI for predicting all-cause mortality and cardiac 
events in HTx recipients.  
Methods. The study population consisted of 166 HTx recipients (mean age 54 ±10 years, 
84% male) who underwent exercise or dobutamine stress 99mTc-tetrofosmin SPECT MPI 
for the assessment of CAV. An abnormal SPECT MPI was defined as the presence of a 
fixed or a reversible perfusion defect. Endpoints were all-cause mortality, cardiac mor-
tality and nonfatal myocardial infarction (MI). 
Results. MPI abnormalities were detected in 55 patients (33%), including fixed defects 
in 28 patients (17%), partially reversible in 17 patients (10%) and completely reversible 
defects in 10 patients (6%). During a median follow-up of 12.8 years (range 0-15), 109 
(66%) patients died (all-cause mortality), of which 67 (40%) were due to cardiac causes. 
A total of 5 (3%) patients experienced a non-fatal MI. HTx recipients with a normal stress 
99mTc-tetrofosmin SPECT MPI had a significantly better prognosis as compared with 
those with an abnormal study, up to 5 years after the initial test. The presence of a re-
versible perfusion defect was a significant predictor of all-cause mortality, cardiac mor-
tality and major cardiac events, during the entire follow-up period.
Conclusions. Stress 99mTc-tetrofosmin SPECT MPI provides valuable prognostic informa-
tion for the prediction of long-term outcome in HTx recipients. Patients with a normal 
stress 99mTc-tetrofosmin SPECT MPI have a significantly better prognosis as compared 
with those with an abnormal study, up to 5 years after initial testing. 
Key Words: heart transplant recipients - cardiac allograft vasculopathy - long-term 
prognosis - stress SPECT MPI.
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INTRODUCTION
Heart transplantation (HTx) is the first choice in treatment of patients with end-stage 
heart failure. However, the long-term outcome is severely hampered by cardiac allog-
raft vasculopathy (CAV), occurring up to 50% of the patients1 and is associated with an 
increased risk of mortality.2-4 As a result of denervation of the transplanted heart, angina 
symptoms resulting from CAV are usually absent and the first clinical sign of CAV can be 
heart failure, myocardial infarction, ventricular arrhythmias or sudden death.5 Serial cor-
onary angiography (CA) and intravascular ultrasound (IVUS) are used for the evaluation 
of significant CAV.6 However these are invasive procedures with inherent risks. Among 
noninvasive modalities, myocardial perfusion imaging (MPI) using single-photon emis-
sion computed tomography (SPECT) is a useful clinical tool to evaluate CAV. Several 
studies have demonstrated that stress SPECT MPI has diagnostic and prognostic value 
in HTx recipients.7-9 However, information regarding the value of stress SPECT MPI for 
the prediction of long-term cardiovascular outcomes in HTx recipients is limited.10 Due 
to the relatively high prevalence and progression of CAV in these patients1, the long-
term prognostic value of stress SPECT MPI may be impaired. This creates uncertainties 
in the clinical management of these patients. Accordingly, the aim of this study was to 
assess the long-term prognostic value of stress SPECT MPI for predicting all-cause mor-
tality and cardiac events in HTx recipients.  
METHODS
Patient Selection
The study population consisted of 166 HTx recipients who underwent exercise (n=65) 
or dobutamine (n=101) stress SPECT MPI >2 years after transplantation at the Thorax-
center, Rotterdam, The Netherlands between 1992 and 1998. The current study details 
the results of a long-term follow-up from a prior study at our center.11 The reason for 
performing this repeat follow-up study was to assess the long-term (>10 year) prog-
nostic value of stress SPECT MPI in HTx recipients. Follow-up was successful in all of the 
166 patients. The Hospital Ethics Committee approved the study protocol. The study 
was conducted according to the Helsinki Declaration.12 All patients consented to par-
ticipation in this study. Before the stress test, a structured interview and clinical history 
were obtained, including assessment of cardiac risk factors. Hypertension was defined 
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as a blood pressure of ≥140/90 mmHg or treatment with antihypertensive medication. 
Diabetes mellitus was defined as a fasting glucose level of ≥7.8 mmol/L or the need for 
insulin or oral hypoglycemic agents. Hypercholesterolemia was defined as a total cho-
lesterol of ≥6.4 mmol/L or treatment with lipid-lowering medication.
Stress Test Protocol
The exercise or dobutamine stress test was performed as described previously.11 
Dobutamine was infused through an antecubital vein starting at a dose of 5 µg/kg/min, 
followed by 10 µg/kg/min at 3 minutes, increasing by 10 µg/kg/min every 3 minutes to 
a maximum of 40 µg/kg/min. Atropine was given to patients who could not achieve the 
85% age-predicted heart rate at the maximal dobutamine dose. The test was discon-
tinued if severe chest pain, ST-segment depression >2 mm, significant arrhythmia, hy-
pertension (blood pressure ≥240/120 mm Hg), systolic blood pressure decrease of >40 
mm Hg, or any intolerable side effect regarded as being due to dobutamine occurred 
during the test. Metoprolol (1 to 5 mg) was used intravenously to reverse the adverse ef-
fects of dobutamine/atropine. An ischemic electrocardiographic response was defined 
as ≥1 mm horizontal or downsloping ST-segment depression persisting 80ms after the 
J point. Symptom-limited upright bicycle ergometry test was performed with stepwise 
increments of 20 W each minute. Blood pressure and electrocardiographic recordings 
were performed as described for the dobutamine stress test. 
SPECT MPI
The single-photon emission computed tomography protocol has been described pre-
viously.11 An intravenous dose of 370 MBq of technetium-99m tetrofosmin (Myoview, 
Amersham, Buckinghamshire, United Kingdom) was administered approximately 1 
minute before the termination of the dobutamine or the exercise stress test.13 Acquisi-
tion of images began 1 hour after the stress test. For studies taken at rest, images were 
acquired 24 hours after the stress study, 1 hour after injection of 370 MBq of tetrofos-
min. Image acquisition was performed with a triple-head gamma camera system (Picker 
Prism 3000 XP, Cleveland, Ohio). For each study, 6 oblique (short-axis) slices from the 
apex to the base and 3 sagittal (vertical long-axis) slices from the septum to the lateral 
wall were defined. Each of the 6 short-axis slices was divided into 8 equal segments. 
The interpretation of the scan was semiquantitatively performed by visual analysis as-
sisted by circumferential profiles analysis. Stress and resting tomographic views were 
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reviewed side by side by an experienced observer who was unaware of the patients’ 
clinical data. A reversible perfusion defect was defined as a perfusion defect on a stress 
image that partially or completely resolved at rest in ≥2 contiguous segments or slices. 
A fixed perfusion defect was defined as a perfusion defect on stress images in ≥2 contig-
uous segments or slices that persisted on images taken at rest. An abnormal study was 
considered in the presence of a fixed and/or reversible perfusion defect. To assess the 
severity of perfusion abnormalities, the left ventricular myocardium was divided into 6 
segments: anterior, inferior, septal anterior, septal posterior, posterolateral, and apical. 
Each of the 6 major left ventricular segments was scored using a 4-grade method (0 = 
normal, 1 = mildly reduced, 2 = moderately reduced, and 3 = severely reduced or absent 
uptake). The perfusion defect scores were derived by the summation of the score of the 
six myocardial segments at rest (summed rest score (SRS) and at stress (summed stress 
score (SSS)). The difference was expressed as the summed difference score (SDS). These 
indices were expressed as the percent of the total myocardium (% myocardium) as de-
scribed previously.14
Patient Follow-up
Follow-up data were obtained in 2011. The patient’s survival status was determined by 
contacting the municipal civil registry. For those patients who were still alive, follow-up 
was obtained by contacting the patients, the patient’s general practitioner or by review-
ing hospital records. The date of the last review or consultation was used to calculate 
the follow-up time. Endpoints were all-cause mortality, cardiac mortality and nonfatal 
myocardial infarction (MI). Causes of death were obtained from the Central Bureau of 
Statistics Netherlands (www.cbs.nl). Cardiac mortality was defined as death caused by 
acute myocardial infarction, significant cardiac arrhythmias, or refractory congestive 
heart failure. Sudden death occurring without another explanation was included as car-
diac mortality. Major cardiac events were defined as cardiac mortality and nonfatal MI.
Statistical Analysis
All statistical analyses were performed using SPSS, version 21.0 (Chicago, IL, USA). Contin-
uous data were expressed as mean value ± SD and compared using the Students t-test. 
Categorical data were expressed in numbers and percentages and compared using 
the Chi-squared test. The probability of survival was calculated using the Kaplan-Meier 
method. Survival curves were compared using the log-rank test. To investigate whether 
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SPECT MPI has additional prognostic value in predicting long-term prognosis, the Cox 
proportional-hazards regression model was used. To determine the perishable date of 
SPECT MPI in HTx recipients, the Kaplan-Meier method and multivariable analysis was 
repeated at 1, 2, 3, and so on years of follow-up. The risk of a variable was expressed as 
a hazard ratio (HR) with a corresponding 95% confidence interval (CI). The incremental 
value of SPECT MPI over the clinical variables in the prediction of the endpoints of in-
terest was performed according to 4 models. In Model 1, the presence of an abnormal 
SPECT MPI was entered. In Model 2 the presence of a reversible or fixed defect was en-
tered. In Model 3, the variable entered was SDS and in Model 4, the variable entered was 
SSS. The predictive value of each model was expressed using the Chi-squared statistic. 
Table 1. Clinical characteristics
(n=166)
Age (years) 54 ± 10
BMI (kg/m2) 26.4 ± 4.5
Male gender 140 (84%)
Hypertension 117 (71%)
Diabetes mellitus 18 (11%)
Smoking 24 (15%)
Hypercholesterolemia 70 (42%)
Beta blocker use 23 (14%)
Target heart rate reached* 117 (70%)
Data are presented as mean ± SD or  numbers (percentages). 
BMI = body mass index. 
*Target heart rate reached is defined as 85% of the maximal predicted heart rate.
RESULTS
Clinical Characteristics
The baseline characteristics of the 166 patients are presented in Table 1. Mean age was 
54 ±10 years and 84% of the patients were male.  SPECT MPI findings were normal in 
111 patients (67%). Myocardial perfusion abnormalities were fixed in 28 patients (17%), 
partially reversible in 17 patients (10%) and completely reversible defects in 10 patients 
(6%). During the stress test there was a significant increase in heart rate (93±13 to 140±17 
beats per minute, p <0.001) and systolic blood pressure (146±18 to 166±30 mmHg, 
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p<0.001). Two patients developed atypical and 1 patient developed typical chest pain 
during the stress test. A total of 117 patients (70%) reached the target heart rate (85% 
of the age-predicted maximal exercise heart rate). Minor side effects of dobutamine 
administration included nausea in 3 patients (3%), flushing in 4 patients (4%), headache 
in 5 patients (5%), and chills in 3 patients (3%). Non-sustained ventricular tachycardia 
during exercise stress testing was observed in 1 patient. 
Figure 1. Kaplan-Meier event-free survival for all-cause mortality in HTx recipients with normal 
and abnormal SPECT MPI.
Figure 2. Kaplan-Meier event-free survival for cardiac mortality in HTx recipients with normal and 
abnormal SPECT MPI.
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Figure 3. Kaplan-Meier event-free survival for major cardiac events in HTx recipients with normal 
and abnormal SPECT MPI.
Patient Outcomes
During a median follow-up time of 12.8 years (range 0-15), 109 (66%) patients died (all-
cause mortality), of which 67 (40%) were due to cardiac causes. A total of 5 (3%) patients 
experienced a non-fatal myocardial infarction. Kaplan-Meier survival curves for all-cause 
mortality, cardiac mortality and major cardiac events are presented in Figures 1, 2 and 
3, respectively. The survival curves showed a significantly better long-term survival of 
HTx recipients with a normal SPECT MPI compared to patients with an abnormal SPECT 
MPI (annualized all-cause mortality rate: 9 vs 15% at 3 years, 8 vs 11% at 6 years and 6 vs 
9% at 9 years, overall P=0.011, Figure 1). To determine up to what time point during fol-
low-up the stress SPECT MPI holds its prognostic value, the log-rank test was performed 
at subsequent follow-up durations (Figure 1, 2 and 3). This analysis demonstrated that 
HTx recipients with a normal stress SPECT MPI had a significantly better prognosis as 
compared with those with an abnormal stress SPECT MPI, up to 5 years after the test 
is performed for all-cause mortality. The “warranty period” of stress SPECT MPI in HTx 
recipients for the prediction of all-cause mortality was approximately 5 years. According 
to cardiac mortality and major cardiac events, patients with a normal stress SPECT MPI 
had a significantly better prognosis as compared with patients with an abnormal stress 
SPECT MPI, up to 2 years and 1 year after testing, respectively. 
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Predictors of long-term outcome
Univariable and multivariable predictors of all-cause mortality are summarized in Ta-
ble 2. Based on the maximum length of prognostic value at Kaplan-Meier analysis the 
univariable and multivariable predictors are shown at a follow-up duration of 5 years. 
Univariable predictors of all-cause mortality were age, gender and an abnormal SPECT 
MPI (Table 2). The presence of a reversible perfusion defect and SDS were univariable 
predictors of cardiac mortality and an abnormal SPECT MPI, the presence of a reversible 
perfusion defect and SDS were univariable predictors of  major cardiac events. 
Multivariable analyses were performed to determine the maximum length of the prog-
nostic value, or the “warranty period”, of SPECT MPI. An abnormal SPECT MPI and the 
presence of a reversible defect provided incremental prognostic information for the 
prediction all-cause mortality up to a follow-up duration of 5 years, (Table 2). An ab-
normal SPECT MPI provided incremental prognostic information for the prediction of 
cardiac mortality up to a follow-up duration of 2 years. The presence of a reversible de-
fect was a significant predictor of cardiac mortality during the entire follow-up. For the 
prediction of major cardiac events, an abnormal SPECT MPI was a significant predictor 
up to 2 years of follow-up. The presence of a reversible defect was a significant predictor 
of major cardiac events during the entire follow-up duration. 
DISCUSSION
The present study evaluated the long-term prognostic value of SPECT MPI in HTx re-
cipients, examining the incremental prognostic value of SPECT MPI over clinical and 
stress test variables. The results show that stress SPECT MPI provides useful prognostic 
information for the prediction of cardiovascular outcomes in HTx recipients. HTx recipi-
ents with a normal stress SPECT MPI have a significantly better prognosis as compared 
to patients with an abnormal stress SPECT MPI, up to 5-years after initial testing. After 
that period, the risk of adverse events does not significantly differ in patients with both 
normal and abnormal SPECT MPI. So, the warranty period of stress SPECT MPI in HTx 
recipients is approximately 5 years. As the multivariable analysis showed, the presence 
of a reversible perfusion defect was a significant predictor of all-cause mortality and 
cardiac events during the entire follow-up. 
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SPECT MPI using either exercise or pharmacological stress is a commonly used non-
invasive technique for the evaluation of known or suspected CAD. The prognostic 
value of dobutamine stress SPECT MPI has been firmly established in non-transplant 
patients.15-17 However, there are scarce data regarding the utility of stress SPECT MPI for 
the prediction of long-term outcome in HTx recipients.10 This creates uncertainties in 
the prognostic stratification in these patients. Previous studies have reported the short- 
and medium term outcome of SPECT MPI in HTx recipients.10, 11, 18-20 Bacal et al.18 studied 
39 patients (mean age was 48±13 years) after orthotopic HTx who underwent thallium 
SPECT MPI for the detection of CAV. In this small number of patients, thallium SPECT 
MPI was not a significant predictor of outcomes during the 4-year follow-up period. 
Hacker et al.8 followed 77 HTx recipients with a mean age of 53±11 years (80% males) 
who underwent dobutamine stress technetium SPECT MPI. Cardiac events (revascular-
ization, heart failure, death and/or MI) occurred in 32% of the patients with an abnor-
mal SPECT MPI during a mean follow-up duration of 22 months. The authors concluded 
that dobutamine stress SPECT MPI identified patients at risk for future cardiac events. 
A normal SPECT MPI was associated with a negative predictive value of 98% for car-
diac events. Wu et al.20 investigated the value of dobutamine thallium SPECT to detect 
CAV and to predict clinical events in 47 HTx recipients. Mean age was 51.6±11.7 years 
(79% males). During a mean follow-up period of 40 months, a total of 6 patients died, of 
whom 4 patients due to cardiac causes. Only large reversible perfusion defects on stress 
SPECT MPI were associated with a significant risk of cardiac mortality (p=0.002).  In 110 
HTx recipients, Manrique et al.19 investigated the diagnostic and prognostic value of 
thallium and technetium SPECT MPI. Mean age was 53±13 years (85% males). During a 
mean follow-up period of 4.8 years, a stress perfusion defect >3 segments was an inde-
pendent predictor of cardiac mortality. SPECT MPI identified patients with a high risk of 
poor outcome. As the authors noted, a normal SPECT MPI might alleviate the need for 
coronary angiography. More recently, Wenning et al.10 studied 104 HTx recipients (mean 
age 50.7±12.2 years and 85% were male) who underwent 99mTc-tetrofosmin SPECT. Dur-
ing a mean follow-up of 9.4 years no difference was observed according to all-cause 
mortality between patients with homogeneous perfusion (defined as <10% decreased 
tracer uptake of the myocardial segments) and inhomogeneous perfusion (defined as 
decreased tracer uptake of >20% of the myocardial segments). 
The present study differs from these previous studies for several reasons. First, these 
previous studies used thallium-20118, 20, 99mTc-tetrofosmin10, 99mTc-sestamibi8 or both 
thallium-201 and 99mTc-sestamibi19 as radionuclide tracers. The current study evaluated 
SPECT MPI in HTx recipients using 99mTc-tetrofosmin as a tracer, which is currently the 
13671_HJBoiten_BW.indd   97 01-08-16   10:28
98
C
ha
p
te
r 6
Prediction of long-term (>10 year) cardiovascular outcomes in heart transplant recipients: value of stress | 99
most commonly used tracer along with 99mTc-sestamibi.21 Second, some of these pre-
vious studies8, 19, 20 concluded that SPECT MPI provides prognostic information for the 
prediction of cardiac events in HTx recipients, whereas other studies found no signifi-
cant prognostic information.10, 18 The latter studies10, 18 had a relatively longer follow-up 
period (9.4 and 4 years respectively). All these previous studies have not investigated 
the warranty period of stress SPECT MPI in HTx recipients. The current study found that 
the warranty period of stress SPECT MPI in HTx recipients is approximately 5 years. Third, 
the range of follow-up duration in these previous studies varies between 22 months 
and 9.4 years. In a previous study of our center11 the same population was studied with 
a median follow-up of 2.5 years. The current study evaluated the long-term outcome 
(>10years) after SPECT MPI in HTx recipients and extends the conclusions drawn from 
these previous studies. The results shows that SPECT MPI has a limited predictive value 
of adverse outcome in these patients. HTx recipients with a normal stress SPECT MPI 
have a relatively favorable outcome compared to patients with an abnormal stress 
SPECT MPI up to 5 years after the test. This is in line with previous studies indicating that 
a warranty period exists after a normal SPECT MPI.22 CAV apparently is a chronic pro-
gressive disease in HTx recipients that may alter the risk status of the patients over time. 
In the annually published report of the International Society for Heart and Lung 
Transplantation (ISHLT) the median survival of HTx recipients between 1982 and 2013 
was 11 years.23 Due to advanced immunosuppressive therapy and prevention and treat-
ment of opportunistic infections survival of patients after HTx has improved.23, 24 The 
median survival in the present study was 12.8 years. Patients in the current study were 
enrolled form 1992. So, according to the median survival the present findings are com-
parable with this ISHLT report. 
Due to denervation of the allograft and incomplete reinnervation, angina pectoris 
is usually lacking in HTx recipients. First clinical signs of CAV in HTx recipients include 
heart failure, silent MI and sudden death.25 As a consequence, screening for early de-
tection of CAV is required. Therefore, in most centers HTx recipients undergo an annual 
or biannual coronary angiography during the first five years following cardiac trans-
plantation to search for asymptomatic CAV.26 However, many HTx recipients with clinical 
cardiac events do not have significant disease on coronary angiography.27 Moreover, 
invasive coronary angiography has inherent risks. As a result, there is a continuing need 
for noninvasive techniques to evaluate CAV. The results of the current study shows that 
dobutamine stress SPECT MPI is useful is risk stratifying HTx recipients up to 5 years after 
testing.  
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The ISHLT guidelines for the care of HTx recipients28 state that SPECT MPI may be use-
ful for diagnosing CAV in HTx recipients unable to undergo invasive evaluation. The 
sensitivity of dobutamine SPECT MPI has been reported to be 90% and a specificity of 
60% in this patient cohort. The negative predictive value of the test was found to be 
79%.13 During the first five years after transplantation annual coronary angiography is 
recommended. In patients with kidney disease, dobutamine stress echocardiography 
(DSE) represents an alternative. After five years following transplantation, DSE is recom-
mended annually in low-risk patients (defined as normal coronary angiography at five 
years). For patients with poor echocardiographic quality dobutamine stress SPECT MPI 
is a feasible alternative.28 The present findings support the frequent monitoring of HTx 
recipients and the role of noninvasive dobutamine stress SPECT MPI in order to avoid 
coronary angiography when possible. In our center, we conduct in the first and fourth 
year after HTx a coronary angiogram, followed by yearly SPECT MPI from the sixth year 
after HTx. CAG was performed after the fourth year if the annual perfusion scintigraphy 
was positive, or when ischemia was suspected due to cardiac markers or clinical, elec-
trocardiographic or echocardiographic criteria. 
This study has some limitations. First, at time of SPECT MPI gated SPECT was not 
routinely performed. Functional data derived from gated SPECT provides additional 
information. Second, no attenuation or scatter correction was used for SPECT MPI. Ap-
plication of attenuation or scatter correction may have further improved the accuracy 
of this technique. Third, CAV is a major complication associated with higher mortality 
in HTx recipients.3 In the present study, angiographic data to examine CAV were not 
evaluated. However, the endpoints used in this study are cardiac events related to CAV. 
In conclusion, stress 99mTc-tetrofosmin SPECT MPI provides valuable prognostic in-
formation for the prediction of outcome in HTx recipients. Patients with a normal stress 
99mTc-tetrofosmin SPECT MPI have a significantly better prognosis as compared with 
those with an abnormal study, up to 5 years after initial testing.
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ABSTRACT
Myocardial perfusion single-photon emission computed tomography is a routine tech-
nique for the evaluation of coronary artery disease. However, information on the very 
long term prognostic value of dobutamine stress single-photon emission computed 
tomographic myocardial perfusion imaging (MPI) in patients with limited exercise ca-
pacity is scarce. The aim of this study was to assess the long-term prognostic value of 
dobutamine stress technetium-99m (99mTc)sestamibi MPI in these patients. The study 
population consisted of a high-risk cohort of 531 consecutive patients with limited ex-
ercise capacity who underwent dobutamine stress 99mTc-sestamibi MPI for the assess-
ment of known or suspected coronary artery disease. Follow-up was successful in 528 
patients. Because of early revascularization, 55 patients were excluded. The present data 
are based on 473 patients. The end points were all-cause mortality, cardiac death, non-
fatal myocardial infarction, and late (>60 days) coronary revascularization. Kaplan-Meier 
survival curves were performed and univariate and multivariate analyses were per-
formed to identify predictors of very long term outcome. The mean age of the patients 
was 61±12 years, and 58% were men. Abnormal results (defined as the presence of re-
versible or fixed defects) were observed in 312 patients (66%). During a mean follow-up 
period of 11.3±6.7 years, 287 patients (61%) died (all-cause mortality), of whom 125 
(26%) died due to cardiac causes. Nonfatal myocardial infarction occurred in 59 patients 
(12%). Late coronary revascularization was performed in 61 patients (13%). Univariate 
predictors of major cardiac events included age, male gender, previous infarction, dia-
betes mellitus, history of angina, heart failure, ST-segment changes, abnormal results on 
99mTc-sestamibi scan, reversible defect, fixed defect, summed rest score, and summed 
stress score. Multivariate analysis identified abnormal results on MPI as a strong inde-
pendent predictor of major adverse cardiac events. 
In conclusion, in patients with limited exercise capacity, dobutamine stress 99mTc-sesta-
mibi single-photon emission computed tomography provides incremental prognostic 
information in addition to clinical and stress test parameters for the prediction of very 
long term outcomes.
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INTRODUCTION
Globally, coronary artery disease (CAD) remains a major cause of both morbidity and 
mortality.1 Myocardial perfusion imaging with single-photon emission computed to-
mography (SPECT) is a routine technique for the diagnosis and risk stratification of pa-
tients with known or suspected CAD.2,3 Technetium-99m (99mTc)-sestamibi is a widely 
used tracer in conjunction with SPECT. In patients with limited exercise capacity be-
cause of disease complications such as stroke, neuropathy, or peripheral vascular dis-
ease, dobutamine stress testing represents an achievable alternative to vasodilator 
stress. The prognostic value of dobutamine stress 99mTc-sestamibi myocardial perfusion 
imaging (MPI) for detecting CAD has been well documented in various patient groups 
for short- and medium-term follow-up.4-10 However, very long term prognostic data on 
dobutamine stress 99mTc-sestamibi MPI are lacking. Accordingly, the aim of this study 
was to determine the long-term prognostic value of dobutamine stress 99mTc-sestamibi 
MPI for the prediction of adverse events in a high-risk cohort of patients with limited 
exercise capacity.
METHODS
The study population consisted of 531 consecutive patients with limited exercise ca-
pacity as previously described.10 These patients were referred between 1990 and 1995 
for dobutamine stress 99mTc-sestamibi SPECT for the evaluation of suspected or known 
CAD. Follow-up was successful in 528 (99.4%) of 531 patients. All patients gave informed 
consent before testing and the local ethics committee approved the study protocol. Fif-
ty-five patients underwent early coronary revascularization 60 days after MPI and were 
excluded from analysis (35 with coronary arterial bypass graft placement and 20 with 
percutaneous transluminal coronary angioplasty). This exclusion was based on the pre-
viously published data indicating that referral to coronary revascularization in the first 
60 days after nuclear testing tends to be based on the results of the scan and that refer-
ral to revascularization >60 days after nuclear testing tends to be based on the worsen-
ing of the patient’s clinical status.11 In September 2012 follow-up was performed. As a 
result, the current data are based on 473 patients with complete follow-up. A structured 
interview and clinical history were obtained, including assessment of cardiac risk fac-
tors, prior to dobutamine stress testing. A blood pressure ≥140/90 mmHg, or treatment 
with antihypertensive medication was considered as hypertension. A fasting glucose 
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level ≥7.8 mmol/L or the need for insulin or oral hypoglycemic agents was considered as 
diabetes mellitus. Hypercholesterolemia was defined as a total cholesterol ≥6.4 mmol/L, 
or treatment with lipid-lowering medication.
The stress testing protocol after dobutamine administration has been described 
previously.10 Dobutamine  was injected intravenously up to a maximum dose of 40 µg/
kg/min. If the test end point was not reached at a maximum dose of dobutamine, up 
to 1 mg of atropine  was administered intravenously. During stress testing, blood pres-
sure, heart rate and electrocardiographic leads were continuously monitored. Test end 
points were achievement of target heart rate (85% of maximum age and sex-predicted 
heart rate); horizontal or downsloping ST segment depression of > 2 mm at an interval 
of 80 msec after the J point, as compared with the baseline measurement; ST segment 
elevation >1 mm in patients without previous myocardial infarction (MI); severe angina; 
systolic blood pressure decrease >40 mm Hg, as compared with the baseline measure-
ment; blood pressure >240/120 mm Hg; or clinically important cardiac arrhythmias. To 
overcome the side effects of dobutamine, metoprolol was intravenously administered 
and atropine was used if the effects did not revert spontaneously after termination of 
dobutamine infusion. 
A dose of 370 MBq of 99mTc-sestamibi (Cardiolite; Bristol-Myers Squibb Pharma Bel-
gium, Brussels, Belgium) was administered intravenously approximately 1 minute be-
fore cessation of the stress test. For studies performed with the patient at rest, 370 MBq 
of sestamibi was injected ≥24 hours after stress testing. Images were acquired with a 
Gammasonics singlehead Rota camera (Orbiter; Siemens, Iselin, NJ) without atten-
uation or scatter correction, by using a low-energy all-purpose collimator. Thirty-two 
projections were obtained over a 180° arc, from left posterior oblique to right anterior 
oblique, with an acquisition time of 45 seconds per projection. Data were collected in 
a 64x64 matrix (word mode), and images were reconstructed by using a filtered back-
projection algorithm and a ramp reconstruction filter. Transverse images were recon-
structed by using a software package (SPETS; Nuclear Diagnostics, Hägersten, Sweden). 
From the 3-dimensional data, oblique (shortaxis) and sagittal (vertical long-axis) images 
obtained perpendicular and parallel to the long axis, respectively, were reconstructed. 
The scan interpretation were semiquantitatively performed by using visual analysis as-
sisted by circumferential profile analysis. Profile curves 2.5 SDs below normal perfusion 
were considered abnormal. Images obtained at stress and rest were reviewed side by 
side at a computer display with consensus reading by 2 experienced observers who 
were blind to the patients’ clinical data. A third observer was consulted in case of dis-
agreement of a decision. In this study, the original interpretations of the images were 
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used. A reversible perfusion defect was defined as a perfusion defect on stress images 
that partially or completely resolved at rest on ≥2 contiguous segments or sections. A 
fixed perfusion defect was defined as a perfusion defect on stress images on ≥2 contig-
uous segments or sections which persist on rest images. The presence of a fixed and/
or reversible perfusion defect was considered as an abnormal scan. Each myocardial 
segment was assigned a score from 0 to 3 (0=normal, 1=slightly reduced, 2=moder-
ately reduced, 3=severely induced / absent uptake). Summed stress score (SSS) and 
summed rest score were calculated by the summation of the scores at stress and rest, 
respectively. The SDS (summed difference score) was considered representative of the 
extent and severity of myocardial ischemia. Standard 17-segment-based scores were 
calculated and converted into % per myocardium by dividing the summed scores by the 
maximum potential score, and multiplying by 100.12
Clinical outcome data were obtained by contacting the patient, the patients’ gen-
eral practitioners, civil registries and reviewing hospital records. Endpoints were car-
diac death, nonfatal myocardial infarction and late coronary revascularization. Cardiac 
death included death caused by acute myocardial infarction, significant arrhythmias 
or refractory congestive heart failure and sudden death occurring without another ex-
planation. Using the participants’ civil registration number, we linked individual level 
information to differentiate cardiac death from non-cardiac death.  Hard cardiac events 
were defined as the occurrence of cardiac death or nonfatal myocardial infarction. The 
combined endpoint of cardiac death, nonfatal myocardial infarction or coronary revas-
cularization was considered as major adverse cardiac events (MACE). 
IBM SPSS statistical software version 22 was used to analyze data. Variables were 
expressed as mean±SD or number. Continuous data were compared by using the Stu-
dent’s t test. Chi-square tests were used to compare categorical variables. Univariable 
and multivariable Cox proportional hazards regression models were used to identify 
independent predictors of late cardiac events. Variables were selected in a stepwise for-
ward selection manner with entry and retention set with a p value of 0.05. A variable’s 
risk was expressed as a hazard ratio with a corresponding 95% confidence interval. The 
incremental value of abnormal myocardial perfusion scintigraphy over the clinical vari-
ables was determined using a multivariate analysis according to 3 models. In model 1, 
an abnormal scan was entered as a scanning variable. In model 2, the scanning vari-
ables, the presence of a fixed and reversible defect, were entered. In model 3, SRS and 
SDS were entered. The probability of survival was calculated by using the Kaplan-Meier 
method, and survival curves were compared by using the log-rank test. A p < 0.05 was 
considered statistically significant.
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RESULTS
The clinical data of the 473 patients are presented in Table 1. During dobutamine stress 
testing there was a significant increase in heart rate (from 70±14 to 136±17 beats/min, 
p<.001) and systolic blood pressure (140±23 mmHg to 146±31 mmHg, P < .001). The 
highest dobutamine dose was 10 µg/kg/min in 3 (1%), 20 µg/kg/min in 15 (3%), 30 µg/
kg/min  in 66 (14%), and 40 µg/kg/min in 389 patients (82%). Atropine was added in 196 
(41%) patients. Patients who received ß-blockers (120 [65%] of 185) more frequently 
received atropine compared to those who not received ß-blockers (76 [26%] of 288, 
P<.001). Test findings were inconclusive (failure to achieve target heart rate in the ab-
sence of perfusion abnormalities) in 43 (9%) patients. These patients were not excluded 
from the prognostic data reported. There were no patients who experienced myocardial 
infarction or ventricular fibrillation. Side effects were atrial fibrillation in five patients 
(1%), short ventricular tachycardia (<10 complexes) in 19 patients (4%), severe hypoten-
sion (decrease in systolic pressure >40 mm Hg) and severe hypertension (blood pres-
sure >240/130 mm Hg) both in 3 patients (0.6%). As minor side effects nausea occurred 
in 18 (4%), chills in 22 (5%), and headache in 29 patients (6%).
Table 1. Baseline characteristics
n = 473 Number (%)
Age (years) 61 ± 12
Men 273 (58%)
Hypertension 214 (45%)
Diabetes mellitus 69 (15%)
Smoker 122 (26%)
Hypercholesterolemia 116 (25%)
Congestive heart failure 84 (18%)
Beta blocker therapy 185 (39%)
Prior myocardial infarction 210 (44%)
Previous coronary artery bypass graft 92 (19%)
Previous percutaneous coronary intervention 75 (16%)
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The results of SPECT were abnormal in 312 patients (66%). Perfusion abnormalities 
were reversible defects in 72 patients (15%). Most of the patients had fixed defects (126 
patients [27%]), suggesting that they had myocardial damage. One hundred fourteen 
patients (24%) had fixed and reversible (or partially reversible) defects. During a mean 
follow-up period of 11.3±6.7 years, 287 patients (61%) died (all-cause mortality), of 
whom 125 (26%) died due to cardiac causes. Nonfatal myocardial infarction occurred 
in 59 patients (12%). Late (>60 days) coronary revascularization was performed in 61 
patients (13%). 
Figure 1. Kaplan-Meier survival curves for all-cause mortality. Survival was significantly different 
between patients with normal and those with abnormal results on dobutamine stress 99mTc-sesta-
mibi myocardial perfusion SPECT.
Figure 2. Kaplan-Meier survival curves for cardiac death. Survival was significantly different be-
tween patients with normal and those with abnormal results on dobutamine stress 99mTc-sesta-
mibi myocardial perfusion SPECT.
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Figure 3. Kaplan-Meier survival curves for hard cardiac events (cardiac death and non fatal myo-
cardial infarction). Event-free survival was significantly different between patients with normal 
and those with abnormal results on dobutamine stress 99mTc-sestamibi myocardial perfusion 
SPECT.
Figure 4. Kaplan-Meier survival curves for major adverse cardiac events (cardiac death, non fatal 
myocardial infarction or revascularization). Event-free survival was significantly different between 
patients with normal and those with abnormal results on dobutamine stress 99mTc-sestamibi myo-
cardial perfusion SPECT.
Kaplan-Meier curves in relation to all-cause mortality, cardiac death, hard cardiac 
events, and major adverse cardiac events are presented in Figures 1 to 4. The survival 
curves demonstrate that patients with normal results on SPECT had a relatively low risk 
for all-cause mortality, cardiac death, hard cardiac events, and major cardiac events 
compared with those with abnormal findings. The annualized event rates for cardiac 
death for patients with normal results on SPECT were significantly lower than for those 
with abnormal findings (1.2% vs 2.5%, p <0.001). The annualized hard cardiac event rate 
for patients with normal results on SPECT was also significantly lower (3.4%) compared 
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with patients with abnormal findings ([4.3%] p <0.001). The annualized rates for major 
adverse cardiac events were 2.2% in patients with normal results on SPECT and 4.4% in 
those with abnormal findings (p <0.001).
Univariate predictors of major cardiac events were age, male gender, prior myocar-
dial infarction, diabetes mellitus, history of angina and congestive heart failure, ST-seg-
ment changes, abnormal results on SPECT, presence of reversible defect, presence of 
fixed defect, summed rest score, and summed stress score (Table 2). Multivariate anal-
ysis demonstrated that clinical data (age, male gender, previous myocardial infarction, 
and congestive heart failure) were predictors of very long-term outcomes. Model 1 
demonstrates that abnormal results on SPECT were an independent predictor of major 
adverse cardiac events (hazard ratio 1.53, 95% confidence interval 1.02 to 2.30).
Table 2. Predictors of major cardiac events (cardiac death, nonfatal infarction or revasculariza-
tion) at univariable and multivariable analysis
Variable Univariable HR (CI)
Multivariable HR (CI)
Clinical data Model I Model II Model III
   Age* 1.02 (1.01-1.04) 1.03 (1.01-1.04) 1.03 (1.01-1.04) 1.03 (1.01-1.04) 1.03 (1.01-1.04)
   Men 1.93 (1.43-2.60) 1.69 (1.22-2.34) 1.61 (1.16-2.23) 1.69 (1.22-2.34) 1.69 (1.22-2.34)
   Prior MI 2.19 (1.65-2.91) 1.63 (1.20-2.22) 1.46 (1.05-2.03) 1.63 (1.20-2.22) 1.63 (1.20-2.22)
   Diabetes mellitus 1.70 (1.19-2.43) P=0.13 P=0.11 P=0.13 P=0.13
   Hypertension P=0.95 P=0.30 P=0.49 P=0.30 P=0.30
   Hypercholesterolemia P=0.22 P=0.34 P=0.30 P=0.34 P=0.34
   Angina pectoris 1.38 (1.02-1.87) P=0.66 P=0.43 P=0.66 P=0.66
   Smoking P=0.84 P=0.76 P=0.76 P=0.76 P=0.76
   Congestive HF 2.37 (1.71-3.29) 1.83 (1.30-2.58) 1.75 (1.24-2.48) 1.83 (1.30-2.58) 1.83 (1.30-2.58)
Stress test results
   Typical angina pectoris P=0.17 P=0.20 P=0.21 P=0.20 P=0.20
   ST-segment changes 1.60 (1.19-2.14) 1.35 (1.00-1.82) P=0.09 1.35 (1.00-1.82) 1.35 (1.00-1.82)
Scan parameters
   Abnormal scan 2.40 (1.70-3.39) - 1.53 (1.02-2.30) - -
   Reversible defect 1.42 (1.07-1.87) - - P=0.38 -
   Fixed defect 1.49 (1.11-1.99) - - P=0.64 -
   SRS** 1.50 (1.23-1.95) - - - P=0.55
   SDS** P=0.35 - - - P=0.97
   SSS** 1.03 (1.01-1.04) - - - -
Statistically significant predictors of outcome are presented as hazard ratio (confidence interval), of all other variables 
the p-value is presented.
- = not included in the model; * = per unit increment; ** = per % myocardium increment; SDS = summed difference 
score; SRS = summed rest score; SSS = summed stress score.
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DISCUSSION
We assessed the very long term prognostic value of dobutamine stress 99mTc-sestamibi 
MPI for the prediction of hard and major adverse cardiac events in a high-risk cohort 
of 473 patients with limited exercise capacity. Patients with normal results on stress 
99mTc-sestamibi MPI had significantly better outcomes compared with those with ab-
normal findings. The survival curves continued to diverge during the follow-up period 
of 11.3±6.7 years, indicating a maintained prognostic value of 99mTc-sestamibi SPECT. 
Patients with abnormal results on SPECT had a significantly increased cardiac event rate 
compared with patients with normal findings. This study showed relatively high event 
rates during the long-term follow-up period. The high event rates may be explained 
by several factors. First, the study population was relatively old, and 44% had previous 
myocardial infarctions. Second, all patients underwent dobutamine stress testing be-
cause they were unable to perform adequate exercise tests. The inability to perform 
an exercise test is an adverse prognostic marker. Third, during the long-term follow-up 
period, which was complete for nearly all patients, natural progression of CAD may have 
occurred.
Previous studies have examined the prognostic value of dobutamine stress SPECT 
for the prediction of cardiac events during short- to medium-term follow-up.4-10 It has 
been demonstrated that normal results on stress SPECT are associated with a benign 
prognosis. Shaw and Iskandrian13 performed a pooled analysis of 19 studies including 
39,173 patients and reported a hard event rate of 0.6%/year for patients with normal 
results on SPECT. Senior et al4 followed 61 patients who underwent coronary arteriog-
raphy for the evaluation of chest pain who underwent dobutamine stress 99mTc-sesta-
mibi single-photon emission computed tomographic MPI for a median follow-up of 19 
months. The investigators concluded that dobutamine stress 99mTc-sestamibi SPECT is 
a good predictor of future cardiac events. Calnon et al5 studied 308 patients who un-
derwent dobutamine stress 99mTc-sestamibi SPECT. During a mean time period of 1.9 
years, cardiac event rates were significantly higher in patients with abnormal results on 
SPECT (10%/year) compared with those with normal findings (2.3%/year). Navare et al8 
described 1,367 patients with known or suspected CAD who underwent dobutamine 
stress 99mTc-sestamibi SPECT. During an average follow-up period of 25 months, the an-
nualized cardiac event rate was 2.5% in patients with normal results on SPECT and 7.6% 
in those with abnormal findings. 
In the present study, the incremental prognostic value of dobutamine stress SPECT 
over clinical data was maintained during the long-term follow-up period in patients 
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with limited exercise capacity. Previously, we reported 8-year follow-up in these 473 
patients who underwent dobutamine stress 99mTc-sestamibi SPECT.10 In that study, pa-
tients with normal results on SPECT maintained a low event rate during entire follow-up 
period. In the present very long term follow-up study, patients with normal results on 
SPECT maintained favorable event-free survival in contrast to patients with abnormal 
findings, who had significantly higher annualized event rates. So, the findings of the 
present study extend the conclusions drawn from the previous prognostic studies on 
short-, medium-, and long-term follow-up.4-10
This study had some limitations. First, 9% of the patients failed to achieve target 
heart rates in the absence of perfusion abnormalities. The prognostic value could have 
been higher if ß blockers were ceased before stress testing. Second, no attenuation or 
scatter correction was used for SPECT. Recent data indicate that attenuation correction 
may improve risk stratification.14,15 Third, previous data have demonstrated the superi-
ority of gated SPECT to nongated SPECT in outcome prediction. However, in this study, 
we analyzed the prognostic value of nongated SPECT. Fourth, recent data16 showed that 
stress MPI underestimates the extent of CAD, possibly because of the low myocardial 
extraction relative to hyperemic flow changes of the 99mTc-labeled tracers and the fact 
that only relative perfusion is evaluated.17 This evidence could have influenced the out-
come of this study. Finally, in this study, 1 of the end points was major adverse cardiac 
events, a composite end point of cardiac death, nonfatal myocardial infarction, and cor-
onary revascularization. The use of a composite end point has inherent limitations.
13671_HJBoiten_BW.indd   113 01-08-16   10:28
114
C
ha
p
te
r 7
Eleven-year prognostic value of dobutamine stress 99mTc-sestamibi myocardial perfusion imaging in patients | 115
REFERENCES
1.  Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner 
S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P, Steinberger J, 
Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Sub-
committee. Heart disease and stroke statistics 2008 update: a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:25-146.
2.  Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease and determining prognosis 
by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res 
2011;4:416-424.
3.  Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, Pohost GM, Williams KA. ACCF/
ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a 
report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Amer-
ican Society of Nuclear Cardiology, the American College of Radiology, the American heart Association, 
the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the 
Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol 
2009;53:2201-2229.
4.  Senior R, Raval U, Lahiri A. Prognostic value of stress dobutamine technetium-99m sestamibi single-pho-
ton emission computed tomography (SPECT) in patients with suspected coronary artery disease. Am J 
Cardiol 1996;78:1092-1096.
5.  Calnon DA, McGrath PD, Doss AL, Harrell FE Jr, Watson DD, Beller GA. Prognostic value of dobutamine 
stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion 
imaging: stratification of a high-risk population. J Am Coll Cardiol 2001;38:1511-1517.
6.  De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion de-
fects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission com-
puted tomography in symptomatic patients with diabetes mellitus and no known coronary artery dis-
ease. Am J Cardiol 2002;90:827-832.
7.  Lima RS, De Lorenzo A, Pantoja MR, Siqueira A. Incremental prognostic value of myocardial perfusion 
99m-technetium-sestamibi SPECT in the elderly. Int J Cardiol 2004;93:137-143. 
8.  Navare SM, Katten D, Johnson LL, Mather JF, Fowler MS, Ahlberg AW, Miele N, Heller GV. Risk stratification 
with electrocardiographicgated dobutamine stress technetium-99m sestamibi single-photon emission 
tomographic imaging. J Am Coll Cardiol 2006;47:781-788.
9.  Schepis T, Benz K, Haldemann A, Kaufmann PA, Schmidhauser C, Frelingsdorf J. Prognostic value of stress-
gated 99m-technetium SPECT myocardial perfusion imaging: risk stratification of patients with multives-
sel coronary artery disease and prior coronary revascularization. J Nucl Cardiol 2013;20:755-762.
10.  Schinkel AFL, Elhendy A, Van Domburg RT, Bax JJ, Valkema R, Roelandt JR, Poldermans D. Long-term 
prognostic value of dobutamine stress 99mTc-Sestamibi SPECT: single-center experience with 8-year fol-
low-up. Radiology 2002;225:701- 706.
11.  Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Exercise myocardial 
perfusion SPECT in patients without known coronary artery disease: Incremental prognostic value and 
use in risk stratification. Circulation 1996;93:905-914.
12.  Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival ben-
efit associated with revascularization compared with medical therapy in patients with no prior coronary 
artery disease undergoing stress myocardial perfusion single photon emission computed tomography. 
Circulation 2003;107:2900-2906.
13.  Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004;11:171-
185.
14.  Baghdasarian SB, Noble GL, Ahlberg AW, Katten D, Heller GV. Risk stratification with attenuation corrected 
stress Tc-99m sestamibi SPECT myocardial perfusion imaging in the absence of ECG-gating due to ar-
rhythmias. J Nucl Cardiol 2009;16:533-539.
15.  Pazhenkottil AP, Ghadri JR, Nkoulou RN, Wolfrum M, Buechel RR, Küest SM, Husmann L, Herzog BA, Gaem-
perli O, Kaufmann PA. Improved outcome prediction by SPECT myocardial perfusion imaging after CT 
attenuation correction. J Nucl Med 2011;52:196-200.
13671_HJBoiten_BW.indd   114 01-08-16   10:28
Eleven-year prognostic value of dobutamine stress 99mTc-sestamibi myocardial perfusion imaging in patients | 115
16.  Beller GA. Underestimation of coronary artery disease with SPECT perfusion imaging. J Nucl Cardiol 
2008;15:151-153.
17.  Bourque JM, Beller GA. Stress myocardial perfusion imaging for assessing prognosis: an update. JACC 
Cardiovasc Imag 2011;4:1305-1319
13671_HJBoiten_BW.indd   115 01-08-16   10:28
13671_HJBoiten_BW.indd   116 01-08-16   10:28
Chapter 8
Prediction of 14-year cardiovascular outcomes 
by dobutamine stress 99mTc-tetrofosmin 
myocardial perfusion SPECT in elderly patients 
unable to perform exercise testing
Hendrik J. Boiten*
Stefan Roest*
Ron T. van Domburg
Roelf Valkema
Felix Zijlstra
Arend F.L. Schinkel
Journal of Nuclear Cardiology. 2016. *in press*
*Both authors contributed equally to this work. 
13671_HJBoiten_BW.indd   117 01-08-16   10:28
118
C
ha
p
te
r 8
Prediction of 14-year cardiovascular outcomes by dobutamine stress 99mTc-tetrofosmin myocardial perfusion | 119
ABSTRACT
Background. Dobutamine stress myocardial perfusion imaging (MPI) is a useful alter-
native for the evaluation of coronary artery disease (CAD) in elderly patients who are 
unable to perform an exercise stress test. However, data on the long-term prognostic 
value of stress MPI in elderly patients are lacking. Therefore, this study evaluated the 
long-term prognostic value of dobutamine stress MPI in elderly patients unable to per-
form an exercise test. 
Methods. The study population consisted of 247 elderly patients (mean age 71±5 years) 
who underwent dobutamine stress single-photon emission computed tomography 
(SPECT) MPI. An abnormal SPECT study was defined as the presence of fixed and/or 
reversible perfusion defects.  A summed stress score (SSS) was obtained to estimate the 
extent and severity of perfusion defects. End points during follow-up were all-cause 
mortality, cardiac mortality, and nonfatal myocardial infarction (MI).  
Results. During a median follow-up of 14 years (range 12-16), 168 (68%) patients died 
(all-cause mortality), of which 56 (23%) were due to cardiac causes. Nonfatal MI oc-
curred in 19 (8%) patients. Kaplan-Meier survival curves showed that MPI provided op-
timal risk stratification in patients with normal and abnormal MPI. Multivariable analysis 
identified an abnormal MPI as a strong significant predictor of all-cause mortality and 
cardiac events. A multivariable analysis also revealed that a reversible defect and SSS 
were strong long-term predictors of cardiac mortality and hard cardiac events. 
Conclusion. Dobutamine stress 99mTc-tetrofosmin SPECT provides incremental prog-
nostic information for the prediction of long-term cardiovascular outcomes in elderly 
patients, unable to perform exercise testing. Dobutamine stress MPI is useful in risk clas-
sifying elderly patients. 
Key Words: 99mTc-Tetrofosmin – dobutamine stress SPECT – long-term prognosis – cor-
onary artery disease – elderly
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INTRODUCTION
Globally, deaths from cardiovascular disease are increasing, in particular due to the 
aging population.  Between 1990 and 2013,  the number of global deaths caused by 
cardiovascular disease has increased by 41%.1 As a result of ageing of the population, 
more elderly patients are referred for diagnostic and prognostic cardiac evaluation. 
Stress myocardial perfusion imaging (MPI) is useful for the evaluation of coronary artery 
disease (CAD) in elderly patients.2,3 A substantial proportion of the elderly population is 
unable to perform exercise stress testing, because of conditions such as degenerative 
joint disease or peripheral vascular disease. In such patients vasodilator stress testing 
is a useful alternative. In patients who also have contraindications for vasodilator stress 
(such as reactive airway disease or high-grade atrioventricular nodal block) dobutamine 
stress MPI is recommended according to the ASNC imaging guidelines for nuclear car-
diology.4 The prognostic value of MPI using single-photon emission computed tomog-
raphy (SPECT) with 99mTc-tetrofosmin or 99mTc-sestamibi as tracers in elderly patients has 
been studied previously for short and medium term follow-up.5-9 Long-term prognostic 
data to define the role of  stress MPI for the prediction of cardiovascular outcomes in 
elderly patients are lacking. The long-term prognostic value of stress MPI in elderly pa-
tients may be impaired because of their increased underlying cardiovascular risk. Ac-
cordingly, the aim of the current study was to assess the long-term prognostic value of 
dobutamine stress 99mTc-tetrofosmin MPI for the prediction of cardiovascular outcomes 
in elderly patients unable to perform exercise testing. 
METHODS
Study Population
This study included 272 consecutive elderly patients ≥65 years old who were unable 
to perform exercise testing and underwent dobutamine stress 99mTc-tetrofosmin SPECT 
for the evaluation of suspected or known CAD. The age cut-off was based on previous 
studies.3,10 The current study is a continuation of a previous study8 in which this popu-
lation of elderly patients was evaluated with a mean follow-up of 3 years  The reason to 
perform the current follow-up study was to assess the very long-term prognostic value 
of dobutamine stress SPECT. At the time of this study dobutamine was the preferred 
stressor in our nuclear cardiology laboratory and the mode of stress was determined by 
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the referring physician. Patients were enrolled between 1995 and 1999. Follow-up was 
complete for 270 (99.3%) patients. Twenty-three patients underwent coronary artery 
revascularization < 60 days of the test and were excluded. This exclusion was based on 
previous data indicating that in the first 60 days after the test, referral for coronary artery 
revascularization tends to be based on the SPECT results, whereas > 60 days after test-
ing, referral for coronary artery revascularization tends to be based on deterioration of 
the patient’s clinical status.11 The present data are based on 247 patients. This study was 
not subject to the Dutch Medical Research Involving Human Subjects Act.12,13 Therefore, 
approval from the local research ethics committee to conduct this retrospective study 
was not required at the time of enrollment. Moreover, the study was conducted accord-
ing to the Declaration of Helsinki.14 All patients consented participation in this study.
Clinical Data
Before dobutamine stress testing, a structured clinical interview and history were ac-
quired and cardiac risk factors were assessed. Hypertension was defined as a blood 
pressure ≥140/90 mmHg or treatment with antihypertensive medication. Diabetes 
mellitus was defined as a fasting glucose level ≥7.8 mmol/L or the need for insulin or 
oral hypoglycemic medication. Hypercholesterolemia was defined as a total cholesterol 
≥6.4 mmol/L or treatment with lipid-lowering medication.
Dobutamine Stress Testing
Dobutamine stress testing was performed according to a standard protocol as previ-
ously reported.15 Dobutamine was infused through the antecubital vein, starting at a 
dose of 10 µg/kg/min for 3 min and increasing by 10 µg/kg/min every 3 min up to a 
maximum dose of 40 µg/kg/min. If the test endpoint was not reached at a dobutamine 
dose of 40 µg/kg/min, atropine (up to 1mg) was given intravenously. Blood pressure 
and heart rate were monitored and electrocardiography was recorded constantly. Test 
endpoints were: achievement of target heart rate (85% of maximum age- and sex-pre-
dicted heart rate); horizontal or downsloping ST-segment depression >2 mm at an 
interval of 80 ms after the J-point, compared with baseline; ST-segment elevation >1 
mm in patients without previous myocardial infarction; severe angina; a systolic blood 
pressure fall >40 mm Hg, compared with baseline; blood pressure >240/120 mmHg; or 
significant cardiac arrhythmias. Metoprolol was available to reverse the adverse effects 
of dobutamine/atropine.
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99mTc-Tetrofosmin SPECT MPI
Approximately 1 min before the termination of the dobutamine stress test, an intrave-
nous dose of 370 MBq of 99mTc-tetrofosmin was administered. For resting studies, 370 
MBq of tetrofosmin were injected at least 24 h after the stress study. Image acquisition 
was performed with a triple-head γ-camera system (Prism 3000 XP; Picker International). 
For each study, 6 oblique (short axis) slices from the apex to the base and 3 sagittal 
(vertical long axis) slices were defined. Each of the 6 short-axis slices was divided into 8 
equal segments. Owing to corresponding of the septal part of the 2 basal slices to the fi-
brous portion of the interventricular septum and normally exhibits reduced uptake, this 
region was excluded from analysis. As a consequence, 47 segments were identified (3 
long axis and 44 short axis). The interpretation of the scan was semiquantitatively per-
formed by visual analysis and aided by circumferential profiles analysis. Stress and rest 
tomographic views were reviewed side by side by an experienced observer who had no 
knowledge of the patients’ clinical information. A reversible perfusion defect was de-
fined as a perfusion defect on the exercise images that partially or completely resolved 
at rest in ≥2 contiguous segments or slices. A fixed perfusion defect was defined as a 
perfusion defect on exercise images in 2 or more contiguous segments or slices, which 
persists on rest images. The presence of a fixed and / or reversible perfusion defect was 
considered as an abnormal study. Each myocardial segment was assigned a score from 
0 to 3 (0 = normal; 1 = slightly reduced; 2 = moderately reduced; 3 = severely reduced 
or absent uptake). Summed stress score (SSS) was calculated by the summation of the 
scores of the myocardial segments at stress. Standard 17-segment based scores were 
calculated and converted to percent of the total myocardium  (% myocardium) by di-
viding the summed scores by the maximum potential score, and multiplying by 100.16 
Patient follow-up
Collection of follow-up data was performed by contacting the patient, the patient’s 
general practitioner, civil registries, and review of hospital records. Follow-up data were 
obtained in September 2011. The date of the last review or consultation was used to de-
termine follow-up time. Endpoints were all-cause mortality, cardiac mortality and non-
fatal myocardial infarction (MI). Causes of death were obtained from the Central Bureau 
of Statistics Netherlands. Cardiac mortality was defined as death caused by myocardial 
infarction, significant cardiac arrhythmias, or refractory congestive heart failure. Sudden 
death occurring without another explanation was included as cardiac mortality. Nonfa-
tal MI was described by chest pain complaints, a rise and fall of cardiac marker levels and 
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typical changes on electrocardiography (ECG). Hard cardiac events were defined as the 
occurrence of cardiac mortality or nonfatal MI.
Statistical Analysis
Continuous data were expressed as mean±SD, and percentages were rounded. Contin-
uous variables were compared using the Student t test for unpaired samples. The cu-
mulative survival was calculated using the Kaplan Meier method. Survival curves were 
compared with the log-rank test. Univariable and multivariable Cox proportional haz-
ards regression models were used to investigate the additional value of MPI parameters. 
The risk of a variable was expressed as a hazard ratio (HR) with a corresponding 95% 
confidence interval. First, clinical data were selected in a stepwise forward selection 
manner with entry and retention set of a significance level of 0.05. Significant clinical 
data were then used for including in the multivariable analysis. The incremental value of 
MPI over the clinical variables in the prediction of events was determined according to 
3 models. In Model 1, the incremental value of abnormal MPI over the clinical data and 
stress test information was assessed. In Model 2, the presence of a fixed or reversible 
defect was entered. In Model 3 the SSS was entered. A p-value < 0.05 was considered 
statistically significant. 
Table 1. Clinical characteristics. 
N = 247 Number (%)
Age (years) 71 ± 5
Male gender 129 (52)
Hypertension 102 (41)
Smoking 52 (21)
Hypercholesterolemia 74 (30)
Heart failure 40 (16)
LBBB 15 (6)
Beta-blockers 105 (43)
Calcium channel blockers 111 (45)
ACE-inhibitors 69 (28)
Diuretics 66 (27)
Nitroglycerine 101 (41)
Digoxine 23 (9)
History of myocardial infarction 89 (36)
History of coronary angioplasty 44 (18)
History of coronary artery bypass surgery                     48 (19)
ACE = angiotensin-converting-enzyme 
LBBB = left bundle branch block
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RESULTS
Demographics and Stress Test Results
Clinical characteristics of the 247 patients are presented in Table 1. The mean age of the 
study population was 71±5 years (range 65 and 86 years). A total of 48 patients (19%) 
were >75 years old. Dobutamine stress increased heart rate significantly (from 72±15 to 
128±16 bpm, P < 0.001) and increased systolic blood pressure modestly (from 140±23 
to 146±31 mm Hg, P < 0.001). The highest dobutamine dose was 10 µg/kg/min in 1 
patient (0.4%), 20 µg/kg/min in 44 (18%), 30 µg/kg/min in 45 (18%), and 40 µg/kg/min 
in 157 (64%). In 88 patients (36%), atropine was added. Patients who were using beta 
blocker therapy during the dobutamine stress test more frequently received atropine 
than did patients not receiving beta blocker therapy (54 of 105, 51%, vs. 34 of 142, 24%, 
P < 0.001). A total of 181 patients (73%) achieved target heart rate. Achieving the target 
heart rate was not significantly different between patients with and without cardiac 
mortality (79 vs 72%, P=0.96) and hard cardiac events (75 vs 80%, P=0.42). 
Side effects that occurred during dobutamine stress testing were generally self-lim-
iting. These included atrial fibrillation in 5 patients (2%), short ventricular tachycardia 
(<10 complexes) in 6 patients (2.4%), and severe hypotension (decrease in systolic 
blood pressure >40 mm Hg) in 4 patients (1.6%). Minor side effects included nausea in 
4 (1.6%), flushing in 3 (1.2%), and headache in 13 (5.3%). No patient experienced a myo-
cardial infarction or ventricular fibrillation during or immediately after the stress test.
Figure 1. Kaplan-Meier survival curves for all-cause mortality. 
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Figure 2. Kaplan-Meier survival curves for cardiac mortality. 
Figure 3. Kaplan-Meier survival curves for hard cardiac events (cardiac mortality and nonfatal 
myocardial infarction). 
SPECT Results and Outcome
Abnormal MPI was detected in 140 patients (57%). A total of 20 (8%) patients showed 
reversible defects, 67 patients (27%) showed a fixed defect, while 53 patients (22%) 
showed both fixed and reversible defects. During a median follow up of 14 years (range 
12-16), 168 (68%) patients died (all-cause mortality), of which 56 (23%) were due to car-
diac causes. Nonfatal MI occurred in 19 (8%) patients. The Kaplan-Meier survival curves 
are shown in Figures 1- 3. The survival curves show that a normal MPI was associated 
with relatively low risk of all-cause mortality, cardiac mortality and hard cardiac events. 
Conversely, elderly patients with an abnormal MPI had a significantly increased risk of 
all-cause mortality and cardiac events. 
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Table 2. Univariable and multivariable predictors of all-cause mortality.
Multivariable
Variable Univariable Clinical data Model 1 Model 2 Model 3
   Men 1.84 (1.30-2.61) 1.69 (1.19-2.38) P=0.12 P=0.07 1.49 (1.02-2.19)
   Prior MI P=0.50 P=0.43 - - -
   Diabetes mellitus 1.58 (1.05-2.38) P=0.07 - - -
   Hypertension 1.88 (1.34-2.64) 1.76 (1.25-2.46) 1.83 (1.29-2.60) 1.77 (1.25-2.51) 1.72 (1.21-2.45)
   Hypercholesterolemia P=0.97 P=0.66 - - -
   Smoking 1.49 (1.01-2.20) P=0.06 - - -
   Heart failure 1.99 (1.32-3.01) 1.75 (1.16-2.65) 1.72 (1.13-2.61) 1.69 (1.10-2.57) 1.63 (1.06-2.51)
Stress test results
   Angina pectoris P=0.46 - P=0.19. P=0.28 P=0.24
   ST-segment changes P=0.41 - P=0.99 P=0.80 P=0.75
   Peak heart rate P=0.37 - P=0.19 P=0.60 P=0.64
Scan parameters
   Abnormal MPI 1.76 (1.24-2.51) - 1.79 (1.22-2.64) - -
   Fixed defect P=0.14 - - P=0.09 -
   Reversible defect 1.76 (1.24-2.51) - - 1.64 (1.13-2.38) -
   SSS* 1.20 (1.11-1.38) - - - P=0.11
Statistically significant predictors of outcome are presented as hazard ratio (confidence interval), of all other variables 
the P-value is presented. -, not included in the model.* per % myocardium increment. 
MI = myocardial infarction. MPI = myocardial perfusion imaging. SSS = summed stress score.
Predictors of Outcome
Univariable and multivariable predictors of all-cause mortality, cardiac mortality and 
hard cardiac events are shown in Tables 2, 3 and 4 respectively. Among clinical vari-
ables, men, diabetes mellitus, hypertension, smoking and heart failure were significant 
predictors of all-cause mortality (Table 2). Diabetes mellitus, hypertension and heart 
failure were significant predictors of cardiac mortality (Table 3). Men, diabetes melli-
tus, hypertension and heart failure were univariable predictors of hard cardiac events 
(Table 4). A multivariable model revealed that an abnormal MPI and reversible defect 
were powerful predictors of all-cause mortality (Table 2). A multivariable analysis also 
revealed that an abnormal MPI,  reversible defect and SSS provided incremental prog-
nostic information over that provided by clinical and stress test variables for predicting 
cardiac mortality (Table 3) and hard cardiac events (Table 4). 
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Table 3. Univariable and multivariable predictors of cardiac mortality.
Multivariable
Variable Univariable Clinical data Model 1 Model 2 Model 3
   Men P=0.16 P=0.31 - - -
   Prior MI P=0.51 P=0.63 - - -
   Diabetes mellitus 2.17 (1.22-3.89) P=0.07 - - -
   Hypertension 2.55 (1.19-4.37) 2.43 (1.42-4.17) 2.41 (1.40-4.17) 2.28 (1.32-3.92) 2.32 (1.34-4.01)
   Hypercholesterolemia P=0.47 P=0.60 - - -
   Smoking P=0.25 P=0.09 - - -
   Heart failure 2.79 (1.56-4.99) 2.60 (1.45-4.65) 2.39 (1.32-4.30) 2.37 (1.31-4.27) 2.18 (1.19-4.00)
Stress test results
   Angina pectoris P=0.93 - P=0.65 P=0.88 P=0.70
   ST-segment changes P=0.50 - P=0.53 P=0.76 P=0.76
   Peak heart rate P=0.87 - P=0.99 P=0.90 P=0.96
Scan parameters
   Abnormal MPI 2.23 (1.26-3.94) - 2.49 (1.39-4.48) - -
   Fixed defect P=0.34 - - P=0.17 -
   Reversible defect 1.94 (1.14-3.33) - - 1.92 (1.11-3.33) -
   SSS* 1.11 (1.00-1.12) - - - 1.09 (1.01-1.18)
Statistically significant predictors of outcome are presented as hazard ratio (confidence interval), of all other variables 
the P-value is presented. -, not included in the model. * per % myocardium increment. 
MI = myocardial infarction. MPI = myocardial perfusion imaging. SSS = summed stress score.
DISCUSSION
The main finding of this study is that dobutamine stress 99mTc-tetrofosmin SPECT pro-
vides long-term prognostic information for the prediction of all-cause mortality and 
cardiac events in elderly patients unable to perform exercise testing. Dobutamine stress 
MPI provided prognostic information incremental to clinical data and stress test results. 
Patients with a normal MPI had a relatively favorable long-term prognosis, in contrast 
to patients with an abnormal study who had a significantly increased risk of all-cause 
mortality and cardiac events. An abnormal MPI and the scan result reversible perfusion 
defect were strong significant predictors of all-cause mortality and cardiac events. Also 
the SSS was a strong long-term predictors of cardiac mortality and hard cardiac events. 
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Table 4. Univariable and multivariable predictors of hard cardiac events. 
Multivariable
Variable Univariable Clinical data Model 1 Model 2 Model 3
   Men 1.70 (1.04-2.76) P=0.07 - - -
   Prior MI P=0.73 P=0.83 - - -
   Diabetes mellitus 1.76 (1.01-3.05) P=0.19 - - -
   Hypertension 2.31 (1.42-3.75) 2.24 (1.38-3.63) 2.16 (1.32-3.54) 2.02 (1.24-3.31) 2.00 (1.22-3.29)
   Hypercholester-
olemia
P=0.43 P=0.59 - - -
   Smoking P=0.28 P=0.14 - - -
   Heart failure 2.24 (1.29-3.89) 2.11 (1.22-3.67) 1.90 (1.09-3.32) 1.90 (1.09-3.31) P=0.05
Stress test results
   Angina pectoris P=0.77 - P=0.47 P=0.65 P=0.54
   ST-segment changes P=0.48 - P=0.31 P=0.91 P=0.95
   Peak heart rate P=0.41 - P=0.31 P=0.44 P=0.34
Scan parameters
   Abnormal MPI 2.32 (1.38-3.91) - 2.72 (1.59-4.66) - -
   Fixed defect P=0.13 - - P=0.05 -
   Reversible defect 1.79 (1.10-2.93) - - 1.85 (1.12-3.04) -
   SSS* 1.11 (1.01-1.12) - - - 1.09 (1.02-1.18)
Statistically significant predictors of outcome are presented as hazard ratio (confidence interval), of all other variables 
the P-value is presented. -, not included in the model. * per % myocardium increment. 
MI = myocardial infarction. MPI = myocardial perfusion imaging. SSS = summed stress score.
In the ageing population, CAD is a major health problem and cardiovascular disease 
is still the leading cause of mortality in elderly patients.17 As a result, elderly patients with 
known or suspected CAD are frequently encountered in a nuclear cardiology practice. 
Stress MPI is an important noninvasive technique for the evaluation of patients with 
known or suspected CAD. Elderly patients are frequently unable to perform an exer-
cise test due to several comorbidities (e.g. obstructive lung disease, peripheral vascular 
disease). Dobutamine stress MPI is a feasible alternative for these patients and also for 
patients who have contraindications for vasodilator (dipyridamole or adenosine) stress 
testing.3 The present study included 247 elderly patients unable to perform an exercise 
test. We found that dobutamine stress MPI had incremental long-term prognostic value 
additional to clinical variables and stress test results. 
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Several previous studies have evaluated the short or medium-term prognostic value 
of SPECT MPI in elderly patients with a follow-up duration ranging from 4.4 to 6.4 years. 
Steingart et al.5 studied 578 patients aged 65 years or older (mean age 70.7±4.4 years) 
who underwent exercise MPI. A multivariable model revealed that age, male gender, 
limitation of exercise tolerance and the number of ischemic segments on MPI were sig-
nificant predictors of death or MI. The authors concluded that an abnormal MPI pro-
vided prognostic information during the 4 year follow-up period. Valeti et al.6 followed 
247 elderly patients with a mean age of 77 years undergoing exercise thallium-201 MPI. 
A total of 42 (17%) patients had a history of CAD (history of MI) compared to 89 (36%) 
patients in the current study. Also, patients without a previous percutaneous coronary 
intervention (PCI) or coronary artery bypass graft surgery (CABG) were included, while 
in the current study 37% had a previous coronary revascularization. In that study of 
Valeti et al.6, exercise MPI was accurate for risk stratification in elderly patients who were 
able to exercise during a median follow-up duration of 6.4 years.
A total of 3 studies have assessed the short to medium-term cardiovascular outcomes 
after pharmacological stress MPI. De Winter et al.7 studied cardiovascular outcomes 
in a total of 294 patients (median age 78 years) that underwent exercise (n=103) or 
dipyridamole stress (n=191) 99mTc-tetrofosmin SPECT. During a median follow-up of 
25.9 months 47 deaths occurred of whom 27 cardiac deaths. The summed rest score 
(SRS) was a significant predictor of all-cause mortality and cardiac mortality. The authors 
concluded that gated SPECT provided independent and incremental information above 
clinical and perfusion SPECT. Nagao et al.9 studied the outcomes of 175 patients (aged 
75–85 years) that underwent exercise (n=49) or vasodilator stress (n=126) 99mTc-sesta-
mibi SPECT. A total of 64 patients (37%) had a previous MI or coronary revascularization 
compared to 73% in the current study. During a mean follow-up of 3.4 years, SPECT 
results were predictive of cardiovascular outcomes. The results of those studies are in 
line with the current study, in that elderly patients with a normal SPECT have a relative 
good prognosis compared to patients with an abnormal SPECT who have an increased 
risk of all-cause mortality and cardiac events. In those studies the maximum follow-up 
duration was limited to 6.4 years. Schinkel et al.8 has described the 3.3 year cardiovas-
cular outcomes of this cohort of 247 elderly patients. Dobutamine stress 99mTc-tetro-
fosmin SPECT provided incremental prognostic information for the prediction of total 
mortality and cardiac events. However, no data exists on the long-term prognostic value 
of pharmacologic stress MPI. The present study extends the observations drawn from 
these previous studies and demonstrates the long-term prognostic value of dobuta-
mine stress MPI in elderly patients.
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More recently, Kwon et al.18 studied a Medicare cohort including 5994 patients (age 
>65years) who underwent exercise (n=1664) or adenosine stress (n=4280) MPI. During a 
median follow-up of 2.4 years, the ability to exercise and the number of METs achieved 
were predictive of outcome. Amongst patients who were able to perform an exercise 
test,  MPI did not provide incremental significant risk stratification. Several factors may 
explain why the findings in the study of  Kwon et al. differ from the current findings. 
First, the current study included only patients who were unable to perform an exercise 
test, which is a marker of an adverse outcome in itself. Second, this study included a sub-
stantial number of patients with known CAD (36% had a previous myocardial infarction, 
18% had previous coronary angioplasty, and 19% had previous coronary bypass sur-
gery). Third, this study had a long-term and nearly complete follow-up which included 
information from the patient, the general practitioner, civil registries, and review of hos-
pital records.  The all-cause mortality rate during the long-term follow-up in the current 
study was 68% versus 6% during the median follow-up of 2.4 years in the previous study 
of Kwon et al. All these factors could have influenced the outcomes.
SPECT MPI is routinely used in conjunction with both 99mTc-sestamibi and 99mTc-tetro-
fosmin as tracers. The latter is used in the current study. Multiple studies have reported 
the prognostic value of 99mTc-sestamibi during dobutamine19, 20 or adenosine induced 
stress21 in various patient subsets. In a previous study of our center, 473 patients were 
studied who underwent dobutamine stress 99mTc-sestamibi SPECT and were followed 
for a mean follow-up of 819 and 11 years.20 A total of 44% of the patients had a previous 
MI and 35% had undergone previous revascularization. A total of 312 (66%) patients had 
abnormal MPI, defined as the presence of a fixed and/or reversible perfusion defect. The 
incremental prognostic value of dobutamine stress SPECT was maintained during a fol-
low-up duration of 11 years. In the present long-term follow-up study, elderly patients 
with normal MPI had a maintained favorable event-free survival compared to patients 
with abnormal MPI. So, the present findings are consistent with these previous studies. 
Also, Hachamovitch et al.21 studied 684 elderly patients (mean age 80.3±4.1 years) who 
underwent 99mTc-sestamibi SPECT MPI. Of the 684 patients, 26% had a previous MI and 
30% had prior revascularization. During a mean follow-up of 6 years, cardiac mortality 
rates were significant lower in patients with normal MPI in contrast to patients with 
abnormal MPI. The findings of the current study extends the conclusions drawn from 
this study. 
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Study limitations
The current study has limitations. First, all elderly patients were unable to perform exer-
cise testing reflecting a high-risk population. The results of these study may not be ap-
plicable to other elderly patients. Second, no attenuation or scatter correction was used 
for MPI. Application of attenuation and scatter correction may have further improved 
the accuracy of SPECT MPI.22 Third, due to the elderly patient population studied, the 
current results may not be extrapolated to younger patients. Fourth, gated SPECT was 
not routinely used in our laboratory at the time that this study was performed. Pre-
vious data have demonstrated the superiority of gated SPECT to non-gated SPECT in 
outcome prediction. However, in the current study, we analyzed the prognostic value 
of non-gated SPECT. Finally, the examined patient population was relatively small. This 
could have influenced the outcome of the multivariable analysis. 
CONCLUSIONS
Dobutamine- stress MPI provides incremental prognostic information for the prediction 
of all-cause mortality and cardiac events on the long-term outcome in elderly patients 
unable to perform exercise testing. Patients with a normal MPI have a favorable progno-
sis of long-term outcome, in contrast to patients with an abnormal study. 
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ABSTRACT
QRS duration is of prognostic relevance in patients with several underlying heart dis-
eases. Short-term data also shows the prognostic value of QRS duration in lower-risk 
groups of patients. The aim of this study was to investigate the long-term prognostic 
value of QRS duration in patients with known or suspected coronary artery disease 
(CAD). The study cohort consisted of 512 patients (308 men, mean age 60±11 years) 
who underwent myocardial perfusion imaging (MPI) for the evaluation of suspected or 
known CAD. Follow-up data were collected to assess the prognostic value of QRS du-
ration, alongside clinical characteristics and MPI results. Endpoints were cardiac death 
and cardiac death or non-fatal myocardial infarction (MI). During a mean follow-up of 
8.6±5.2 years, 290 patients (60%) died, with 139 deaths (27%) attributable to cardiac 
causes. Non-fatal MI occurred in 28 patients (6%), and 127 patients (25%) underwent late 
coronary revascularization (>3mo). Patients with QRS duration <120ms had annualized 
cardiac death rates and cardiac death/non-fatal MI rates of 2.2% and 2.3%, respectively, 
compared to 4.1% and 4.4% in patients with QRS duration ≥120ms. Multivariate models 
identified QRS duration ≥120ms as an independent predictor of both endpoints, on top 
of clinical characteristics and MPI results. 
In conclusion, QRS duration ≥120ms is an independent predictor of cardiac death and 
cardiac death/non-fatal MI, after adjustment for clinical characteristics and MPI results.
Key Words: Coronary artery disease; Prognosis; QRS duration. 
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INTRODUCTION
Surface 12-lead electrocardiography (ECG) is a valuable tool for diagnostics due to its 
low cost and simplicity. These features also make ECG an attractive option for cardiac 
risk stratification. Several studies have reported the prognostic value of QRS duration 
in patients with heart failure, left ventricular systolic dysfunction and acute coronary 
syndrome.1-5 Recent studies have also aimed to assess the prognostic value of QRS du-
ration in the general population and in groups of lower risk patients on a short term.9,10 
As long-term data in the latter group of patients is lacking, this study aims to assess 
the long-term prognostic value of QRS duration in patients with known or suspected 
coronary artery disease (CAD) referred for myocardial perfusion imaging (MPI) for the 
evaluation of myocardial ischemia.
METHODS
The study population consisted of 512 patients (308 men, 204 women, mean age 60±11 
years) referred for MPI for evaluation of suspected or known CAD. This study was not 
subject to the Dutch Medical Research Involving Human Subjects Act. Therefore, ap-
proval from the local research ethics committee to conduct this prospective follow-up 
study was not required at the time of enrollment. Moreover, the study was conducted 
according to the Helsinki Declaration.11 All patients consented participation in this 
study. An assessment of cardiac risk factors was done prior to the procedure. Hyperten-
sion was defined as a blood pressure ≥140/90 mmHg or treatment with antihyperten-
sive medication. Diabetes mellitus was defined as a fasting glucose level of ≥140mg/dL 
or the need for insulin or oral hypoglycemic agents. Hypercholesterolemia was defined 
as a total cholesterol level ≥200mg/dL or treatment with lipid-lowering medication. 
Twelve-lead surface electrocardiography was performed at rest, digitally stored, 
and analyzed by an experienced observer unaware of any other data, according to rec-
ommendations for the standardization and interpretation of the electrocardiogram.12 
QRS duration was calculated as the mean of 3 separate measurements using a dedi-
cated computer system (Mortara Instruments, Bilthoven, The Netherlands). The dobuta-
mine-atropine stress test was performed as described.13 Dobutamine was injected 
intravenously up to a maximum dose of 40 µg/kg/min. If the test end point was not 
reached at a maximum dose of dobutamine, up to 1 mg of atropine was administered 
intravenously. Blood pressure, heart rate, and electrocardiography were monitored 
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continuously. Test endpoints were achievement of target heart rate (85% of maximum 
age-predicted heart rate), horizontal or downsloping ST-segment depression of >2 mm, 
ST-segment elevation of >1 mm in patients without previous myocardial infarction (MI), 
severe angina, systolic blood pressure fall of >40 mmHg, blood pressure of >240/120 
mm Hg, or significant arrhythmia. Metoprolol was available to reverse the (side) effects 
of dobutamine or atropine if these did not revert spontaneously after termination of 
dobutamine infusion. 
Approximately 1 min before the termination of the stress test, an intravenous dose of 
370 MBq technetium-99m-tetrofosmin was administered. For resting studies, 370 MBq 
tetrofosmin were injected at least 24 h after the stress study. Image acquisition was per-
formed with a triple-head gamma-camera system (Prism 3000 XP; Picker International, 
Cleveland, OH). For each study, 6 oblique (short axis) slices from the apex to the base 
and 3 sagittal (vertical long axis) slices were defined. Each of the 6 short-axis slices was 
divided into 8 equal segments. The septal part of the 2 basal slices was excluded from 
analysis because this region corresponds to the fibrous portion of the interventricular 
septum and normally exhibits reduced uptake. The interpretation of the MPI was per-
formed semi-quantitatively by visual analysis assisted by analysis of the circumferential 
profiles. Stress and rest tomographic views were reviewed side by side by an experi-
enced observer who was unaware of each patient’s clinical data. A reversible perfusion 
defect was defined as a perfusion defect on stress images that partially or completely 
resolved at rest in ≥2 contiguous segments or slices in the 47-segment model. A fixed 
perfusion defect was defined as a perfusion defect on stress images in ≥2 contiguous 
segments or slices, which persists on rest images in the 47-segment model. An abnor-
mal study was considered in the presence of a fixed or reversible perfusion defect (or 
both). 
Follow-up data were obtained in 2011. The mean follow-up period was 8.6±5.2 years, 
the median follow-up for all survivors was 13.4 years. Outcome data were obtained by 
a questionnaire, evaluation of hospital records, contacting the patient’s general prac-
titioner, and/or review of civil registries. The cause of death was retrieved at Statistics 
Netherlands (www.cbs.nl). The date of the last review or consultation was used to cal-
culate the follow-up time. Outcome events were cardiac death and cardiac death or 
non-fatal MI. Cardiac death was defined as death caused by acute MI, significant cardiac 
arrhythmias, or refractory congestive heart failure. Sudden death occurring without an-
other explanation was included as cardiac death.
Values were expressed as mean ±SD or number (%) and compared using Student’s t 
test or chi-square test. The probability of survival was calculated using the Kaplan-Meier 
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method, and survival curves were compared using log-rank test. Univariate and multi-
variate Cox proportional hazard regression models were used to assess the prognostic 
value of QRS duration in relation to the outcomes described above. All variables were 
forced to enter the model simultaneously. The risk of a variable was expressed as a haz-
ard ratio with a corresponding 95% confidence interval (CI). A p-value <0.05 was consid-
ered statistically significant. All statistical analyses were performed using SPSS version 
22 (IBM Corp., Armonk, NY, USA).
Table 1. Baseline characteristics
Variable All patients (n = 512)
QRS duration 
<120ms (n = 397)
QRS duration 
≥120 ms (n = 115) p value
Age (years) 60 ± 11 60 ± 11 62 ± 10 0.062
Men 308 (60%) 224 (56%) 84 (73%) <0.005
Hypertension 232 (45%) 178 (45%) 54 (47%) 0.688
Smoker 137 (27%) 104 (26%) 33 (29%) 0.594
Hypercholesterolemia 175 (34%) 135 (34%) 40 (35%) 0.877
Diabetes mellitus 91 (18%) 71 (18%) 20 (17%) 0.903
Prior heart failure 88 (17%) 49 (12%) 39 (34%) <0.001
Old myocardial infarction 152 (30%) 106 (27%) 46 (40%) <0.05
Prior CABG 83 (16%) 56 (14%) 27 (23%) <0.01
Prior PCI 92 (18%) 70 (18%) 22 (19%) 0.7
ACE inhibitor 149 (29%) 104 (26%) 45 (39%) <0.01
Betablocker 204 (40%) 163 (41%) 41 (36%) 0.297
Calcium channel blocker 229 (45%) 170 (43%) 59 (51%) 0.04
Diuretic 126 (25%) 80 (20%) 46 (40%) <0.001
Nitrate 159 (31%) 118 (30%) 41 (36%) <0.01
ACE = angiotensin converting enzyme; CABG = coronary artery bypass graft; PCI = percutaneous coronary interven-
tion.
RESULTS
Clinical characteristics are presented in Table 1. Electrocardiography at rest demon-
strated a QRS duration ≥120ms in 115 patients (22%), of which 41 (36%) had a right bun-
dle branch block, 19 (17%) had a left bundle branch block, 1 had Wolff-Parkinson-White 
syndrome (1%) and 54 (46%) had an unspecified intraventricular block. QRS duration 
≥120ms was significantly more observed in men and in patients with a previous MI, 
congestive heart failure and an abnormal MPI result. 
13671_HJBoiten_BW.indd   139 01-08-16   10:28
140
C
ha
p
te
r 9
Eight-year prognostic value of QRS duration in patients with known or suspected coronary artery disease referred | 140
An abnormal MPI was observed in 297 patients (58%). This included fixed defects in 
143 patients (28%) and reversible defects in 154 patients (30%). Of the 154 patients with 
reversible defects, 107 patients (21%) had partially reversible defects and 47 patients 
(9%) had completely reversible defects. During follow-up, 290 patients (57%) died, of 
which 139 deaths (27%) were attributed to cardiac causes. Non-fatal MI occurred in 28 
patients (6%), and late coronary revascularization (>3 months) was performed on 127 
patients (25%).
Figure 1. Kaplan-Meier survival curves for cardiac death according to QRS duration. 
Figure 2. Kaplan-Meier survival curves for cardiac death or nonfatal MI according to QRS duration.
During the 8.6±5.2 year follow-up period, annualized cardiac death rates were 3.0% in 
patients with an abnormal MPI compared to 2.1% patients with normal MPI (p=0.0375). 
Cardiac death or non-fatal MI occurred at a rate of 3.2% in the abnormal MPI group com-
pared to 2.3% in the normal MPI group (p=0.0185). Annualized cardiac death rates were 
2.2% in patients with QRS duration <120ms and 4.1% in patients with QRS duration 
≥120ms (p<0.0001). Cardiac death or non-fatal MI occurred at a rate of 2.3% in patients 
with QRS duration <120ms and 4.4% in patients with QRS duration ≥120ms (p<0.0001).
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Figure 3.  Kaplan-Meier survival curves for cardiac death according to QRS duration and MPI. 
Figure 4. Kaplan-Meier curves for cardiac death or nonfatal MI according to QRS duration and 
MPI.
Kaplan-Meier survival curves for the endpoints cardiac death and cardiac death or non-
fatal MI are presented in Figures 1 and 2. A significantly longer event-free survival for 
patients with QRS duration <120ms was seen for both endpoints. In Figures 3 and 4 
survival is shown according to the combination of QRS duration and MPI results. QRS 
duration <120ms and a normal MPI was associated with a favorable prognosis and the 
combination of QRS duration ≥120ms and an abnormal MPI was associated with an ad-
verse prognosis. An intermediate prognosis was observed in patients with normal QRS 
duration and an abnormal MPI, and in patients with QRS duration ≥120ms and normal 
MPI. This pattern was observed in both endpoints.
Univariate analysis results for each endpoint are shown in Tables 2 and 3. QRS du-
ration ≥120ms was a strong predictor of cardiac death and cardiac death or non-fatal 
MI. An abnormal MPI was associated with an increased risk of cardiac death and cardiac 
death or non-fatal MI.
13671_HJBoiten_BW.indd   141 01-08-16   10:28
142
C
ha
p
te
r 9
Eight-year prognostic value of QRS duration in patients with known or suspected coronary artery disease referred | 142
Table 2. Univariate and multivariate predictors of cardiac death
Variable
Univariate analysis Model 1:
Clinical variables
Model 2:
Clinical variables 
and QRS duration
Model 3:
Clinical variables, 
QRS duration, 
and MPI
Age (per year) 1.02 (1.01-1.04) 1.03 (1.01-1.04) 1.02 (1.01-1.04) 1.02 (1.01-1.04)
Male gender 1.80 (1.25-2.58) 1.94 (1.34-2.81) 1.81 (1.25-2.63) 1.77 (1.21-2.60)
Hypertension 1.63 (1.17-2.28) 1.68 (1.19-2.38) 1.71 (1.20-2.43) 1.75 (1.22-2.49)
Diabetes mellitus 1.96 (1.34-2.85) 1.86 (1.27-2.73) 1.93 (1.32-2.83) 1.87 (1.28-2.75)
Smoker 1.07 (0.74-1.56) 1.15 (0.77-1.70) 1.18 (0.80-1.76) 1.12 (0.75-1.67)
Hypercholesterolemia 0.91 (0.64-1.30) 0.82 (0.57-1.18) 0.81 (0.57-1.17) 0.78 (0.54-1.12)
QRS duration ≥120 ms 2.13 (1.50-3.02) - 1.95 (1.36-2.78) 1.93 (1.35-2.76)
Abnormal MPI 1.45 (1.20-2.06) - - 1.24 (0.85-1.82)
Cox proportional hazard regression models were used to assess QRS duration as an 
independent predictor of cardiac death and cardiac death or non-fatal MI (Tables 2 and 
3, respectively). Multivariate analysis was done separately for each endpoint accord-
ing to 3 models. Clinical characteristics were entered into model 1. In model 2 clinical 
characteristics were entered together with QRS duration and model 3 combined clinical 
characteristics with QRS duration and abnormal MPI.
QRS duration ≥120ms was an independent predictor of cardiac death and cardiac 
death/MI and provides additional prognostic information over clinical variables and 
MPI. It was an especially strong predictor for cardiac death, even with the addition of 
MPI and clinical variables (HR 1.93, 95% CI [1.35-2.76]) (Table 2).
Table 3. Univariate and multivariate predictors of cardiac death or non-fatal myocardial infarction
Variable Univariate analysis
Model 1:
Clinical variables
Model 2:
Clinical vari-
ables and QRS 
duration
Model 3:
Clinical variables, 
QRS duration, 
and MPI
Age (per year) 1.03 (1.01-1.04) 1.03 (1.01-1.04) 1.03 (1.01-1.04) 1.02 (1.01-1.04)
Male gender 2.01 (1.43-2.82) 2.11 (1.50-2.96) 2.06 (1.46-2.92) 1.87 (1.31-2.67)
Hypertension 1.62 (1.19-2.21) 1.67 (1.22-2.29) 1.72 (1.66-2.40) 1.77 (1.27-2.45)
Diabetes mellitus 1.71 (1.19-2.45) 1.56 (1.09-2.24) 1.66 (1.16-2.39) 1.57 (1.09-2.26)
Smoker 0.98 (0.69-1.39) 1.04 (0.72-1.50) 1.07 (0.74-1.55) 1.02 (0.70-1.48)
Hypercholesterolemia 0.93 (0.68-1.29) 0.85 (0.61-1.18) 0.83 (0.59-1.16) 0.82 (0.59-1.15)
QRS duration ≥120 ms 1.94 (1.37-2.65) - 1.69 (1.21-2.36) 1.68 (1.20-2.35)
Abnormal MPI 1.48 (1.07-2.05) - 1.28 (0.90-1.82)
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DISCUSSION
This study shows that QRS duration on surface electrocardiography is a strong predictor 
of long-term outcome of patients with known or suspected CAD. Patients with a QRS 
duration ≥120ms had an increased risk of cardiac death and the combined endpoint 
cardiac death/non-fatal MI. Kaplan-Meier survival curves showed that a QRS duration 
≥120ms on surface electrocardiogram is associated with a significantly worse prognosis 
when compared to a QRS duration <120ms after a mean follow-up of 8.6±5.2 years for 
both endpoints. This association was still significant after adjustment for clinical vari-
ables and MPI results.
Previous studies have shown the prognostic significance of QRS duration in patients 
with cardiac disease, including heart failure,1,2 left ventricular systolic dysfunction3, 
acute coronary syndrome4 and atrial fibrillation.5 In the past years more evidence has 
come into existence addressing the prognostic significance of prolonged QRS duration 
in a relatively lower-risk group of patients, including patients referred for suspected 
CAD and the general population. Aro et al.6 investigated prolonged QRS duration and 
found an increased risk of all-cause mortality, cardiac mortality and sudden arrhythmic 
death in 10.899 Finnish subjects after 30±11 years. Kurl et al.7 found a 2.50-fold relative 
risk in subjects with QRS >110ms compared to subjects with QRS <96ms in 2049 men 
after a 19-year follow-up. Finally, a retrospective study conducted by Badheka et al.8 
found improved cardiovascular risk prediction when adding QRS duration to a model 
with traditional risk factors.
In a clinical setting, Schinkel et al.9 demonstrated the predictive value of QRS du-
ration for cardiac mortality (RR 1.8, 95% CI [1.2-2.7]) and cardiac death or non-fatal MI 
(RR 1.6, 95% CI [1.2-2.3]) in patients without known CAD referred for dobutamine stress 
echocardiography with a mean follow-up of 4.2±2.4 years. Elhendy et al.,10 with a me-
dian follow-up of 3 years (maximum 8), have shown the prognostic significance of QRS 
prolongation as a predictor of mortality in a cohort of 4.033 patients with known or 
suspected CAD referred for exercise echocardiography, with QRS duration being incre-
mental to clinical evaluation, exercise electrocardiography and echocardiography re-
sults. Our study adds to these results by showing the long-term prognostic significance 
of QRS duration for cardiac death and cardiac death or nonfatal MI.
The present study has some limitations. First, the study population consisted of both 
patients with suspected or known CAD and therefore our results cannot readily be ex-
trapolated to a broader, asymptomatic low-risk population. Second, outcome data were 
obtained by a questionnaire, evaluation of hospital records, contacting the patient’s 
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general practitioner, and/or review of civil registries. Data collection by a questionnaire 
has inherent limitations. Furthermore, inevitably the treating physicians of the patients 
in our study had access to our MPI results. It is possible and expected that physicians 
will opt for more intensive medical therapy and possibly coronary revascularization for 
patients with abnormal results. The prognosis of these patients will therefore be altered 
in their favor, possibly underestimating the prognostic value of QRS duration and MPI in 
these patients. In the period that the SPECT studies were performed, electrocardiogram 
gated acquisition was not routinely performed in our laboratory. Gated SPECT provides 
information on regional and global left ventricular function, which is an important pre-
dictor of prognosis. Future studies are needed to clarify the value of gated SPECT for the 
assessment of very long-term prognosis.
QRS duration is a simple, cheap and objective parameter and as such is a valuable 
tool in risk stratification. This is the first study with a long-term follow-up in patients with 
suspected or known CAD and extends the results of earlier studies.9,10 The current find-
ings suggest that both QRS duration and MPI results should be considered for optimal 
risk stratification. Future research is needed to develop a risk calculator for daily practice 
that incorporates both electrocardiographic and MPI data.
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ABSTRACT
Aims. Many studies have examined the prognostic value of myocardial perfusion im-
aging (MPI) using single-photon emission computed tomography (SPECT) for the pre-
diction of short- to medium term outcomes. However, the long-term prognostic value 
of MPI in patients with diabetes mellitus remains unclear. Therefore, this study assessed 
the long-term prognostic value of MPI  in a high-risk cohort of  patients with diabetes 
mellitus . 
Methods and results. A high-risk cohort of 207 patients with diabetes mellitus who 
were unable to undergo exercise testing underwent dobutamine stress MPI. Follow-up 
was successful in 206 patients; 12 patients were excluded due to early revascularization. 
The current data are based on the remaining 194 patients. Follow-up endpoints were 
all-cause mortality, cardiac mortality and nonfatal myocardial infarction. Kaplan-Meier 
survival curves were constructed and univariable and multivariable analyses were per-
formed to identify predictors of long-term outcome. During a mean follow-up of 8.1±5.9 
years, 134 (69%) patients died of which 68 (35%) died due to cardiac causes. Nonfatal 
myocardial infarction occurred in 24 patients (12%) and late (>60 days) coronary re-
vascularization was performed in 61 (13%) patients. Survival analysis showed that MPI 
provided optimal risk stratification up to 4 years after testing. After that period, the out-
come was comparable in patients with normal and abnormal MPI. Multivariable analy-
ses showed that MPI provided incremental prognostic value up to 4 years after testing. 
Conclusion. In high-risk patients with diabetes mellitus, dobutamine MPI provides in-
cremental prognostic information in addition to clinical data for a 4-year period  after 
testing.
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INTRODUCTION
The worldwide prevalence of diabetes mellitus is increasing, concurrently with obesity 
and other comorbid conditions.1 Despite significant advances in medical and invasive 
therapy, the leading cause of death in patients with diabetes mellitus remains coronary 
artery disease (CAD).2 Myocardial perfusion imaging (MPI) is clinically useful for the eval-
uation of CAD in patients with diabetes mellitus. In patients with diabetes mellitus and 
suspected or known CAD, a strong evidence base has been accumulated that MPI pro-
vides diagnostic and prognostic information. Previous studies have shown that MPI pro-
vides incremental prognostic information in these patients for a short- to medium-term 
follow-up.3–9 The follow-up period in these studies was on average 3.5 years. Currently, 
the long-term prognostic value of MPI in patients with diabetes mellitus is unclear. It is 
important to elucidate the long-term prognostic value of MPI in patients with diabetes 
mellitus because there are indications that over time a significant change in risk may 
occur, which may increase the annual cardiac event rate to 2% even in patients with a 
normal MPI.10 Moreover, an accelerated progression of CAD may occur in patients with 
diabetes mellitus, which may influence the prognostic value of MPI. Diabetes mellitus is 
an important predictor of CAD progression.11 Accordingly, this study assessed the long-
term prognostic value of MPI in a high-risk cohort of patients with diabetes mellitus and 
limited exercise capacity. 
METHODS
Patients selection
The study population consisted of a high-risk cohort of 207 consecutive patients with 
diabetes mellitus who were unable to undergo exercise testing and underwent dobuta-
mine stress MPI. This study is a continuation of the study of Schinkel et al.9 in which the 
same population was evaluated with a mean follow-up of 4 years. The test was requested 
for assessment of myocardial ischemia in all patients; 91 patients had known or sus-
pected CAD, 63 had atypical angina, and 53 had typical angina. Diabetes was defined as 
a fasting blood glucose level of >140 mg/dL or the need for insulin or oral hypoglycemic 
agents. Follow-up was successful in 206 patients (99.5%). A total of 12 patients who had 
undergone coronary revascularization within 60 days of the test were excluded from 
the analysis. This exclusion was based on previously published data that indicated that 
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referral to coronary revascularization in the first 60 days after nuclear testing tends to be 
based on the results of the scan and that referral to revascularization >60 days after nu-
clear testing tends to be based on worsening of the patient’s clinical status.12 Data of the 
remaining 194 patients are described in this study. All patients gave informed consent 
before testing. The local medical ethics committee approved the study protocol. Before 
the test, a structured interview was performed and a clinical history was obtained, in-
cluding assessment of cardiac risk factors. Hypertension was defined as blood pressure 
>140/90 mmHg or need for antihypertensive medication. Hypercholesterolemia was 
defined as total cholesterol level >6.4 mmol/L or need for lipid-lowering medication.
Stress test protocol
Dobutamine–atropine stress testing was performed according to a standard protocol.13 
Dobutamine was administered intravenously, starting at a dose of 10 µg/kg/min for 3 
min, which was increased by 10 µg/kg/min every 3 min, up to a maximum dose of 40 
µg/kg/min. If the test end point was not reached at a dobutamine dose of 40 µg/kg/min, 
atropine was administered intravenously (≤1 mg). Blood pressure and heart rate were 
monitored, and electrocardiography (ECG) was performed constantly. Test end points 
included the following:achievement of target heart rate (85% of maximum age- and 
sex predicted heart rate), horizontal or downsloping ST-segment depression >2 mm at 
an interval of 80 ms after the J-point compared with baseline, ST-segment elevation >1 
mm in patients without previous myocardial infarction,decrease in systolic blood pres-
sure >40 mmHg, blood pressure >240/120 mmHg, severe angina, or significant cardiac 
arrhythmia. Metoprolol was available for administration to reverse the adverse effects 
of dobutamine/atropine.
SPECT MPI
Approximately 1 min before the termination of the dobutamine–atropine stress test, 
an intravenous dose of 370 MBq of technetium-99m (99mTc)-sestamibi (in 69 patients) 
or 99mTc-tetrofosmin (in 125 patients) was injected. For resting studies, 370 MBq of the 
same tracer was injected at least 24 h after the stress test. Image acquisition was per-
formed with a commercially available single-photon emission computed tomography 
(SPECT) camera system (Orbiter camera; Siemens, Iselin, NJ; or Picker Prism 3000XP 
camera; Picker, Cleveland, OH). For each study, six oblique (short-axis) slices from the 
apex to the base and three sagittal (vertical long-axis) slices were defined. Each of the 
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six short-axis slices was divided into eight equal segments. The septal part of the two 
basal slices was excluded from analysis because this region corresponds to the fibrous 
portion of the interventricular septum and normally exhibits reduced uptake. Therefore, 
a total of 47 segments were identified (3 long axis and 44 short axis). The interpretation 
of the scan was semiquantitatively performed by visual analysis assisted by the circum-
ferential profiles analysis. Stress and rest tomographic viewswere reviewed side by side 
by two experienced observers who were unaware of the patients’ clinical data. In case of 
disagreement, a majority decision was achieved by a third observer.
A reversible perfusion defect was defined as a perfusion defect on stress images that 
partially or completely resolved at rest in two contiguous segments or slices. A fixed 
perfusion defect was defined as a perfusion defect on stress images in two or more 
contiguous segments or slices that persisted on rest images. An abnormal study was 
considered in the presence of a fixed and/or reversible perfusion defect.
Patient follow-up
Collection of follow-up data was obtained by reviewing hospital records and/or by con-
tacting the patient’s general practitioner. The date of the last review or consultation was 
used to determine follow-up time. End points were all-cause mortality, cardiac mortal-
ity, and nonfatal myocardial infarction. Cardiac mortality was defined as a death caused 
by acute myocardial infarction, significant cardiac arrhythmias, or refractory conges-
tive heart failure. Sudden death occurring without another explanation was included 
as cardiac mortality. Nonfatal myocardial infarction was described by elevated cardiac 
enzyme levels and typical changes on ECG. Hard cardiac events were defined as the 
occurrence of cardiac mortality or nonfatal myocardial infarction.
Statistical analysis
Values were expressed as mean value SD or number and were compared using Stu-
dent’s t-test or X2 test. Univariable and multivariable Cox proportional hazard regression 
models were used to identify independent predictors of late cardiac events. Variables 
were selected in a stepwise forward-selection manner with entry and retention set at 
a significance level of 0.05. The risk of a variable was expressed as a hazard ratio with 
corresponding 95% confidence interval (CI). The incremental value of myocardial per-
fusion scintigraphy over the clinical variables in the prediction of cardiac events was 
determined according to two models. In Model I, the variable entered was the presence 
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of an abnormal scan; in Model II, the variables entered were fixed and reversible defect. 
The multivariable analysis was repeated per year of follow-up. Survival curves were per-
formed using the Kaplan–Meier method, and survival curves were compared using the 
log-rank test. A P-value of <0.05 was considered statistically significant.
RESULTS
Demographics and stress test results
The clinical data of the 194 high-risk patients with diabetes mellitus are presented in 
Table 1. The Diamond and Forrester pretest probability of CAD was low in 39 (20%), 
intermediate in 94 (49%), and high in 61 patients (31%). 
Table 1. Baseline characteristics
N = 194 Number (%)
Age (years) 61 ± 10
Men 116 (60)
Hypertension 110 (57)
Smoking 458 (25)
Hypercholesterolemia 64 (33)
Congestive heart failure 51 (26)
Prior myocardial infarction 82 (42)
Previous coronary artery bypass graft 32 (16)
Previous percutaneous coronary intervention 35 (18)
Beta-blockers 66 (34)
ACE inhibitors 83 (43)
Calcium channel blockers 102 (53)
Significant increases in heart rate (77±17–136±17 bpm, P<0.0001) and systolic blood 
pressure (144±26–158±33 mmHg, P <0.001) were achieved from rest to peak stress. The 
peak dobutamine dose was 10 µg/kg/min in 5 patients (3%), 20 µg/kg/min in 24 pa-
tients (12%), 30 µg/kg/min in 35 patients (18%), and 40 µg/kg/min in 130 patients (21%). 
Atropine was added in 78 patients (40%). Atropine was more frequently administered 
in patients using B-blocker therapy (41 of 66 patients, 62%) than in those not taking 
B-blockers (37 of 128, 29%, P<0.0001). Adverse effects during the test were ventricular 
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tachycardia (>10 beats) in 1 patient (0.5%), short ventricular tachycardia (<10 beats) in 
7 patients (3.6%), atrial fibrillation in 2 patients (1%), severe hypotension (decrease in 
systolic blood pressure .40 mmHg) in 3 patients (1.5%), nausea in 11 patients (5.7%), and 
headache in 12 patients (6.2%). No patient experienced a myocardial infarction or fatal 
complication. Typical angina occurred in 53 patients (27%), whereas 54 patients (28%) 
exhibited ST-segment changes.
SPECT results and outcome
Abnormal MPI was detected in 125 (64%) patients. Perfusion abnormalities were revers-
ible defects in 17 (9%) patients. Fixed defects were detected in 61 patients (31%) sug-
gesting that they have had myocardial damage. Forty-seven patients (24%) had both 
fixed and reversible defects. During a mean follow-up of 8.1+5.9 years,134 (69%) pa-
tients died (all-cause mortality) of whom 68 (35%) died due to cardiac causes. Nonfatal 
myocardial infarction occurred in 24 patients (12%). Late (>60 days) coronary revascu-
larization was performed in 61 (13%) patients. 
The Kaplan–Meier survival curves are presented in Figure 1. The survival curves accord-
ing to all-cause mortality demonstrate that up to 4 years after MPI, patients with a nor-
mal MPI had a better prognosis compared with patients with an abnormal MPI (Figure 
1A). After 4 years of follow-up, the survival curves converge, indicating no significant 
difference in all-cause mortality for normal or abnormal MPI. Figure 1B and C shows the 
event-free survival curves for cardiac mortality and hard cardiac events, respectively. 
Both cumulative survival free of cardiac mortality (P=0.034) and hard cardiac events 
(P=0.036) show a significantly better prognosis in favor of a normal MPI. Conversely, 
patients with an abnormal MPI had a significant increased risk of cardiac mortality and 
hard cardiac events. 
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Figure 1. Kaplan-Meier survival curves with normal vs. abnormal MPI for all endpoints of interest: 
(A) all-cause mortality, (B) cardiac mortality, and (C) hard cardiac events. y=year.
A
B
C
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Table 2. Univariable and multivariable predictors of cardiac mortality at 4-year follow-up
Multivariable HR (CI)
Variable Univariable HR (CI) Clinical data Model I Model II
Agea 1.03 (1.00–1.06) 1.04 (1.01-1.08) 1.06 (1.02-1.10) 1.06 (1.02-1.09)
Men 1.83 (1.09–3.09) 2.30 (1.27-4.20) 2.02 (1.04-3.91) P=0.11
Typical angina pectoris P=0.72 P=0.71 P=0.96 P=0.92
Hypertension P=0.76 P=0.78 P=0.61 P=0.27
Hypercholesterolemia P=0.18 P=0.35 P=0.10 1.90 (1.06-3.39)
Smoking P=0.17 P=0.47 P=0.38 P=0.19
Scan parameters
Abnormal scan 1.80 (1.04-3.12) - 1.96 (1.10-3.88) -
Reversible defect 1.72 (1.06-2.77) - - 2.14 (1.14-3.67)
Fixed defect P=0.31 - - P=0.20
Statistically significant predictors of outcome are presented as hazard ratio (CI), of all other variables the P-value is 
presented. —, Not included in the model. aPer unit increment.
Predictors of long-term outcome
Multivariable analyses were performed for every year of follow-up to determine the 
maximum length of prognostic value of SPECT MPI. Tables 2 and 3 demonstrates the 
last year were the scan parameters had significant incremental value for the prediction 
of cardiac events. At a mean follow-up of 8.1 years, univariable analysis demonstrated 
that age, abnormal MPI, and reversible perfusion defect were predictors of cardiac mor-
tality and hard cardiac events (Tables 2 and 3, respectively). In the multivariable analysis, 
the maximum length of prognostic value of SPECT MPI in diabetic patients was 4 years. 
After that follow-up duration, multivariable analysis demonstrated that SPECT MPI pa-
rameters failed to predict cardiac mortality (Table 2) and hard cardiac events (Table 3).
DISCUSSION
The current study assessed the long-term outcome after MPI in high-risk patients with 
diabetes mellitus and limited exercise capacity. The main finding of this study is that 
dobutamine stress MPI provides useful information for the prediction of outcome in 
patients with diabetes mellitus. Diabetic patients with a normal MPI
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Table 3. Univariable and multivariable predictors of hard cardiac events at 4-year follow-up
Multivariable HR (CI)
Variable Univariable HR (CI) Clinical data Model I Model II
Agea 1.03 (1.00–1.06) 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.08)
Men 1.73 (1.03–2.92) 1.92 (1.13-3.26) P=0.06 P=0.07
Typical angina pectoris P=0.77 P=0.85 P=0.86 P=0.80
Hypertension P=0.86 P=0.74 P=0.73 P=0.40
Hypercholesterolemia P=0.26 P=0.49 P=0.11 P=0.09
Smoking P=0.71 P=0.74 P=0.38 P=0.36
Scan parameters
Abnormal scan 1.91 (1.04-3.50) - 1.83 (1.01-3.29) -
Reversible defect 1.65 (1.02-2.67) - - 1.85 (1.09-3.13)
Fixed defect P=0.50 - - P=0.28
Statistically significant predictors of outcome are presented as hazard ratio (CI), of all other variables the P-value is 
presented.
—, Not included in the model.
aPer unit increment.
have a significantly better prognosis compared with those with an abnormal study, up 
to 4 years after testing. The survival curves suggest that dobutamine MPI was predictive 
of outcome (for the end points cardiac mortality, and cardiac events) over the entire 
follow-up duration. However, the multivariate analysis demonstrated that dobutamine 
MPI was an independent predictor of outcome (all-cause mortality, cardiac mortality, 
and cardiac events) up to 4 years after the test. After this 4-year period, the predictive 
value of dobutamine stress MPI does not hold its independent predictive value.
 This is the first study that has evaluated the long-term prognostic value of MPI in 
patients with diabetes mellitus. Several studies have established that MPI is a useful 
tool for short- and medium-term risk stratification of diabetic patients. The follow-up 
period in these previous studies was on average 3.5 years. Kang et al.14 described 1271 
patients with diabetes mellitus who underwent stress 99mTc- sestamibi MPI. During a 
mean follow-up of 23.7±7.7 months, patients with diabetes mellitus had higher cardiac 
event rates in comparison with patients without diabetes. The authors concluded that 
stress MPI was a valuable tool for risk stratification in diabetic patients. De Lorenzo et 
al.3 demonstrated that an abnormal stress MPI significantly increased the risk of cardiac 
events in 108 diabetic patients during a follow-up of 36±18 months. Giri et al.4 studied 
929 diabetic patients undergoing stress MPI for a follow-up time of 2.5±1.5 years. Sig-
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nificant more cardiac events occurred in the diabetic group (8.6%) compared with the 
nondiabetic cohort (4.5%; P<0.0001). Jeong et al.5 studied 337 diabetic patients who 
were followed for 32±12 months. The gated SPECT data provided significant incremen-
tal prognostic information over that provided by historical, clinical, physiological vari-
ables and normal perfusion status in diabetic patients without known CAD. Acampa et 
al.6 studied 436 asymptomatic patients with diabetes mellitus with a median follow-up 
of 50 months. Stress-induced ischemia by gated MPI influenced the temporal charac-
teristic of the patient’s risk. In 575 patients with diabetes mellitus, Bourque et al.7 found 
that known CAD and MPI ischemia were independent predictors of cardiac events dur-
ing a mean follow-up of 4.4 years. In ischemic patients, the rate of cardiac events was 
5.7%/year compared with 2.6%/year in the total patient group. More recently, Acampa 
et al.8 studied 828 patients of whom 260 with diabetes mellitus. During a median fol-
low-up of 53 months after a normal stress MPI, diabetic patients were at significantly 
higher risk for cardiac events compared with nondiabetic patients. The current study 
differs from previous studies mainly because of the long-term mean followup time of 
8.1 years. This study extends the results from previous studies, and it demonstrates that 
the prognostic value is maintained up to 4 years after MPI. Hence, the ‘perishable date’ of 
stress MPI for the prediction of outcome in patients with diabetes mellitus and limited 
exercise capacity is ~4 years.
 There are several explanations why stress MPI has no incremental value for the pre-
diction of outcome beyond 4 years after the test in patients with diabetes mellitus. In 
the current study, we describe a high-risk group of patients with diabetes mellitus and 
limited exercise capacity. The mean age of these patients was relatively high (61 years). 
A total of 82 patients (42%) have had a previous myocardial infarction. Moreover, 32 
(16%) and 35 patients (18%) have had a previous coronary artery bypass graft and previ-
ous percutaneous coronary intervention, respectively. Overall, these factors indicate the 
high-risk status of the study population, which may have influenced the risk of cardiac 
events. Additionally, during follow-up, progression of CAD may have occurred and dia-
betes may have accelerated the natural progression of CAD.15 Furthermore, the inability 
to perform an exercise test is a strong predictor of adverse outcome in itself.
A study of Hachamovitch et al.10 showed that after a normal SPECT MPI a warranty 
period exists. The underlying clinical risk of diabetic patients may significantly influence 
the event rate after a normal SPECT scan. Recently, Acampa et al.8 also suggest that 
the warranty period for a normal stress SPECT scan varies depending on patient clini-
cal characteristics. The existence of hypertension, a previous myocardial infarction, and 
consequently myocardial damage can affect the risk on cardiac events. Depending on 
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the patient’s clinical status, repeated testing is therefore recommended. To determine 
whether repeating SPECT MPI is indicated, the appropriateness criteria for cardiac im-
aging should be used.16
Pharmacologic stress MPI is a widely used technique for the evaluation of CAD. Ade-
nosine and dipyridamole (coronary vasodilators) are the most used agents for stress 
testing and are superior in creating blood flow heterogeneity.17,18 However, in patients 
who have contraindications for vasodilators, such as reactive airway disease or high-
grade atrioventricular nodal block, dobutamine is the pharmacological stress agent 
of choice. Previous data showed that increased blood flow (hyperemia) induced by 
dobutamine–atropine stress testing is of equal magnitude to hyperemia induced by 
vasodilator stress agents.19 Both sensitivity and specificity for diagnosing CAD are gen-
erally comparable among adenosine and dobutamine.20 In a canine model, dobutamine 
attenuates the myocardial uptake of 99mTc-sestamibi and, as a result, underestimates the 
extent of significant coronary artery stenoses.21,22 The radiotracers 99mTc-sestamibi and 
99mTc-tetrofosmin have a nonlinear myocardial extraction at high flow rates. To date, 
however, 99mTc radiotracers in conjunction with MPI are of great value to assess progno-
sis of patients with known or suspected CAD.  
The current study has limitations. First, during SPECT, no attenuation or scatter cor-
rection was used. Previous studies have shown that attenuation correction contributes 
to optimize further risk stratification23,24; application of attenuation or scatter correction 
could have improved the accuracy of the MPI studies. Second, the prognostic value of 
gated SPECT was not examined, due to the fact that at the time of data collection, gated 
SPECT was not routinely performed. Third, the study population consisted of 194 high-
risk patients with diabetes mellitus with limited exercise capacity. The results of this 
study may not be applicable to patients with diabetes in general. Fourth, the examined 
patient population was relatively small.
 In conclusion, in this study with a mean follow-up of 8.1±5.9 years, dobutamine 
stress MPI provided incremental information in addition to clinical and SPECT MPI re-
sults for the prediction of cardiac events of patients with diabetes mellitus up to 4 years 
after the test.
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ABSTRACT
Objective. To determine the incremental prognostic value of dobutamine stress echoc-
ardiography (DSE) at 13-year follow-up (SD 3.2 years) for predicting mortality and car-
diac events in diabetic patients.
Research Design and Methods. A total of 396 diabetic patients (mean age 61±11 
years; 252 men [64%]) with limited exercise capacity who underwent DSE for evaluation 
of ischemia were studied. End points were all causes of mortality, cardiac death, and 
hard cardiac events (cardiac death and nonfatal myocardial infarction).
Results. During a mean follow-up of 13 years, 230 patients (58%) died (121 cardiac 
deaths), and 30 patients had nonfatal myocardial infarction. Cumulative survival in pa-
tients with an abnormal DSE at 5, 10, and 15 years was 68, 49, and 41%, respectively. In 
patients with a normal DSE, these respective numbers were 74, 57, and 44%. Multivar-
iate analyses showed that DSE provided incremental value over clinical characteristics 
and stress test parameters for prediction of mortality and cardiac events. Survival analy-
sis showed that DSE provided optimal risk stratification up to 7 years after initial testing; 
after that period, the risk of adverse outcome increased comparably in both normal and 
abnormal DSE patients.
Conclusions. DSE provided restricted predictive value of adverse outcome in patients 
with diabetes who were unable to performan adequate exercise stress test. DSE pro-
vided optimal risk stratification up to 7 years after initial testing. Repeated DSE at that 
time might add to its prognostic value.
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INTRODUCTION
Coronary artery disease (CAD) is a major cause of mortality and morbidity in diabetic 
patients.1
To optimize therapeutic intervention, it is essential to identify patients at risk. Exercise 
stress testing is the most common stress modality used for the noninvasive evaluation 
of CAD. However, exercise tolerance in diabetic patients may be impaired, particularly 
because of the higher prevalence of peripheral vascular disease. Dobutamine stress 
echocardiography (DSE) is used to assess the severity of CAD in patients unable to 
perform an adequate exercise test. The safety, feasibility, and accuracy of DSE are com-
parable in diabetic and nondiabetic patients.2 DSE has shown an incremental value in 
predicting death and hard cardiac events at short- and intermediateterm follow-up.3–5 
However, it is not known whether this incremental value can be maintained at long-
term follow-up.
The goals of the current study with 13-year follow-up were to 1) assess very long-
term outcome after DSE in patients with diabetes, 2) identify predictors of increased risk 
in patients with diabetes, and 3) define a low-risk period after normal DSE.
RESEARCH DESIGN AND METHODS
This retrospective study included 408 consecutive patients with diabetes who were 
unable to perform an adequate exercise test and who underwent DSE at the Thorax-
center between January 1994 and January 2001. Diabetes was defined in the presence 
of fasting blood glucose ≥140mg/dL or requirement for insulin or oral hypoglycemic 
agents. A total of 12 patients were excluded because of inadequate echocardiographic 
images. The final population of this study consisted of 396 patients.
Clinical data including hypercholesterolemia, smoking, hypertension, a history 
of heart failure, a previous myocardial infarction (MI), and/or revascularization were 
collected at the time of DSE. Hypercholesterolemia was defined as total cholesterol 
>200mg/dL or use of cholesterol-lowering agents. Hypertension was defined as systolic 
blood pressure ≥140 mmHg, diastolic blood pressure >90 mmHg, or use of antihyper-
tensive medication. Heart failure was defined in line with the New York Heart Associa-
tion classification. For the clinical characteristics of the patients, we refer to the short-
term study of this population done by Sozzi et al.5 in 2003. Patients who underwent 
revascularization within 3 months after DSE were excluded. This exclusion was based on 
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previously published data indicating that referral to coronary revascularization within 3 
months after testing tends to be based on the results of the test and that referral to re-
vascularization>3 months after the test tends to be based on worsening of the patients 
clinical status.
DSE protocol
Left ventricular ejection fraction (LVEF) at rest was assessed using the modified biplane 
Simpson rule.6 After baseline echocardiography, dobutamine was infused at a starting 
dose of 5 µg/kg/min for 3 min followed by 10 µg/kg/min for 3 min (low-dose stage). 
The dobutamine dose was increased by 10 µg/kg/min every 3 min up to a maximum 
dose of 40 µg/kg/min. Atropine (up to 1 mg) was administered intravenously at the end 
of the last stage if the target heart rate was not achieved. End points of the test were 
an achievement of the target heart rate (85% of the maximal heart rate predicted for 
age), the maximal dose of dobutamine and atropine, >2 mV downsloping ST-segment 
depression measured 80 ms from the J point compared with baseline, hypertension 
(blood pressure >240/120 mmHg), a decrease in systolic blood pressure of >40 mmHg, 
and significant arrhythmias.
Echocardiographic imaging and interpretation
Imaging was acquired at rest and continuously during the test and recovery. Images 
were recorded on videotapes and, in addition, the baseline, low-dose, peak-stress, and 
recovery images were recorded in a quad-screen format. The interpretation of images 
was performed by two independent observers blinded to the patients’ clinical data. In 
case of disagreement, a majority decision was achieved by a third observer. In our lab-
oratory, the inter- and intraobserver agreement for DSE assessments are 92 and 94%, 
respectively.7 A 16-segment model was used for segmental analysis of LV function.6 Wall 
Motion Score Index (WMSCI) was determined at rest and peak stress as the sum of the 
segmental scores of the 16 segments divided by 16. Each segment was scored using 
a 5-point Likert scale as follows: 1=normal, 2=mild hypokinesis, 3=severe hypokinesis, 
4=akinesis, and 5=dyskinesis. Ischemia was defined as new or worsened wall motion 
abnormalities (WMAs) during stress, which was indicated by an increase of wall mo-
tion score ≥1 grade in ≥1 segment.8 Ischemia was not considered to be present when 
akinetic segments at rest became dyskinetic during stress. DSE results were defined as 
abnormal if there was ischemia during stress9 or fixed WMAs.8
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Follow-up
Patients were contacted to retrieve followup information twice, in 2001 and in 2010. 
Prior to contacting them, the online municipal civil registry was used to determine the 
patients’ present survival status. Survival status was retrieved in 100% of the patients. A 
mailed questionnaire was sent to all living patients. The response rate of the question-
naire was 85%. There were no significant differences between patients who responded 
to the survey and those who did not respond. This questionnaire was used together 
with medical records to obtain information about end points. The end points consid-
ered were all-cause mortality, cardiac death, and hard cardiac events (defined as non-
fatal MI and cardiac death). Causes of death were obtained from the Central Bureau of 
Statistics Netherlands. Deaths were classified as either documented cardiac death or 
other. Nonfatal MI was confirmed by using clinical and electrocardiographic criteria and 
a typical rise and fall of cardiac markers.
Statistical analysis
Continuous variables were reported as mean±SD and compared with Student t test. 
Categorical variables were summarized as percentages; the X2 test was used to compare 
groups. Cumulative survival was estimated by the Kaplan-Meier method, with compar-
isons between groups based on the log-rank test. Cox proportional hazards regression 
model was used to examine the additional value of DSE with the end points of interest 
at 7, 8, and 15 years after the test. Variables were selected in a stepwise forward selec-
tion manner with entry and retention set at a significance level of 0.05. The incremental 
value of DSE information over clinical data was assessed in two modeling steps. First, 
clinical data only were selected to fit a multivariable model. These clinical data were 
then used as baseline risk factors, and DSE variables were added in a stepwise forward 
selection manner. The incremental value was determined by comparing the log likeli-
hood X2 values of both prediction models.
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Figure 1. Kaplan-Meier survival curves with normal vs. abnormal DSE for all end points of interest. 
A: All-cause mortality: normal 88, 58, 41, and 12; abnormal 308, 164, 99, and 20 patients at risk at 
start, 5-, 10-, and 15-year follow-up (FUP), respectively. B: Cardiac death: normal 88, 58, 41, and 12; 
abnormal 308, 164, 99, and 20 patients at risk at start, 5-, 10-, and 15-year FUP, respectively. C: Hard 
cardiac events: normal 79, 48, 32, and 10; abnormal 296, 146, 82, and 20 patients at risk at start, 5-, 
10-, and 15-year FUP, respectively.
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RESULTS
Dobutamine-atropine induced a significant increase of heart rate (from 77±13 at rest 
to 132±16 bpm at peak dose, P<0.0001), whereas systolic blood pressure did not in-
crease (137±27 at rest and 136±32 mmHg at peak stress). Atropine was administered in 
179 patients (45%). Angina occurred in 89 patients (22%), and ST-segment depression 
occurred in 61 patients (15%). Reasons for termination of the test were achievement of 
the target heart rate in 320 patients (81%), angina in 42 patients (11%), ST-segment de-
pression in 22 patients (5%), hypotension in 7 patients (2%), and ventricular arrhythmia 
in 5 patients (1%). 
Resting WMAs were detected in 292 patients (74%), and 176 (60%) of these patients 
had a history of previous MI. Ischemia was detected in 141 patients (36%), and 125 
(89%) of these patients had resting WMAs as well. 
Outcome
During a mean follow-up of 13 years (SD 3.2), 230 patients (58%) died (121 cardiac 
deaths), 30 patients (8%) had a nonfatal MI, and 86 (22%) underwent myocardial revas-
cularization. A total of 50 and 45, respectively, underwent percutaneous coronary inter-
vention and coronary artery bypass procedures during follow-up, of whom 9 had both. 
Among the 141 patientswith ischemia by DSE, 62 underwent subsequent revasculari-
zation (72% of the total patients revascularized). The remaining patients with ischemia 
were treated medically. 
Tabel 1. Independent predictors of all-cause mortality, cardiac death, and hard cardiac events 
using a two-step model. 
All-cause mortality Cardiac death Hard cardiac events
HR (95% CI) X2 HR (95% CI) X2 HR (95% CI) X2
Clinical
  Age 1.05 (1.03–1.06) 1.03 (1.01–1.05) 1.02 (1.00–1.04)
  Heart failure 2.08 (1.56–2.78) 67 2.62 (1.80–3.82) 55 2.41 (1.68–3.45) 41
  Old MI -- 1.76 (1.21–2.58) 1.53 (1.07–2.19)
  Smoking 1.43 (1.08–1.88) -- --
Clinical + Imaging
  Peak WMSCI 1.74 (1.38–2.19) 93 1.93 (1.40–2.66) 77 1.74 (1.28–2.37) 55
  LVEF 0.15 (0.06–0.40) 76 0.07 (0.02–0.30) 65 0.13 (0.04–0.48) 49
HR, hazard ratio. X2, Chi-square. WMSCI, wall motion score index.
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Clinical and DSE variables associatedwith an increased risk of all end points of interest 
in the multivariate model analysis are presented in Table 1.WMSCI at peakdose dobuta-
mine and LVEF at rest added incremental value to the clinical parameters in predicting 
all-cause mortality (67 to 93 [P<0.0001] and 76 [P <0.0001],respectively). The additional 
value of DSE, however, did not increase any further after 7 years after the test for all 
end points of interest. Multivariate analysis showed that WMA at rest, new or worsened 
WMA, and these DSE parameters combined did not significantly improve the prediction 
model for adverse outcome.
The cumulative survival showed a better, although not significant, survival of normal 
DSE in comparison with abnormal DSE (74 vs. 68% at 5 years, 57 vs. 49% at 10 years, 
and 44 vs. 41% at 15 years; overall P=0.06) (Figure 1A). Figure 1B and 1C, respectively, 
shows the event-free survival curves for cardiac death and hard cardiac events with nor-
mal versus abnormal DSE. Both cumulative survival free of cardiac death (89 vs. 78% 
at 5 years, 84 vs. 69% at 10 years, and 81 vs. 66% at 15 years; overall P=0.003) and hard 
cardiac events (84 vs. 75%at 5 years, 81 vs. 65% at 10 years, and 77 vs. 63% at 15 years; 
overall P = 0.009) show a significantly better prognosis in favor of a normal DSE. The 
interaction between LVEF and peak WMSCI is shown in Figure 2.
Figure 2. Kaplan-Meier survival curves demonstrating the interaction between peak WMSCI and 
LVEF. Group 1: ○, LVEF ≥50% and peak WMSCI = 1; 82, 58, 42, and 10 patients at risk at start, 5-, 
10-, and 15-year follow-up (FUP), respectively. Group 2: , LVEF<50% and peak WMSCI = 1; 13, 7, 
5, and 0 patients at risk at start, 5-, 10-, and 15-year FUP, respectively. Group 3: ●, LVEF≥50% and 
peak WMSCI>1; 39, 24, 15, and 7 patients at risk at start, 5-, 10-, and 15-year FUP, respectively. 
Group 4: , LVEF<50% and peak WMSCI>1; 240, 120, 67, and 10 patients at risk at start, 5-, 10-, 
and 15-year FUP, respectively. 
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CONCLUSIONS
DSE is widely used for diagnosis and risk stratification, but the very long-term prognos-
tic value of this test in patients with diabetes is not defined. Accurate long-term risk 
stratification of these patients is required to optimize patient management. Patients 
with normal DSE are considered at low risk of cardiac events; the annualized event rate 
is generally, <1% during the first years after testing.Accordingly, in these low-risk pa-
tients, further (invasive) diagnostic and therapeutic strategies and associated medical 
care costs can be avoided.
Still, over time, a significant change in risk may occur after a normal DSE. The under-
lying clinical risk of patients with diabetes and history of CAD may significantly influ-
ence the event rate after a normal DSE. These observations have lead to the perception 
that a “warranty period” exists after a normal DSE. In the currently available literature, 
mean follow-up after DSE was ~3 years. Very long-term outcome data after DSE are lack-
ing and, consequently, the duration of the low-risk status after a normal test is not clear.
This study is a continuation of the 2003 study of Sozzi et al.5 in which the same pop-
ulation of 396 patients with diabetes was evaluated, with a median followup of 3 years. 
The current study assesses the very long-term outcome after DSE in patients with diabe-
tes and shows that DSE provides restricted predictive value of adverse outcome in pa-
tients with diabetes at very long mean follow-up of 13±3.2 years. The prognostic value 
of DSE was optimal till ~7 years after the initial test. DSE provided data in predicting 
all-cause mortality incremental to clinical parameters and increased the X2 of the clinical 
and exercise electrocardiogram model from 67 to 93 (P<0.0001) at 15-year follow-up, 
but the additional value of DSE did not increase any further after 7 years after the test. 
This is in line with the Kaplan-Meier survival curves, which diverge until ~7 years. After 
that point, the lines start to run parallel. The most powerful echocardiographic predictor 
of outcome was peak WMSCI, with LVEF at rest coming up second. Multivariate analysis 
showed that peak WMSCI and LVEF were independent predictors of longterm outcome. 
Kaplan-Meier survival analysis (Figure 2) showed that patients with LVEF ≥50% and 
peak WMSCI=1 had a favorable prognosis, whereas patients with LVEF <50% and peak 
WMSCI>1 had an adverse long-term prognosis. Patients with LVEF ≥50% and peak WM-
SCI>1 and those with LVEF <50% and peak WMSCI <1 had an intermediate prognosis. 
The survival curves continued to diverge up to ~7 years, implying that the incremental 
prognostic value of both LVEF and peak WMSCI was maintained up to 7 years after ini-
tial testing. These findings indicate that the prognosis in diabetic patients is related not 
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only to the extent of stress induced ischemia but also to LV function at rest. Similar DSE 
results were found for the end points cardiac death and hard cardiac events.
In 74% of the population, fixed WMA were found. It is likely that this high number 
has to do with the fact that our population consists of patients with impaired exercise 
capability, with a great portion of patients with a history of MI. Furthermore, it is well 
established that diabetes could result in myocardial dysfunction even in the absence of 
CAD. This could explain the high incidence of resting WMAs in this study.
We currently are not aware of any other study that has evaluated the prognostic 
value of DSE after such an extended follow-up time. Several studies prove that DSE is a 
useful tool for short- to medium-term risk stratification of diabetic patients. Bigi et al.10 
reported in 2001 that peak WMSCI was a significant predictor of hard cardiac events in a 
population of 259 diabetic patients at 2-year follow-up. D’Andrea et al.11 concluded the 
same in 2003 in a population of 325 diabetic patients at a follow-up of 2.8 years. Both 
studies are in line with our long-term study. In 2006, Cortigiani et al.12 compared the 
prognostic value of dipyridamole and DSE in 749 diabetic patients with 4.707 nondia-
betic patients with known or suspected CAD during a median time of 2.6 years. In the 
diabetic population, restingWMSCI and ischemia at stress echo were the DSE variables 
with incremental value. 
Chaowalit et al.3 verified the prognostic significance of DSE in predicting mortal-
ity and cardiovascular morbidity during a mean period of 5.4 years in a large cohort 
(N=2,349) of patients with diabetes in 2006. Inmultivariate analyses, age, failure to 
achieve target heart rate, and the percentage of ischemic segments were important 
predictors of bothmortality and cardiovascular morbidity (nonfatal MI and late revas-
cularization). Innocenti et al.4 assessed the prognostic role of clinical, rest, and stress 
echocardiographic data in a group of 322 diabetic patients with known or suspected 
CAD during a mean follow-up duration of 3.3 years.4 This study shows that presence 
of viability and severe ischemia during DSE was independently associated with higher 
occurrence of hard cardiac events.
The current study has limitations. The long-term prognostic value of the test is based 
on a population referred to DSE for clinical indications. Because of the clinical factors 
leading patients to be referred for DSE at the time of initial testing, they are likely to 
have had increased risk. This may limit application of the present findings to patients 
with diabetes in general. The results may not be necessarily applicable to patients with 
diabetes and without clinical indication for DSE. Therefore, the use of DSE for risk strati-
fication of all patients with diabetes cannot be recommended.
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Exercise or pharmacologic stress myocardial perfusion imaging has been recommended 
by the American Heart Association for evaluation of ischemic heart disease in diabetic 
patients.13 However, DSE has the advantages of wider availability and lower cost, and 
it avoids radiation exposure to the patient. Appropriateness criteria have been devel-
oped to provide an estimate of the reasonableness of the use of DSE for several clinical 
scenarios. A detailed description of appropriate indications of DSE has been published 
recently14, including detection of CAD/risk assessment in selected asymptomatic and 
symptomatic patients, preoperative evaluation before noncardiac surgery, risk assess-
ment after acute coronary syndrome/postrevascularization, assessment of viability/is-
chemia, and stress study for hemodynamics.
In conclusion, in this study with a mean follow-up of 13±3.2 years, DSE provided re-
stricted predictive value of adverse outcome in patients with diabetes who were unable 
to perform an adequate exercise stress test. The value of the test seems optimal till ~7 
years after initial DSE. Repeating the test at that time might add to its diagnostic value.
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ABSTRACT
The prognostic value of dobutamine stress echocardiography (DSE) at >10-year fol-
low-up is unknown. The aim of this study was to assess the very long-term prognostic 
value of DSE in a high-risk cohort of patients with known or suspected coronary artery 
disease. This prospective, single-center study included 3,381 patients who underwent 
DSE from January 1990 to January 2003. Two-dimensional echocardiographic images 
were acquired at rest, during dobutamine stress, and during recovery. Follow-up events 
were collected and included overall mortality, cardiac death, nonfatal myocardial infarc-
tion, and revascularization. The incremental value of DSE in the prediction of selected 
end points was evaluated using multivariate Cox proportional hazard analysis. During a 
mean follow-up of 13±3.2 years (range 7.3 to 20.5 years), there were 1,725 deaths (51%), 
of which 1,128 (33%) were attributed to cardiac causes. Patients with an abnormal DSE 
had a higher mortality rate (44% vs 35% at 15-year follow-up, p<0.001) than those with 
a normal DSE. When comparing echocardiographic variables at rest to variables at maxi-
mum dose dobutamine, the chi-square of the test improved from 842 to 870 (p<0.0001) 
and from 684 to 740 (p<0.0001) for all-cause mortality and cardiac death, respectively. 
DSE provided incremental value in predicting all-cause mortality, cardiac death, and 
hard cardiac events. There seems, however, to be a “warranty period” of approximately 7 
years, when the survival curves of a normal and abnormal DSE no longer diverge. 
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INTRODUCTION
Exercise electrocardiography is the most frequently used method for noninvasive eval-
uation of coronary artery disease (CAD). Still, a substantial number of patients have an 
impaired exercise capacity, because of a weak general physical condition, neuropathy, 
or peripheral vascular disease. Dobutamine stress echocardiography (DSE) has been re-
ported as a safe1 and effective noninvasive tool to provide diagnostic and prognostic in-
formation in various clinical scenarios.2-7 Currently, it is not known whether the prognos-
tic value of DSE in patients with limited exercise capacity is preserved at very long-term 
(>10 years) follow-up. The goals of this study were to assess the very long-term outcome 
after DSE in a high-risk group of consecutive patients and to evaluate whether DSE has 
incremental prognostic value over clinical variables and echocardiographic data at rest.
METHODS
This prospective study included 3,875 consecutive patients at high risk with known or 
suspected CAD, who were unable to perform an adequate exercise test. Indications for 
DSE were diagnosis of CAD (54%), preoperative evaluation before noncardiac surgery 
(34%), and risk stratification after myocardial infarction (MI, 12%). Of all patients who 
underwent DSE, 30% had a history of typical angina, and 13% had a history of atypi-
cal angina.8 Data were collected from patients who underwent DSE from January 1990 
to January 2003 at the Thoraxcenter, Rotterdam, the Netherlands. Follow-up data at 
shorter intervals and of specific subgroups of this study cohort have been previously 
published.2,5,9 Thirty-nine patients were lost to follow-up, and 455 patients underwent 
early coronary revascularization in the first 60 days after DSE and were excluded from 
the analysis because referral for revascularization within this period is likely to be based 
on DSE results. The final population of this study consisted of 3,381 patients. This study 
was not subject to the Dutch Medical Research Involving Human Subjects Act. There-
fore, approval from the local research ethics committee to conduct this prospective 
follow-up study was not required at the time of enrollment. The study was conducted 
according to the Declaration of Helsinki.10 All patients consented participation in this 
study. 
Clinical characteristics including hypertension, hypercholesterolemia, smoking, pre-
vious MI, a history of heart failure, and/or revascularization were recorded at the time of 
DSE in a computerized database. Hypertension was defined as systolic blood pressure 
≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or the use of antihypertensive med-
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ication. Hypercholesterolemia was defined as total cholesterol >200 mg/dl or the use of 
cholesterol-lowering agents. Heart failure was defined according to the New York Heart 
Association classification and based on established guidelines at the time of diagnosis.11
After baseline echocardiography, dobutamine was infused at a starting dose of 5 
µg/kg/min for 3 minutes followed by 10 µg/kg/min for 3 minutes (low-dose stage). The 
dobutamine dose was increased by 10 µg/kg/min every 3 minutes up to a maximum 
dose of 40 µg/kg/min. Atropine (up to 1 mg) was administered intravenously at the end 
of the last stage if the target heart rate was not achieved. End points of the test were 
an achievement of the target heart rate (85% of the maximal heart rate predicted for 
age), the maximal dose of dobutamine and atropine, >2 mV downsloping ST-segment 
depression measured 80 ms from the J point compared with baseline, hypertension 
(blood pressure >240/120 mm Hg), a decrease in systolic blood pressure of >40 mm Hg, 
and significant arrhythmias.
Two-dimensional echocardiographic images were acquired at rest, during dobuta-
mine stress, and during recovery using standard views. Regional wall motion and sys-
tolic wall thickening were scored on a 5-point scale using a standard 16 segment left 
ventricular model. Ischemia was defined as new or worsened wall motion abnormalities 
(WMA) during stress indicated by an increase of wall motion score ≥1 grade in ≥1 seg-
ment. A biphasic response in an akinetic or severely hypokinetic segment was consid-
ered as an ischemic response. Ischemia was not considered present when akinetic seg-
ments at rest became dyskinetic during stress.12 For each patient, a wall motion score 
index (WMSI) was calculated by dividing the sum of segment scores by the total number 
of interpreted segments. The test was considered abnormal if WMA were seen either at 
rest or during stress. 
Follow-up
Outcome data were obtained by a questionnaire, evaluation of hospital records, con-
tacting the patient’s general practitioner, and/or review of civil registries. The cause of 
death was retrieved at Statistics Netherlands (www.cbs.nl). This permitted high accuracy 
for determination of survival status. Deaths were classified as either documented car-
diac death or other. Before contacting the patient, the online municipal civil registry was 
used to determine the patient’s present survival status. Survival status was retrieved in 
99% of the patients. Questionnaires were sent to all patients alive. The response rate of 
this questionnaire was 83%. The date of response was used to calculate follow-up time. 
Follow-up events noted were overall mortality, hard cardiac events (non-fatal MI and 
cardiac death), and revascularization. 
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Statistical analysis
Continuous data are expressed as mean values ± SD. The Student t test was used to 
analyze continuous data, and the chi-square test was used for differences between pro-
portions. The incremental value of DSE over the clinical variables in the prediction of 
selected end points was evaluated using multivariate Cox proportional hazard analysis 
(SPSS Software, version 21.0) including a model with baseline characteristics and clinical 
variables. Only variables that were significant in a univariate model were added to the 
multivariate model. Using a stepwise model, echocardiographic variables at rest were 
then added to the clinical model to investigate the increase in chi-square value of the 
model. Finally, the variables at peak-dose dobutamine were added to the model. The 
test was considered of additional value if there was a significant increase in chi-square 
value at the third step of the test. The echocardiographic variables that were added 
at rest and peak-dobutamine dose were heart rate, systolic and diastolic blood pres-
sure, rate pressure product (defined as maximum heart rate times the maximum sys-
tolic blood pressure), WMSI, and WMA. The probability of survival was calculated using 
the Kaplan-Meier method, and survival curves were compared using the log-rank test. 
To determine the warranty period of DSE, the Cox proportional hazard analysis for an 
abnormal DSE was repeated at 1, 2, 3, and so on years of follow-up. A p value <0.05 was 
considered statistically significant. 
Table 1. Clinical characteristics. 
Variable N = 3381
Men 2275 (67%)
Age (years) 61.4 ± 12
Hypertension 1005 (30%)
Hypercholesterolemia 770 (23%)
Smoking 988 (29%)
Diabetes mellitus 378 (11%)
Heart failure 454 (13%)
Coronary artery disease 1525 (13%)
Beta-blockers 1116 (33%)
Calcium-channel blockers 816 (24%)
Angiotensin-converting-enzyme blockers 845 (25%)
Diuretics 477 (14%)
Nitrates 1031 (31%)
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RESULTS
Mean age at time of DSE was 61±12 years. There were 2,275 men (67%) and 1,106 
women (33%). Forty-five percent of the patients had known CAD. Clinical characteristics 
are presented in Table 1. The test was terminated for achievement of the target heart 
rate in 89% of the patients, maximal dobutamine/atropine dose in 3%, ST-segment 
changes in 3%, arrhythmias in 1%, severe angina in 1%, abnormal blood pressure in 1%, 
and other symptoms in 2%. Five hundred sixty eight (17%) patients had typical angina 
during dobutamine stress.
DSE was normal in 1,170 of the patients (35%). Ischemia on DSE was detected in 
1,610 patients (48%); of which 1,441 (90%) had WMA at rest. Six hundred one (18%) pa-
tients had WMA at rest alone. During a mean follow-up of 13±3.2 years (range 7.3 to 20.5 
years), there were 1,725 deaths (51%), of which 1,128 (33% of total study cohort) were 
attributed to cardiac causes. Two hundred ninety-seven patients (8.8%) had a nonfatal 
MI, and 793 patients were revascularized (23.5%) at during follow-up. The annualized 
mortality rate of patients who underwent revascularization after an ischemic event was 
comparable to the group who did not undergo percutaneous coronary intervention 
(3.9% vs 4.2%, respectively).
Cumulative survival curves (Figure 1) showed a significantly better survival of patients 
with normal DSE in comparison with abnormal DSE (76% vs 69% at 5 years, 57% vs 50% 
at 10 years, and 44% vs 35% at 15 years; overall p<0.001). Figure 1 illustrates that also for 
the end points cardiac death (87% vs 77% at 5 years, 74% vs 62% at 10 years, and 63% 
vs 47% at 15 years; overall p<0.001) and hard cardiac events (82% vs 69% at 5 years, 65% 
vs 51% at 10 years, and 52% vs 34% at 15 years; overall p<0.001), the population with a 
normal DSE had significant lower chance of adverse events. 
Univariate and multivariate predictors associated with an increased risk of all end points 
of interest are presented in Tables 2 and 3. Echocardiographic variables at peak-dose 
dobutamine significantly increased the value of the test for all end points. When com-
paring echocardiographic variables at rest to variables at maximum dose dobutamine, 
the chi-square of the test improved from 842 to 870 (p<0.0001) and from 684 to 740 
(p<0.0001) for all-cause mortality and cardiac death, respectively. WMSI during stress 
predicted both all-cause mortality and cardiac death. At 5 years of follow-up, the hazard 
ratio of having an abnormal DSE reached a maximum of 1.37 and started to decrease 
after 7 years of follow-up.
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Figure 1. Kaplan-Meier survival curves for all-cause mortality (A), cardiac death (B), and hard car-
diac events (C) in patients with normal (dark gray) versus abnormal (light gray) DSE. The dummy 
lines illustrate that the curves start to run parallel at approximately 7 years (dashed line).
DISCUSSION
DSE is a commonly used tool to predict short to medium-term outcome of patients with 
limited exercise capacity. In this high-risk patient cohort, DSE has incremental value at 
very long-term follow-up for predicting all end points of interest in a consecutive pop-
ulation with known or suspected CAD. DSE added prognostic value to clinical variables 
and stress test data in predicting all-cause mortality, cardiac death, and hard cardiac 
events. Heart rate, WMSI, and new or worsened WMA during peak-dose dobutamine 
were significant predictors depending on the end points of interest (Tables 2 and 3). 
Kaplan-Meier curves confirmed the previously described findings because outcome for 
all end points of interest was in favor of a normal DSE in comparison with an abnormal 
DSE at 18 years after initial testing (p<0.001).
Although the Kaplan-Meier curves showed a significant improved outcome in favor 
of a normal DSE for all end points, it is of interest to see that the curve of all-cause mor-
tality (Figure 1) diverges up to approximately 7 years after DSE. At this point, the test 
seems to stop to further discriminate between abnormal and normal DSE and both lines 
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Table 2. Independent predictors of all-cause mortality. 
Univariate
I:
Clinical
II:
I + DSE at rest
III:
II + DSE at peak
Variable HR (CI) HR (CI) HR (CI)
Male gender 1.45 (1.31-1.62) 1.39 (1.25-1.55) 1.39 (1.25-1.55) 1.38 (1.23-1.54)
Age 1.06 (1.05-1.06) 1.06 (1.05-1.06) 1.06 (1.06-1.07) 1.06 (1.06-1.07)
Coronary artery disease n.s. - - -
Heart failure 1.91 (1.68-2.17) 1.59 (1.38-1.82) 1.36 (1.18-1.58) 1.40 (1.21-1.62)
Diabetes mellitus 1.44 (1.25-1.65) 1.49 (1.30-1.72) 1.41 (1.22-1.62) 1.40 (1.21-1.61)
Hypertension n.s. - - -
Hypercholesterolaemia 0.71 (0.62-0.80) 0.74 (0.65-0.84) 0.68 (0.60-0.77) 0.69 (0.60-0.78)
Smoking 1.24 (1.12-1.37) 1.42 (1.28-1.57) 1.42 (1.28-1.58) 1.42 (1.28-1.58)
Beta-blockers 0.81 (0.73-0.89) 0.86 (0.77-0.96) n.s. -
Calcium-channel blockers n.s. - - -
Angio-converting enzyme 
inhibitors
1.29 (1.16-1.43) n.s. - -
Diuretics 1.73 (1.53-1.97) 1.33 (1.15-1.53) 1.23 (1.07-1.42) 1.23 (1.07-1.42)
Digoxin 2.24 (1.88-2.68) 1.36 (1.12-1.65) n.s. -
Nitrates n.s. - - -
Heart rate rest 1.11 (1.07-1.15) - 1.13 (1.09-1.18) n.s.
Systolic blood pressure rest 1.05 (1.03-1.07) - n.s. -
Diastolic blood pressure rest n.s. - - -
Rate pressure product rest 1.01 (1.00-1.01) - n.s. -
Wall motion score index rest 1.48 (1.38-1.59) - 1.32 (1.22-1.44) -
Rest wall motion abnormalities 1.29 (1.17-1.42) - n.s. -
Heart rate peak 0.97 (0.95-0.99) - - n.s.
Systolic blood pressure peak 0.97 (0.95-0.99) - - n.s.
Diastolic blood pressure peak 0.95 (0.92-0.98) - - n.s.
Rate pressure product peak 1.00 (1.00-1.00) - - n.s.
Wall motion score index peak 1.54 (1.43-1.67) - - 1.35 (1.23-1.48)
Peak wall motion abnormalities 1.37 (1.25-1.51) - - n.s.
Any wall motion abnormalities 1.27 (1.15-1.41) - - n.s.
X2-test 842 870 870
P-value - P<0.0001 P<0.0001
n.s. = not significant, - = variable not included.
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Table 3. Independent predictors of cardiac death. 
Univariate
I:
Clinical
II:
I + DSE at rest
III:
II + DSE at peak
Variable HR (CI) HR (CI) HR (CI)
Male gender 1.56 (1.36-1.78) 1.46 (1.27-1.67) 1.40 (1.22-1.61) 1.38 (1.20-1.59)
Age 1.07 (1.05-1.05) 1.06 (1.06-1.07) 1.06 (1.06-1.07) 1.06 (1.05-1.07)
Coronary artery disease 1.33 (1.18-1.50) n.s. - -
Heart failure 2.47 (2.14-2.86) 2.00 (1.70-2.35) 1.60 (1.36-1.89) 1.65 (1.40-1.94)
Diabetes mellitus 1.40 (1.17-1.67) 1.42 (1.19-1.70) 1.32 (1.11-1.58) 1.30 (1.09-1.56)
Hypertension n.s. - - -
Hypercholesterolaemia 0.78 (0.67-0.90) 0.80 (0.69-0.94) 0.72 (0.62-0.84) 0.73 (0.63-0.86)
Smoking 1.36 (1.20-1.54) 1.54 (1.36-1.74) 1.54 (1.35-1.74) 1.53 (1.35-1.73)
Beta-blockers 0.81 (0.71-0.92) 0.86 (0.75-0.98) n.s. -
Calcium-channel blockers n.s. - - -
Angio-converting enzyme 
inhibitors
1.48 (1.30-1.68) n.s. - -
Diuretics 1.95 (1.67-2.26) 1.34 (1.12-1.59) n.s. -
Digoxin 2.68 (2.18-3.28) 1.46 (1.17-1.83) 1.36 (1.09-1.70) 1.33 (1.06-1.66)
Nitrates 1.32 (1.16-1.49) n.s. - -
Heart rate rest 1.12 (1.06-1.17) - 1.13 (1.08-1.18) 1.14 (1.09-1.19)
Systolic blood pressure rest 1.03 (1.01-1.06) - n.s. -
Diastolic blood pressure rest n.s. - - -
Rate pressure product rest 1.01 (1.00-1.01) - n.s. -
Wall motion score index rest 1.78 (1.64-1.94) - 1.54 (1.39-1.69) n.s.
Rest wall motion abnormalities 1.70 (1.50-1.93) - n.s. -
Heart rate peak 0.96 (0.94-0.99) - - n.s.
Systolic blood pressure peak 0.95 (0.93-0.97) - - n.s.
Diastolic blood pressure peak 0.93 (0.89-0.96) - - n.s.
Rate pressure product peak 1.00 (0.99-1.00) - - n.s.
Wall motion score index peak 1.93 (1.77-2.12) - - 1.63 (1.47-1.81)
Peak wall motion abnormalities 1.76 (1.57-1.99) - - n.s.
Any wall motion abnormalities 1.70 (1.49-1.94) - - n.s.
X2-test 684 734 740
P-value - P<0.0001 P<0.0001
n.s. = not significant, - = variable not included.
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The prognostic significance of DSE at short- to medium-term follow-up has been 
demonstrated in several studies.13-17 Currently, there are no studies evaluating the very 
long-term prognostic role of DSE. In a meta-analysis, Shaw et al18 investigated the prog-
nostic role of dipyridamole and DSE in preoperative screening before vascular surgery. 
The meta-analysis included 15 studies, of which 5 studies (n=445) were based on studies 
on DSE. The analysis demonstrated that echocardiographic WMA were predictive of ad-
verse perioperative outcomes. Their analysis supports pharmacologic stress imaging as 
a tool for preoperative screening in patients at intermediate risk. These previous studies 
provide useful information about the clinical importance of DSE, but the very long-term 
prognostic value of a DSE remains unclear. This study provides unique information on 
the very long-term prognostic value of the test in a consecutive population of subjects 
with known or suspected CAD. It demonstrates the clinical importance of DSE results for 
assessment of very long-term outcome.
The event rate in this present study is high (51% of the patients died during fol-
low-up). There are multiple factors that may explain the relatively high event rate in this 
study. First, this cohort is a high-risk group, the mean age was 61 years and 45% had 
known CAD, whereas 65% of the patients had an abnormal DSE. Second, all patients un-
derwent DSE because of limited exercise capacity. The inability to perform an adequate 
exercise test is an indicator of adverse outcome in itself. Third, the follow-up of this co-
hort was nearly complete. Finally, this study has followup period of >10 years, which is 
significantly longer than previous studies.
Although this study included a high-risk population, Table 1 demonstrates that pa-
tients seemed undertreated according to current standards. Inclusion of patients in 
this study started as early as 1990, a time at which medical treatment was suboptimal 
compared with current standards, as has been demonstrated in the EUROASPIRE (EU-
ROpean Action on Secondary and Primary prevention through Intervention to Reduce 
Events) registry.19 Referral to coronary revascularization (23.5%) was also relatively low 
given the 48% of the patients with detected ischemia. However, previous studies have 
demonstrated that the timing of revascularization requires careful consideration. Pa-
tients with no or mild symptoms and little ischemia can safely be treated with medical 
treatment alone. Furthermore, the COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) trial21 has demonstrated that clinical outcome in 
start to run parallel. This effect is less pronounced in the Kaplan-Meier curves of cardiac 
death and hard cardiac events (Figure 1), but it suggests a certain “warranty period” of 
a DSE. This in line with what we observed in the diabetic subcohort of this population,5 
where a similar phenomenon was observed at 7 years.
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patients with stable angina does not significantly differ between patients who receive 
an initial therapy of coronary revascularization and optimal medical therapy compared 
to patients with optimal medical therapy alone.
The American College of Cardiology recommends pharmacologic stress with either 
nuclear myocardial infusion imaging or echocardiography for risk assessment in pa-
tients with stable ischemic heart disease who are either unable to exercise to an ade-
quate workload regardless of interpretability of electrocardiogram, patients with left 
bundle branch block on electrocardiogram regardless of ability to exercise to an ade-
quate workload or patients who are being considered for revascularization of known 
coronary stenosis of unclear physiological significance.22 The appropriateness criteria 
for stress echocardiography formulated by the American College Cardiology illustrate 
these recommendations and add several clinical scenarios in which stress echocar-
diography is the preferred technique or can be considered.23 The present study dem-
onstrates that DSE is a valuable test in predicting all-cause mortality, cardiac death, and 
hard cardiac events, even at very long-term follow-up. The long-lasting follow-up of this 
study is unique and reinforces the finding from shorter follow-up studies that stress 
echo is a powerful prognostic test. There seems to be a “warranty period” of approxi-
mately 7 years after which a DSE start to lose its ability to further discriminate between 
a normal and abnormal DSE.
This study has some limitations. First, because of the clinical factors leading patients to 
be referred for DSE at the time of initial testing, they are likely to have had increased risk 
for adverse events with a worse prognosis than a general population. This may limit ap-
plication of the present findings to patients suspected for CAD in general. Furthermore, 
left ventricular ejection fraction was not available in all patients because it was only 
measured on indication and could therefore not be used in the analysis.
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ABSTRACT
Background. Both dobutamine stress echocardiography (DSE) and myocardial perfu-
sion imaging (MPI) using single-photon emission computed tomography (SPECT) are 
frequently used for cardiac risk stratification. The long-term relative prognostic value 
of these modalities has not been studied. Therefore, this study evaluated the long-term 
prognostic value of DSE compared to MPI in patients unable to perform exercise testing. 
Methods. This prospective, single center study included 301 patients (mean age 59±12 
years, 56% men) unable to perform exercise tests who underwent DSE and dobutamine 
stress 99mTc-sestamibi MPI. End-points during follow-up were all-cause mortality, cardiac 
mortality and nonfatal myocardial infarction (MI). Univariable and multivariable Cox 
proportional hazards regression models were used to identify independent predictors 
of outcome. The probability of survival was calculated using the Kaplan-Meier method. 
Results. A total of 182 patients (60%) had an abnormal DSE and 198 (66%) patients had 
an abnormal MPI. The agreement between DSE and MPI was 82% (κ=0.62). During a me-
dian follow-up of 14 years (range 5-18) , 172 deaths (57%) occurred, of which 72 (24 %) 
were due to cardiac causes. Nonfatal MI occurred in 46 patients (15%). The multivariable 
analysis demonstrated that an abnormal DSE was a significant predictor of cardiac mor-
tality (HR 2.35, 95% CI [1.17-4.73]) and hard cardiac events (HR 2.11, 95% CI [1.25-3.57]). 
Also, an abnormal MPI result was a significant predictor of cardiac mortality (HR 3.03, 
95% CI [1.33-6.95]) and hard cardiac events (HR 2.06, 95% CI [1.12-3.79]).
Conclusions. DSE and MPI are comparable in predicting long-term cardiac mortality 
and hard cardiac events in patients unable to perform exercise testing.  
Key Words: DSE, myocardial perfusion imaging, SPECT, long-term prognostic value, car-
diac events. 
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ABBREVIATIONS
CAD Coronary artery disease
C-index Concordance index
DSE Dobutamine stress echocardiography
ECG Electrocardiography
LVEF Left ventricular ejection fraction
MBq Megabecquerel
MI Myocardial infarction
MPI Myocardial perfusion imaging
SPECT Single-photon emission computed tomography
99mTc Technetium-99m
INTRODUCTION
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality 
worldwide. As such, noninvasive imaging techniques are important to diagnose and 
risk stratify patients with CAD.1 In patients who cannot exercise, due to conditions such 
as degenerative joint disease and peripheral vascular disease, pharmacologic stress 
testing is an appropriate alternative. Both dobutamine stress echocardiography (DSE) 
and stress myocardial perfusion imaging (MPI) are widely used for the evaluation of 
stress-induced myocardial ischemia, and provide significant prognostic information.2-7 
Currently, information on the long-term relative prognostic value of DSE compared to 
MPI is lacking. Therefore, this study evaluated the long-term prognostic value of DSE 
compared to MPI in patients unable to perform exercise testing.
METHODS
Study population
The study population consisted of 354 consecutive patients. This study is a continuation 
of the previously reported study in which the same patient population was evaluated 
with a mean follow-up of 7.3 years.3 All patients underwent simultaneous dobutamine 
stress echocardiography and dobutamine stress 99mTc-sestamibi SPECT for the evalua-
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tion of suspected or known CAD. Follow-up was successful in 351 (99%) patients. Fifty 
patients underwent early coronary revascularization <60 days after MPI and were ex-
cluded from analysis. This exclusion was based on previously published data indicating 
that referral to coronary revascularization in the first 60 days after testing tends to be 
based on the results of the test. Referral to revascularization >60 days after testing tends 
to be based on the worsening of the patient’s clinical status.8 All patients gave informed 
consent before testing and the local ethics committee approved the study protocol. 
Patients were enrolled between January 1991 and January 1995. The test in these pa-
tients with known or suspected CAD was requested for evaluation of ischemia. Before 
the stress test, a structured interview was achieved, including assessment of cardiac 
risk factors. Hypertension was defined as blood pressure ≥140/90 mmHg or the use of 
antihypertensive medication. Diabetes mellitus was defined as a fasting glucose level 
>140 mg/dL or use of insulin or oral hypoglycemic agents. Hypercholesterolemia was 
defined as a total cholesterol ≥6.4 mmol/L or treatment with lipid-lowering medication. 
Dobutamine stress testing protocol
The dobutamine stress testing was performed using a standard protocol as described 
previously.3 Dobutamine was injected intravenously, starting at a dose of 10 µg/kg/min 
for 3 minutes and increasing by 10 µg/kg/min to a maximum dose of 40 µg/kg/min. If 
the test end point was not reached at a maximum dose of dobutamine, up to 1 mg of at-
ropine was administered intravenously. During stress testing, blood pressure, heart rate 
and electrocardiography were continuously monitored. Test endpoints were achieve-
ment of target heart rate (85% of maximum age and sex-predicted heart rate), horizon-
tal or downsloping ST segment depression of more than 2 mm, ST-segment elevation 
of more than 1 mm, severe angina, systolic blood pressure decrease >40 mmHg, blood 
pressure > 240/110 mmHg or clinically important cardiac arrhythmias. An intravenous 
beta-blocker was used to reverse the effects of dobutamine/atropine. 
99mTc-sestamibi SPECT MPI
An intravenous dose of 370 MBq of 99mTc-sestamibi was administered approximately 1 
minute before the termination of the stress test. For resting studies, 370 MBq of 99mTc- 
sestamibi was injected ≥ 24 hours after the stress study. Image acquisition was achieved 
with a Gammasonics single-head camera (Siemens, Iselin, NJ) without attenuation or 
scatter correction, using a low-energy all-purpose collimator. In all cases, transaxial 
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tomograms were reconstructed; for each study, six short-axis and three sagittal long-
axis slices were analysed. To compare the rest and stress studies, each of the short-axis 
slides was divided into eight equal segments. The septal part of the two basal slices was 
excluded from analysis because this region corresponds to the fibrous portion of the 
interventricular septum and normally exhibits reduced uptake. The apical region was 
assessed from the three sagittal cross-sections. A total of 47 segments per patient were 
analysed. Data interpretation was performed visually and semiquantitatively. Circum-
ferential profile analysis was used to assist visual analysis of images.
Stress and rest tomographic views were reviewed side-by-side by two experienced 
observers who were unaware of clinical data and echocardiograms, using a 5-point scor-
ing system (1 =  normal, 2 = slightly reduced, 3 = moderately reduced, 4 = severely re-
duced, 5 = absent uptake). Ischemia was defined as a perfusion defect on stress images 
that partially or completely resolved at rest in at least two contiguous segments. A re-
gion was classified as infarcted in the case of a perfusion defect on stress images in two 
or more contiguous segments, which persisted on rest images. An abnormal scan was 
considered in the presence of a fixed or reversible perfusion defect. To overcome mis-
alignment between the myocardial perfusion data and the echocardiographic data, an 
identical six-segment model was used for both techniques. The 16 echocardiographic 
and 47 scintigraphic segments were regrouped into six major myocardial regions (ante-
rior, septum anterior, septum inferior, inferoposterior, lateral and apical). 
Dobutamine stress echocardiography
Two dimensional echocardiograms were acquired at rest, during dobutamine  stress 
testing, and during recovery. Two experienced observers, unaware of any other data, 
scored the echocardiograms using a standard 16-segment model. Regional wall motion 
and systolic wall thickening were scored on a 5-point scale (1=normal, 2= mild hypoki-
nesia, 3 = severe hypokinesia, 4 = akinesia, 5 = dyskinesia). Ischemia was defined as new 
or worsened wall motion abnormalities during stress, indicated by an increase in wall 
motion score of ≥ 1grade in one or more segments. Ischemia was not considered to be 
present when akinetic segments at rest became dyskinetic during stress. Dobutamine 
stress echocardiographic results were defined as abnormal if there was ischemia during 
stress or fixed wall motion abnormalities. Echocardiographic segments were grouped 
into six major segments for comparison with SPECT.9 Tests that were stopped prema-
turely in the absence of perfusion or wall motion abnormalities were considered neg-
ative. 
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Follow-up
Clinical outcome data were obtained in 2012 by contacting the patient, the patients’ 
general practitioners, civil registries and reviewing hospital records. The date of the last 
review or consultation was used to calculate follow-up time. The endpoints were all-
cause mortality, cardiac mortality and nonfatal myocardial infarction (MI). Cardiac mor-
tality was defined as death caused by MI, cardiac arrhythmias, refractory heart failure, or 
sudden death occurring without another explanation. The combined endpoint of car-
diac mortality and nonfatal MI was considered as hard cardiac events. MI was defined 
according to the Joint European Society of Cardiology/American College of Cardiology 
Committee criteria.10 Diagnosis of an acute, evolving, or recent MI was fulfilled either by 
a typical rise and gradual fall (troponin) or more rapid rise and fall (creatinine kinase–MB) 
of biochemical markers of myocardial necrosis with at least one of the following criteria: 
ischemic symptoms, development of pathological Q waves on the electrocardiogram, 
electrocardiogram changes indicative of myocardial ischemia (ST-segment elevation or 
depression), or coronary artery intervention; or by pathological findings of an acute MI. 
Statistical analysis
Values were expressed as means (±SD) or number, and compared using the Student t 
test or chi-squared test. Agreement between DSE and MPI was assessed by κ statistics. 
Univariable and multivariable Cox proportional hazard models were used to identify 
variables that were independently predictive of late cardiac events. The risk of a variable 
was expressed as hazard ratios with corresponding 95% confidence intervals. Clinical 
data, stress test variables, and non-invasive imaging data were incorporated into the 
analysis. The multivariable analysis was performed by first considering the clinical data, 
and next the combination of clinical and stress test variables. In the final models, the 
stress echocardiographic or 99mTc-sestamibi SPECT data were added. The discrimina-
tive ability of the Cox regression models was determined by calculating the concor-
dance-(C)-index. Models are typically considered reasonable when the C-index > 0.7.11 
The probability of survival was calculated using the Kaplan-Meier method, and survival 
curves were compared using the log-rank test. P values <0.05 were considered statis-
tically significant. All statistical analyses were performed using SPSS 22 (IBM Corp., Ar-
monk, NY, USA).
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RESULTS
Patient demographics and stress test results
The clinical characteristics are presented in Table 1. The mean age of the 301 patients 
was 59±12 years, and 56% were men. A total of 149 patients (50%) had a previous MI. 
During the dobutamine-atropine stress test, heart rate increased from a mean (±SD) of 
69 ± 13 beats per minute to 136 ± 17 beats per minute (P<0.0001) and systolic blood 
pressure increased from 136 ± 23 mm Hg to 147 ± 30 mm Hg (P<0.001). Atropine, which 
was added in 129 patients (43%), was more frequently administered in patients taking 
beta-blockers (67% (84/125]) than in those who were not (26% (45/176], P<0.0001). Side 
effects during stress testing included non-sustained ventricular tachycardia in 13 pa-
tients (4%), atrial fibrillation in 4 patients (1%), severe hypotension in 2 patients (0.7%), 
nausea in 15 patients (5%), and headache in 15 patients (5%). No patient experienced a 
MI or fatal complication. The test was terminated because of side effects in 17 patients 
(6%). 
Table 1. Clinical characteristics. 
Variable 
(number and %) Total
Cardiac 
mortality
No cardiac 
mortality p-value
Cardiac 
events
No 
cardiac 
events p-value
N=301 N=72 N=229 N=118 N=183
Clinical data 
    Age>70 years 55 (18) 22 (31) 33 (14) 0.65 23 (19) 32 (17) 0.38
    Male gender 168 (56) 50 (69) 118 (52) 0.01 79 (67) 89 (49) 0.002
    Previous MI 149 (50) 51 (71) 98 (43) <0.001 79 (34) 70 (38) <0.001
    Hypertension 132 (44) 34 (47) 98 (43) 0.49 54 (46) 78 (43) 0.45
    Hypercholesterolemia 76 (25) 23 (32) 53 (23) 0.21 34 (29) 42 (23) 0.27
    Smoking 79 (26) 26 (36) 53 (23) 0.03 34 (29) 45 (25) 0.42
    Heart failure 57 (19) 26 (36) 31 (14) <0.001 30 (25) 27 (15) 0.003
    Diabetes mellitus 43 (14) 14 (19) 29 (13) 0.16 19 (16) 24 (13) 0.55
Stress test results
    Typical angina 72 (24) 16 (22) 56 (24) 0.69 33 (28) 39 (21) 0.21
    ST-segment changes 85 (28) 31 (43) 54 (24) 0.001 47 (21) 38 (21) 0.001
    Abnormal DSE 182 (60) 59 (82) 123 (54) <0.001 92 (78) 90 (49) <0.001
    Abnormal MPI 198 (66) 62 (86) 136 (59) <0.001 97 (82) 101 (55) <0.001
*MI = myocardial infarction.  DSE = dobutamine stress echocardiography. MPI = myocardial perfusion imaging
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Imaging results and follow-up
Abnormal DSE was detected in 182 (60%) patients, whereas 198 (66%) patients had an 
abnormal MPI. The agreement between DSE and MPI  was 82% (κ = 0.62). When con-
sidered the 152 patients without previous MI the agreement between DSE and MPI 
was 81% (κ = 0.60). The agreement between DSE and MPI was 86% (κ = 0.36) when 
only ischemia was considered. Normal DSE and abnormal MPI was observed in 35 pa-
tients, whereas 19 patients had a normal MPI and an abnormal DSE. During a median 
follow-up of 14 years (range 5-18),  172 deaths (57%) occurred, of which 72 (24 %) were 
due to cardiac causes. Nonfatal MI occurred in 46 patients (15%).  
Clinical data and outcome
Univariable predictors of both endpoints (cardiac mortality and hard cardiac events) 
were age, male gender, previous MI, heart failure and ST-segment changes (Table 1). 
When analyzed as a dichotomous variable age was not a significant predictor. Smoking 
was also a significant predictor of cardiac mortality. Both an abnormal DSE and an ab-
normal MPI were strongly associated with both endpoints. 
Survival analysis and predictors of long-term outcome
Annualized event rates for cardiac mortality for patients with normal DSE was signifi-
cantly lower (0.8%) than for those with abnormal DSE (2.8%, p< 0.001). According to 
hard cardiac events, annualized event rates for normal DSE were 1.5% compared to 
3.8%  in abnormal DSE (p< 0.001). Equally, the annualized event rates for cardiac mor-
tality for patients with normal MPI was significantly lower than for those with abnormal 
MPI (0.6% versus 2.8%, p < 0.001). The annualized rates for hard cardiac events were 
1.3% in normal MPI and 3.7% in abnormal MPI  (p< 0.001). 
Kaplan-Meier survival curves are presented in Figures 1, 2 and 3. The survival curves 
show that a normal DSE and a normal MPI were associated with relatively low risk for 
all-cause mortality, cardiac mortality and hard cardiac events. Conversely, patients with 
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Figure 1. Kaplan-Meier survival curves for all-cause mortality using DSE (1A) and MPI (1B).
y=years. MPI = myocardial perfusion imaging. DSE = dobutamine stress echocardiography. 
Figure 2. Kaplan-Meier survival curves for cardiac mortality using DSE (2A) and MPI (2B). 
y=years. MPI = myocardial perfusion imaging. DSE = dobutamine stress echocardiography. 
Figure 3. Kaplan-Meier survival curves for hard cardiac events using DSE (3A) and MPI (3B). 
y=years. MPI = myocardial perfusion imaging. DSE = dobutamine stress echocardiography. 
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an abnormal test result had a significantly increased risk of all-cause mortality (Figure 1), 
cardiac mortality (Figure 2) and hard cardiac events (Figure 3). The survival curves con-
tinued to diverge during the long-term follow-up period, which indicated a maintained 
prognostic value of both imaging modalities.  
Multivariable analysis demonstrated that age, previous MI, smoking and heart failure 
were independent predictors of cardiac mortality (Table 2). Previous MI and heart failure 
were independent predictors of hard cardiac events (Table 2). Age was of borderline 
significance. A multivariable model also revealed that both an abnormal DSE and an 
abnormal MPI had an incremental prognostic value over clinical variables and stress test 
parameters. For the prediction of cardiac mortality, the C-index for clinical and clinical 
and stress test data was 0.73 and 0.76 respectively. The C-index was 0.76 when DSE or 
MPI was added. For the prediction of hard cardiac events, the C-index for clinical and 
clinical and stress test data was 0.70 and 0.71 respectively and 0.71 when DSE or MPI 
were added. 
DISCUSSION
The present study is the first to assess the prognostic value of DSE compared to MPI 
for long-term outcome. During a median follow-up of 14 years, 172 deaths occurred, 
of which 72 were due to cardiac causes. Nonfatal MI occurred in 46 patients. The sur-
vival curves continued to diverge during the follow-up period, indicating a maintained 
prognostic value of both DSE and MPI. Both patients with a normal DSE and  a normal 
MPI had a relatively favourable long-term prognosis in contrast to patients with an ab-
normal imaging result. A multivariable model revealed that both an abnormal DSE and 
an abnormal MPI had an incremental prognostic value over clinical variables and stress 
test parameters. Ischemia on DSE but not ischemia on MPI was predictive of outcome. 
Both modalities were comparable in identifying patients with low or high risk of cardiac 
events during long-term follow-up.
Non-invasive imaging techniques are central in diagnosing patients with known 
of suspected CAD. Both DSE and MPI play important roles in this regard, in particular 
in patients with an intermediate likelihood of CAD12, and show similar accuracy in the 
diagnosis of CAD.5, 6 Data on the long-term prognostic implications of these imaging 
techniques are lacking.13
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A few previous studies have compared the prognostic value between DSE and MPI 
with a mean follow-up time of less than 8 years.2, 3 ,5-7, 14, 15 Geleijnse et al.2 studied 220 
patients with chest pain undergoing DSE and simultaneous 99mTc-sestamibi SPECT. 24 
patients experienced hard cardiac events. During a follow-up of 31±15 months, event 
rates after both stress modalities were similar. They concluded that DSE and MPI pro-
vided comparable prognostic information. Olmos et al.14 reported a study of 248 pa-
tients who underwent exercise echocardiography and thallium-201 SPECT. During a 
mean follow-up of 3.7 ± 2.0 years, 8 nonfatal infarctions and 7 cardiac deaths occurred. 
They reported that exercise echocardiography and thallium-201 SPECT provide compa-
rable prognostic information for cardiac death and cardiac events. In 146 patients with 
previous MI, Acampa et al.15 compared the prognostic value of DSE and SPECT MPI. Dur-
ing a mean follow-up of 44±19 months, 20 cardiac events occurred. Ischemia at MPI, but 
not at echocardiography, was a significant predictor of cardiac events. Previously, we 
reported the 7-year follow-up in these 301 patients. In that study, patients with normal 
DSE and MPI maintained a relatively low event rate compared to patients with an abnor-
mal DSE and MPI. Compared to these previous studies, our study included 301 patients 
who were followed for a median time of 14 years. The present study extends the obser-
vations from these previous studies and demonstrates that the long-term prognostic 
value of DSE is similar to that of stress MPI.
A meta-analysis reported higher annualized cardiac events for patients with normal 
pharmacological SPECT (1.78%) compared to patients with normal exercise SPECT 
(0.65%).16 Several reasons has been attributed for these difference; patients who un-
derwent pharmacological stress SPECT are older, have more co-morbidities and has an 
increased number of risk factors for CAD. In the current study, we found an annualized 
hard cardiac event rate of 1.3% for normal dobutamine stress MPI. From a clinical per-
spective, patients unable to perform exercise tests who have a normal MPI have a good 
prognosis and could be spared invasive evaluation of the coronary arteries. Based on 
the current findings, both a normal DSE and a normal stress MPI identified low- and 
high-risk patient groups. As a consequence, both stress modalities could be used inter-
changeably in identifying low-risk patient group.  
Both DSE and MPI have developed rapidly over the past years and have emerged as 
a valuable tool for diagnosis and prognosis of CAD. These imaging methods have inher-
ent differences: SPECT probes myocardial hypoperfusion, whereas DSE probes systolic 
dysfunction.13 According to the ischemic cascade, a series of biochemical reactions that 
occurs after inadequate myocardial blood supply, perfusion abnormalities precede sys-
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tolic dysfunction.13 This may influence the sensitivity and specificity of MPI and DSE for 
the evaluation of myocardial ischemia. DSE is less sensitive in detecting CAD for mild 
disease, but more specific for the overall patient group. Stress SPECT has a higher diag-
nostic accuracy in patients with multivessel CAD.17 A recent multicenter study18 com-
pared commonly used  imaging techniques and found that both MPI and stress echoc-
ardiography had good diagnostic accuracy for CAD (area under the curve 0.74 and 0.70 
respectively). Our findings show that there are comparable implications in risk-strat-
ifying patients, using either modality. Which of these modalities is most suitable still 
depends on the patients clinical status, availability and local expertise and costs. 
This study has some limitations. First, the prognostic value of gated SPECT was not 
examined, due to the fact that at the time of data collection gated SPECT was not rou-
tinely performed in our center. As a result left ventricular ejection fraction (LVEF) was 
not available. Also, LVEF was not routinely examined during DSE. Information about 
LVEF could have improved the current analysis. Second, attenuation or scatter correc-
tion during stress SPECT was not routinely performed. Previous studies have shown that 
attenuation correction contribute to optimize further risk stratification.19, 20 Third, the 
patient population was relatively small. This could have influenced the results.  
New knowledge gained
Dobutamine stress echocardiography and dobutamine stress 99mTc-sestamibi SPECT 
are comparable in predicting long-term (>14 years) cardiac mortality and hard cardiac 
events in high risk patients (patients unable to perform exercise testing). From a clinical 
view, both techniques can be used interchangeably to classify patients as low or high 
risk of cardiac events. 
CONCLUSIONS
In this study DSE and MPI provide comparable prognostic information for the prediction 
of cardiac mortality and hard (cardiac mortality and nonfatal MI) cardiac events in pa-
tients unable to perform exercise testing. Both techniques can be used interchangeably 
to classify patients as low or high risk of cardiac events. 
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ABSTRACT
The role of early coronary revascularization in the management of stable coronary 
artery disease (CAD) remains controversial. The aim of this study was to evaluate the 
impact of early coronary revascularization on long-term outcomes (>10 years) after an 
ischemic DSE in patients with known or suspected CAD. Patients without stress-induced 
ischemia on DSE and patients who underwent late coronary revascularization (>90 days 
after DSE) were excluded. The final study cohort consisted of 905 patients. A DSE with 
a peak wall motion score index (WMSI) of 1.1 to 1.7 was considered mild to moderately 
abnormal (n=460), and >1.7 was markedly abnormal (n=445). Endpoints were all-cause 
mortality and cardiac mortality. The impact of early coronary revascularization on out-
comes was assessed using Kaplan Meier survival analysis and Cox’s proportional hazard 
regression models. Early coronary revascularization was performed in 222 patients (PCI 
in 113 [51%] and CABG in 109 patients [49%]). During a median follow-up time of 10 
years (range 8-15), 474 deaths (52%) occurred, of which were 241 (51%) due to cardiac 
causes. Kaplan-Meier survival curves showed that both in patients with a markedly ab-
normal DSE and a mild to moderately abnormal DSE, early revascularization was asso-
ciated with better long-term outcomes. Multivariable analyses revealed that early re-
vascularization had a beneficial effect on all-cause mortality (HR 0.60, 95% CI 0.46-0.79) 
and cardiac mortality (HR 0.49, 95% CI 0.34-0.72). In conclusion, early coronary revascu-
larization has a beneficial impact on long-term outcomes in patients with myocardial 
ischemia on DSE. Early coronary revascularization was associated with better outcomes 
not only in patients with a markedly abnormal DSE but also in those with a mild to mod-
erately abnormal DSE.
Key Words: Early Revascularization; Long-term; Ischemia; DSE.
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INTRODUCTION
Coronary artery disease (CAD) remains the leading cause of mortality worldwide.1 Med-
ical therapy and revascularization (either percutaneous coronary intervention [PCI] or 
coronary artery bypass grafting [CABG]) are both valuable treatment options of patients 
with stable CAD.2,3 Major advances in medical therapy and invasive coronary procedures 
have contributed to improved outcomes. In patients with acute coronary syndrome, 
it has been shown that coronary revascularization substantially reduces mortality.4 
However, the role of early coronary revascularization in the management of stable CAD 
remains controversial. The COURAGE trial, among patients with stable ischemic heart 
disease, demonstrated  no difference in long-term mortality rates with medical therapy 
and PCI compared to medical therapy alone.5 Information on the impact of coronary re-
vascularization on long-term outcome in patients with myocardial ischemia at dobuta-
mine stress echocardiography (DSE) is scarce. The follow-up period in previous studies 
was on average 3 years.6,7 Accordingly, the objectives of the present study were twofold: 
1 to evaluate the impact of early coronary revascularization on long-term (>10 years) 
mortality after an ischemic DSE and 
2 to evaluate whether the amount of ischemia determines the prognostic benefit of 
revascularization. 
METHODS
The study population consisted of 3922 consecutive patients with known or suspected 
CAD who underwent DSE between January 1990 and January 2003. Only patients with 
stress-induced ischemia on DSE were included (n=1191). Early coronary revasculariza-
tion was defined as percutaneous coronary intervention (PCI) or coronary artery by-
pass grafting (CABG) ≤90 days after DSE. Patients who underwent late revascularization 
(defined as >90 days after DSE) were excluded (n=286). The reason for this exclusion 
was based on the primary goal of the current study, i.e. to evaluate the impact of early 
revascularization (≤90 days after DSE). The decision to revascularization was made on 
clinical grounds. The final study cohort consisted of 905 patients. The test was requested 
for diagnostic reasons in 517 (57%) patients, for preoperative cardiac risk assessment 
in 211 (23%), or for evaluation of viable myocardium in 177 (20%) with left ventricular 
dysfunction. Clinical data were collected at the time of DSE. Hypercholesterolemia was 
defined as total cholesterol >200mg/dL or use of lipid-lowering medications. Hyperten-
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sion was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 
mmHg, or use of antihypertensive medication. Diabetes was defined in the presence 
of fasting blood glucose ≥140 mg/dL or requirement for insulin or oral hypoglycemic 
agents. Heart failure was defined according to the New York Heart Association classi-
fication.8 This study was not subject to the Dutch Medical Research Involving Human 
Subjects Act. Therefore, approval from the local research ethics committee to conduct 
this prospective follow-up study was not required at the time of enrollment. The study 
was conducted according to the Helsinki Declaration.9 All patients consented participa-
tion in this study.
After baseline echocardiography, dobutamine was infused at a starting dose of 5 
μg/kg per minute for 3 min, followed by 10 μg/kg/min for 3 min (low-dose stage). The 
dobutamine dose was increased by 10 μg/kg/min every 3 min, up to a maximum dose 
of 40 μg/kg/min. Atropine (up to 1 mg) was administered intravenously at the end 
of the last stage if the target heart rate was not achieved. End points of the test were 
an achievement of the target heart rate (85% of the maximal heart rate predicted for 
age), the maximal dose of dobutamine and atropine, >2 mV downsloping ST-segment 
depression measured 80 ms from the J point compared with baseline, hypertension 
(blood pressure >240/120 mmHg), a decrease in systolic blood pressure of >40 mmHg, 
and significant arrhythmias. Typical angina during dobutamine stress testing was de-
fined as substernal chest discomfort provoked by dobutamine stress and relieved by 
withdrawing dobutamine.  
Echocardiographic images (two dimensional, using standard views) were acquired 
at rest and continuously during the test and recovery. The interpretation of images 
was performed by two independent blinded observers. In case of disagreement a third 
observer also interpreted the images. In our laboratory, the inter- and intraobserver 
agreement for DSE assessments are 92 and 94%, respectively.10 Regional wall motion 
and systolic wall thickening were scored using a standard 16-segment left ventricular 
model. Each segment was scored using a 5-point scale as follows: 1 = normal, 2 = mild 
hypokinesis, 3 = severe hypokinesis, 4 = akinesis, 5 = dyskinesis. Ischemia was defined 
as new or worsened wall motion abnormalities during stress, which is indicated by an 
increase of  ≥ 1 grade in ≥ 1 segment of the wall motion score. A biphasic response in 
an akinetic or severely hypokinetic segment was considered as an ischemic response. 
When akinetic segments at rest became dyskinetic during stress, this was not consid-
ered as ischemia.11 DSE results were defined as abnormal if there was ischemia during 
stress or fixed wall motion abnormalities. The wall motion score index (WMSI) was calcu-
lated by dividing the sum of segment scores by 16. The WMSI was obtained at rest and 
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at peak stress. A DSE with a peak WMSI of 1.1 to 1.7 was considered mild to moderately 
abnormal, and >1.7 was markedly abnormal.12
Outcome data were obtained by a questionnaire, evaluation of hospital records, 
contacting the patient’s general practitioner, and/or review of civil registries. The on-
line municipal civil registry was used to determine the patient’s present survival status. 
The date of response was used to calculate follow-up time. The endpoints considered 
were all-cause mortality and cardiac mortality. Causes of death were obtained from the 
Central Bureau of Statistics (CBS) Netherlands. A death caused by acute MI, significant 
arrhythmias,  refractory heart failure, or sudden death without other explanation, was 
defined as cardiac mortality. 
Table 1. Clinical characteristics. 
Value
All
(N=905)
Early revascularization
(N=222)
No early revascularization
(N=683) P-value
   Age (years ± SD) 61.4±11.9 60.0±9.6 61.9±12.6 0.41
   Men 688 (76%) 177 (80%) 511 (75%) 0.14
   Smoker 300 (33%) 81 (36%) 219 (32%) 0.22
   Hypertension 260 (29%) 61 (27%) 199 (29%) 0.64
   Hypercholesterolemia 283 (31%) 100 (45%) 183 (27%) <0.001
   Heart failure 198 (22%) 76 (34%) 122 (18%) <0.001
   Diabetes mellitus 117 (13%) 28 (13%) 89 (13%) 0.87
   Previous revasculari- 
   zation
73 (8%) 5 (2%) 68 (9%) <0.001
   Previous MI 519 (57%) 166 (75%) 353 (52%) <0.001
Medications
   ACE-inhibitors 303 (33%) 95 (43%) 208 (30%) <0.001
   ß-blockers 381 (42%) 121 (55%) 260 (82%) <0.001
   Calcium-channel  
   blockers
294 (32%) 98 (44%) 196 (29%) <0.001
   Diuretics 170 (19%) 51 (23%) 119 (17%) 0.07
   Nitrates 397 (44%) 148 (67%) 249 (36%) <0.001
Echocardiographic results
   Rest WMSI 1.68±0.60 1.76±0.55 1.65±0.61 0.01
   Peak WMSI 1.79±0.55 1.94±0.52 1.74±0.54 <0.001
   Peak WMSI >1.7 445 (49%) 138 (31%) 307 (69%) <0.001
Values are expressed as means ± SD or numbers  (%). MI = myocardial infarction. WMSI = wall motion score index. 
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Continuous data were presented as mean± SD and were compared using the Student 
t test. Categorical data were presented as percentages and were compared using the 
chi-square test. Correlation between continuous variables was estimated with Pearson’s 
correlation coefficient. Survival curves were generated using the Kaplan-Meier method 
to assess the probability of (event-free) survival and were compared using the log-rank 
test. The impact of early coronary revascularization on survival was investigated using 
univariable and multivariable Cox’s proportional hazard regression models. The multi-
variable model was performed using known prognostic factors, including clinical char-
acteristics and DSE results. The risk of a variable was expressed as a hazard ratio with a 
corresponding 95% confidence interval. P <0.05 was considered statistically significant. 
All analyses were performed with ÌBM SPSS statistical software version 22.  
RESULTS
The clinical characteristics of the 905 patients with myocardial ischemia on DSE are pre-
sented in Table 1. The mean age was 61 years and the majority of the patients were 
men (76%). During the dobutamine stress test, heart rate increased from a mean of 
70±13 beats per minute to 128±19 beats per minute (P<0.001), whereas overall systolic 
blood pressure did not significantly change (132±25 mmHg at rest and 132±29 mmHg 
at stress). During dobutamine stress testing, 295 patients (33%) experienced typical an-
gina, and ST-segment changes occurred in 293 patients (32%).
All patients had myocardial ischemia on DSE. A total of 445 patients (49%) had a 
peak WMSI>1.7. Patients with a peak WMSI >1.7 had more cardiac mortality compared 
to patients with a peak WMSI ≤1.7 (30% versus 23%, respectively, p=0.013). Early cor-
onary revascularization was performed in 222 patients (25%); a total of 113 patients 
underwent PCI (51%) and 109 patients underwent CABG (49%); a total of 3 patients (1%) 
underwent both PCI and CABG. The mean interval between DSE and early revasculariza-
tion was 37±6 days. The remaining 683 patients with myocardial ischemia were treated 
medically. Patient groups were comparable according to age, male gender, smoking, 
hypertension, diabetes mellitus and the use of diuretics, digoxin and platelet inhibi-
tors. Patients who underwent early  revascularization more frequently had a history of 
cardiac disease (previous MI and heart failure) and less frequently had a previous re-
vascularization. Mean rest WMSI and  mean peak WMSI were 1.68 ±0.60 and 1.79±0.50, 
respectively. Both rest WMSI and peak WMSI were significantly higher in patients who 
underwent early revascularization (Table 1). This probably has contributed to the reason 
for intervention. 
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During a median follow-up time of 10 years (range 8-15), 474 deaths (52%) occurred, of 
which were 241 (51%) due to cardiac causes. Kaplan-Meier survival curves showed that 
patients with myocardial ischemia on DSE who underwent early revascularization had a 
lower risk for all-cause mortality (event-free survival: 80 vs 65% at 5 years, 65 vs 46% at 
10 years; overall p<0.001, Figure 1) and cardiac mortality (event-free survival: 86 vs 77% 
at 5 years, 83 vs 66% at 10 years; overall p<0.001, Figure 2). Figures 3 and 4 demonstrates 
the event-free survival for all-cause mortality and cardiac mortality respectively accord-
ing to strata of revascularization and  peak WMSI. In the 445 patients with markedly 
abnormal DSE results, early revascularization was associated with better long-term out-
comes compared to patients without early revascularization (all-cause mortality [Figure 
3] and cardiac mortality [Figure 4] both p<0.001). Also, in the 460 patients with mild 
to moderately abnormal DSE results, early revascularization was associated with better 
long-term outcomes compared to patients without early revascularization (all-cause 
mortality, p<0.008, Figure 3; cardiac mortality, p<0.001, Figure 4). 
Univariable associations of long-term outcome are presented in Table 2 and 3. Univari-
able predictors of all-cause mortality were age, male gender, hypertension, hypercho-
lesterolemia, history of heart failure, prior revascularization, rest and peak WMSI (Table 
2). Univariable predictors of cardiac mortality were age, male gender, hypercholester-
olemia, history of heart failure, previous revascularization, previous MI and rest and 
peak WMSI (Table 3). The univariable analysis demonstrated that early revascularization 
was inversely related to both endpoints of interest. 
Figure 1. Kaplan-Meier curves for all-cause 
mortality according to strata of early coronary 
revascularization.
Figure 2. Kaplan-Meier curves for cardiac mor-
tality according to strata of early coronary re-
vascularization. 
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Figure 3. Kaplan-Meier curves for all-cause mortality according to strata of wall motion score 
index (WMSI) and early coronary revascularization.
Figure 4. Kaplan-Meier curves for cardiac mortality according to strata of wall motion score index 
(WMSI) and early coronary revascularization.
Multivariable predictors of clinical data, DSE results and early revascularization are 
shown in Table 2 and 3. Age, hypertension, hypercholesterolemia, smoking, history of 
heart failure, previous revascularization were associated with both all-cause mortality 
(Table 2) and cardiac mortality (Table 3). A multivariable Cox regression model revealed 
that revascularization had a beneficial effect on all-cause mortality (HR 0.60, 95% CI 
0.46-0.79) and cardiac mortality (HR 0.49, 95% CI 0.34-0.72).
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Table 2. Univariable and multivariable predictors of all-cause mortality
Variable Univariable Multivariable
HR 95% CI HR 95% CI
Age* 1.05 1.04-1.06 1.05 1.04-1.06
Men 1.31 1.06-1.63 1.24 0.98-1.56
Hypertension 1.33 1.10-1.61 1.46 1.18-1.79
Diabetes mellitus 0.92 0.76-1.29 1.06 0.80-1.40
Hypercholesterolemia 0.67 0.54-0.84 0.69 0.55-0.88
Smoking 1.19 0.99-1.43 1.48 1.21-1.82
Heart failure 1.46 1.18-1.81 1.30 1.02-1.66
Previous revascularization 0.44 0.25-0.77 0.42 0.23-0.76
Previous MI 1.10 0.92-1.32 0.94 0.77-1.16
Rest WMSI 1.51 1.29-1.75 1.31 0.90-1.89
Peak WMSI 1.53 1.29-1.80 1.34 0.90-2.01
Early revascularization 0.64 0.50-0.83 0.60 0.46-0.79
*per unit increment. MI = myocardial infarction. WMSI = wall motion score index. 
Table 3. Univariable and multivariable predictors of cardiac mortality
Variable Univariable Multivariable
HR 95% CI HR 95% CI
Age* 1.06 1.05-1.07 1.06 1.04-1.07
Men 1.46 1.06-1.99 1.29 0.93-1.79
Hypertension 1.13 0.86-1.49 1.33 1.00-1.77
Diabetes mellitus 0.95 0.65-1.38 1.04 0.71-1.52
Hypercholesterolemia 0.62 0.45-0.84 0.65 0.47-0.90
Smoking 1.29 1.00-1.67 1.55 1.18-2.03
Heart failure 1.80 1.35-2.38 1.50 1.10-2.04
Previous revascularization 0.32 0.13-0.78 0.26 0.10-0.64
Previous MI 1.46 1.12-1.90 1.27 0.96-1.68
Rest WMSI 1.67 1.36-2.04 1.13 0.69-1.88
Peak WMSI 1.74 1.39-2.18 1.65 0.96-2.84
Early revascularization 0.54 0.38-0.78 0.49 0.34-0.72
*per unit increment. MI = myocardial infarction. WMSI = wall motion score index. 
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DISCUSSION
In this study, the impact of early coronary revascularization (≤90days) on long-term 
outcomes  was assessed in 905 patients with myocardial ischemia. During a median 
follow-up duration of 10 (range 8-15 years), 474 patients died of which 241 deaths were 
due to cardiac causes. Kaplan-Meier survival curves showed that early revascularization 
(PCI or CABG) after an ischemic DSE had a beneficial effect on all-cause mortality and 
cardiac mortality. This benefit was apparent during the entire follow-up period, with 
survival curves diverging up to 10 years. Both in patients with a mild to moderately 
abnormal DSE (peak WMSI≤1.7) and in patients with a markedly abnormal DSE  (peak 
WMSI>1.7), early revascularization was associated with better long-term outcomes. 
When adjusting for clinical characteristics and DSE results, as the multivariable analysis 
demonstrates, early revascularization had a beneficial effect on all-cause mortality (40% 
reduction) and cardiac mortality (51% reduction) during long-term follow-up. 
In the present study, patients with markedly abnormal DSE (peak WMSI>1.7) had 
benefit from early revascularization. This is in line with previous data13 indicating that 
a certain amount of ischemia has to be present for revascularization to be beneficial.14 
Also, contrary to previous studies15, patients with a mild to moderately abnormal DSE 
(peak WMSI≤1.7) who underwent early revascularization had lower mortality compared 
to patients without early revascularization. 
To date, CAD is the leading cause of mortality worldwide. Patients with ischemic 
heart disease may be treated with either medical therapy alone or combined with re-
vascularization (PCI or CABG). In patients with CAD, it has been shown that left ventricle 
dysfunction may be reversible after coronary revascularization.16, 17 Two randomized tri-
als were undertaken to study the potential benefit of coronary revascularization com-
pared to medical therapy in patients with stable CAD. The COURAGE trial2 included 2287 
patients who had objective evidence of myocardial ischemia and significant coronary 
artery disease and studied PCI as the revascularization procedure. Both patients in the 
PCI group and patients in the medical-therapy group had a preserved left ventricular 
ejection fraction (mean LVEF 60.8 versus 60.9%, respectively). During a median fol-
low-up of 4.6 years, the authors concluded that there was no benefit of PCI on death and 
MI. More recently, during the long-term follow-up of up to 15 years in these patients, 
the authors did not find a benefit of survival of PCI in 1211 patients with stable ischemic 
heart disease, objective evidence of ischemia, and significant coronary artery disease.5 
Additionally, in the BARI-2D trial 2368 diabetic patients with evidence of ischemia, or 
symptoms of angina in the presence of angiographic defined CAD, were studied with 
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either PCI or CABG.18 Both revascularization techniques showed no benefit on survival. 
From a clinical perspective, both mentioned trials have important implications; patients 
with the characteristics of the included patients of these trials needs intensive medical 
therapy and lifestyle intervention. In the present study, the impact of early coronary re-
vascularization of  patients with myocardial ischemia on DSE was evaluated. The current 
study differs from these previous trials demonstrating that survival was significantly dif-
ferent between patients with revascularization and those without during long-term 
follow-up. Jeremias et al.19 performed a meta-analysis and demonstrated that both PCI 
and CABG were associated with improved survival in patients with nonacute CAD. The 
findings of the current study (describing also patients with nonacute CAD) are in line 
with this meta-analysis. There are several explanations why early revascularization in the 
present patient cohort had a  beneficial effect on long-term outcomes. In the current 
study, we describe a high-risk group of patients who were unable to perform an exer-
cise test. Previous mentioned trials enrolled low-risk patients in contrast to the current 
study. Also, 57% of the 905 patients (versus 38%) had previous myocardial infarction 
and 198 (22%) patients (versus 4.7%) had known heart failure compared to the COUR-
AGE trial; this also may have caused beneficial effect of early coronary revascularization 
in this patient cohort. 
Despite major developments of  PCI , advanced  techniques of CABG and improve-
ments in medication, the optimal therapy in patients with CAD remains controversial. 
The guidelines of the European Society of Cardiology (ESC) indicates revascularization 
in case of a large area of ischemia [defined as >10% of the left ventricle].3 The American 
guidelines recommend CABG in preference to PCI to improve survival in patients with 
multivessel CAD.20 In both guidelines, special considerations are made for diabetic pa-
tients; revascularization should be considered for diabetic patients whose symptoms 
compromise their quality of life. Also, diabetic patients with stable CAD and an accept-
able surgical risk, CABG is recommended over PCI. The current study included 117 pa-
tients (13%) with diabetes mellitus. Clearly multiple factors influence the decision to 
perform coronary revascularization. including symptoms, presence of myocardial is-
chemia, coronary anatomy, and comorbid conditions.   Moreover, daily clinical practice 
requires the need of balancing between invasive CABG and less invasive PCI. The ISCHE-
MIA trial (including > 8000 patients with at least moderate ischemia on an ischemia test) 
aims to demonstrate whether patients will benefit from a treatment of cardiac catheter-
ization, revascularization, and medical therapy or a treatment of medical therapy alone 
with cardiac catheterization specially for those who fail medical therapy.21 
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Patients with stable coronary artery disease (CAD) and myocardial ischemia who un-
dergo no or delayed revascularization are at  increased risk of adverse events. This may 
have several reasons. First, chronic myocardial ischemia may result in hibernating or 
scarred myocardium and an impairment of LV function.17 Second, patients with myo-
cardial ischemia are at increased risk of developing ventricular arrhythmias, especially 
those with a severely impaired LV function.22 Third, natural progression of CAD may re-
sult in adverse events, including myocardial infarction.
Patients in the present study were unable to perform exercise testing, because of 
comorbid conditions. DSE may be a valuable alternative method for the evaluation of 
myocardial ischemia in these patients. DSE has been established as a relatively safe 
stress modality.23 Noncardiac side effects (nausea, headache, chills, urgency and anx-
iety) are usually well tolerated, without the need for test termination. The most com-
mon cardiovascular side effects are angina, hypotension and cardiac arrhythmias.23 
Life-threatening complications are rare, and in patients at increased risk for these com-
plications (those with impaired LV function and/or a previous infarction), close mon-
itoring is required also during the recovery phase, and any possible cardiovascular or 
neurological symptoms should be addressed immediately. The risk-benefit ratio of DSE 
should always be evaluated carefully.
This study has some limitations. First, the decision to revascularize was made on clin-
ical grounds. The decision to perform early coronary revascularization may have been 
influenced by multiple factors like age, life expectancy and comorbid conditions. These 
factors may also have influenced long-term outcomes. Second, at time of data collec-
tion, contrast-enhanced stress echocardiography was not routinely performed.  The use 
of an ultrasound contrast agent could further increase the accuracy and simultaneous 
evaluation of myocardial function and perfusion.24 Medications that reduce mortality in 
patients with CAD include β-blockers, angiotensin-converting enzyme inhibitors and 
statins. At time of data collection, however, these medications were underused, prob-
ably because the beneficial effect of these medications was not yet fully understood.25 
Finally, at the time of data collection, left ventricular ejection fraction (LVEF) was not 
routinely performed in our center. Information about LVEF could have improved the 
present analysis. 
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ABSTRACT
Background. Coronary revascularization may be beneficial when added  to medical 
therapy in selected patients with stable coronary artery disease (CAD). It is not entirely 
clear whether ischemia burden on stress single-photon emission computed tomogra-
phy (SPECT) effectively identifies patients who have a long-term benefit from coronary 
revascularization.
Methods and Results. The study population consisted of 719 patients with ischemia 
(defined as the presence of a reversible or partially reversible perfusion defect) on stress 
SPECT. Follow-up was complete in 702 (98%) patients. Early coronary revascularization 
was defined as percutaneous coronary intervention (PCI) or coronary artery bypass 
grafting (CABG) ≤90 days after SPECT. Patients who underwent late revascularization 
(>90 days after SPECT) were excluded (n=164). The final study population consisted of 
538 patients who underwent exercise (n=220) or dobutamine (n=318) stress SPECT. The 
extent of myocardial ischemia on stress SPECT was defined by the number of segments 
with reversible perfusion defects. Kaplan-Meier curves and Cox proportional hazard 
models were performed to assess the impact of ischemia burden and early coronary 
revascularization on all-cause mortality and cardiac mortality. Of the 538 patients (73% 
men, mean age 59.8±11 years) 348 patients (65%) had low ischemia burden (defined as 
<3 ischemic segments) and 190 patients (35%) had moderate to high ischemia burden 
(defined as ≥3 ischemic segments). A total of 76 (14%) patients underwent early revas-
cularization. During a median follow-up of 12 years (range 4-17), 283 (53%) patients 
died of whom 125 (44%) due to cardiac causes. Kaplan-Meier survival curves showed 
that patients with myocardial ischemia on stress SPECT who underwent early revascu-
larization had a lower risk for all-cause mortality and cardiac mortality. This was mainly 
caused by patients with moderate to high ischemia burden on SPECT. Multivariable 
analyses showed that early revascularization was beneficial on all-cause mortality (HR 
0.47, 95% CI 0.31-0.72) and cardiac mortality (HR 0.51, 95% CI 0.28-0.93). 
Conclusions. Patients with myocardial ischemia on stress SPECT who underwent early 
revascularization had a lower all-cause mortality and cardiac mortality during long-term 
follow-up as compared to patients who received pharmacological therapy alone. This 
difference in long-term outcomes was mainly caused by the survival benefit of early 
revascularization in the patients with moderate to high ischemia burden. 
Key Words: Early revascularization, Long-term, Ischemia, SPECT. 
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INTRODUCTION
Advances in pharmacotherapy have substantially improved the symptoms and long-
term outcomes of patients with stable coronary artery disease (CAD) over the last de-
cades. A subset of these patients may also benefit from coronary revascularization. The 
survival benefit of coronary revascularization  is related to the amount of myocardial 
ischemia. Stress single-photon emission computed tomography (SPECT) myocardial 
perfusion imaging (MPI) is a reliable tool to assess the ischemia burden, and may be 
used to identify coronary revascularization candidates.1 Patients with CAD and ischemia 
on stress SPECT have higher risk of all-cause mortality and myocardial infarction (MI) 
compared to patients without ischemia.2 Previous data showed that coronary revascu-
larization may be beneficial over medical therapy in patients with moderate to severe 
ischemia.3 Randomized trials showed that early revascularization showed no improve-
ment in all-cause mortality or myocardial infarction (MI) compared to optimal medi-
cal therapy.4,5 However, nuclear substudies of these randomized trials are conflicting.6,7 
Moreover, long-term information after early coronary revascularization in patients with 
ischemia on stress SPECT is lacking. Therefore, the primary aim of this study was to eval-
uate the impact of early coronary revascularization on long-term outcomes in patients 
with myocardial ischemia on stress SPECT. The second goal was whether the ischemia 
burden  on stress SPECT determines the prognostic benefit of revascularization. 
METHODS
Study Design
The study population consisted of 719 patients with ischemia (defined as the presence 
of a reversible or partially reversible perfusion defect) on stress SPECT performed be-
tween November 1990 and May 2002. Follow-up was complete in 702 (98%) patients. 
Early coronary revascularization was defined as percutaneous coronary intervention 
(PCI) or coronary artery bypass grafting (CABG) ≤90 days after SPECT MPI. Patients who 
underwent late revascularization (defined as >90 days after SPECT MPI) were excluded 
(n=164). Thus, the data presented are based on 538 patients. Patients underwent ex-
ercise bicycle (n=220) or dobutamine (n=318) stress SPECT. The type of stress test was 
selected based on the patient’s ability to exercise. Before the stress test, a structured 
clinical interview and cardiac risk factors were acquired. A blood pressure ≥140/90 mm 
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Hg, or treatment with antihypertensive medication was considered as hypertension. A 
fasting glucose level ≥7.8 mmol/L or the need for insulin or oral hypoglycemic agents 
was considered as diabetes mellitus. A total cholesterol ≥6.4 mmol/L, or treatment with 
lipid-lowering medication was considered as hypercholesterolemia. Heart failure was 
defined according to the New York Heart Association classification.8 This study was not 
subject to the Dutch Medical Research Involving Human Subjects Act. Therefore, ap-
proval from the local research ethics committee to conduct this prospective follow-up 
study was not required at the time of enrollment. The study was conducted according 
to the Helsinki Declaration.9 All patients consented participation in this study.
Stress Test Protocol
Symptom-limited, upright, bicycle ergometry with stepwise increments of 20 W every 
minute was performed. Three electrocardiographic leads were continuously monitored. 
Cuff blood pressure measurements and 12-lead electrocardiograms were recorded at 
rest and every minute during exercise and recovery. In patients who were unable to per-
form exercise tests, dobutamine stress testing was performed as previously reported.10 
Dobutamine was administered intravenously, starting at a dose of 5 µg/kg/minutes for 
3 minutes, then 10 µg /kg/minutes for 3 minutes, increasing by 10 µg /kg/minutes every 
3 minutes up to a maximum dose of 40 µg /kg/minutes. If the test endpoint was not 
reached at a dobutamine dose of 40 µg /kg/minutes, atropine (up to 2 mg) was given 
intravenously. Blood pressure, heart rate, and electrocardiography were monitored con-
tinuously. Test endpoints were achievement of target heart rate (85% of maximum age 
and gender-predicted heart rate), horizontal or downsloping ST segment depression 
>2 mm at an interval of 80 ms after the J point, ST-segment elevation >1 mm in patients 
who had no previous myocardial infarction, severe angina, systolic blood pressure de-
crease >40 mm Hg, blood pressure >240/120 mm Hg, or significant cardiac arrhythmias.
SPECT Imaging
An intravenous dose of 370 MBq of 99mTc-tetrofosmin (n=234) or 99mTc-sestamibi (n=304) 
was injected approximately 1 minute before the cessation of exercise. In rest studies, 
370 MBq of tetrofosmin or sestamibi was administered at least 24 hours after the stress 
test. Myocardial images were acquired with a triple-head gamma-camera system (Picker 
Prism 3000 XP, Cleveland, Ohio, USA). The interpretation of the SPECT was semiquantita-
tively performed by visual analysis and aided by circumferential profiles analysis. Stress 
and rest tomographic views were reviewed side by side by an experienced observer 
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who was blind to the patients’ clinical information. A reversible perfusion defect was de-
fined as a perfusion defect on the exercise images that partially or completely resolved 
at rest. A fixed perfusion defect was defined as a perfusion defect on exercise images, 
which persists on rest images. To assess the severity of perfusion abnormalities, the left 
ventricular myocardium was divided into 6 segments: anterior, inferior, septal anterior, 
septal posterior, posterolateral, and apical. Each of the 6 major left ventricular segments 
was scored using a 4-point scoring method (0 = normal, 1 = slightly reduced, 2 = mod-
erately reduced, and 3 = severely reduced or absent uptake). The extent of myocardial 
ischemia on stress SPECT was defined by the number of segments with reversible or 
partially reversible perfusion defects. Low ischemia burden was defined as the presence 
of reversible perfusion abnormalities in <3 segments, whereas moderate to high ische-
mia burden was defined as ≥3 ischemic segments on SPECT.7
Follow-up
Outcome data were obtained by a questionnaire, evaluation of hospital records, con-
tacting the patient’s general practitioner, and/or review of civil registries. The online 
municipal civil registry was used to determine the patient’s present survival status. The 
date of response was used to calculate follow-up time. The endpoints considered were 
all-cause mortality and cardiac mortality. Causes of death were obtained from the Cen-
tral Bureau of Statistics Netherlands (www.cbs.nl). A death caused by acute MI, signifi-
cant arrhythmias,  refractory heart failure, or sudden death without other explanation, 
was defined as cardiac mortality.
Statistical Analysis
Statistical analysis was performed using SPSS version 22 (IBM, Armonk, New York). 
Continuous data are expressed as mean ± SD and percentages are rounded. Contin-
uous variables were compared with Student’s t test for unpaired samples. Differences 
between proportions were compared with the chi-squared test. Kaplan-Meier survival 
curves were performed and were compared using the log-rank test. The impact of early 
coronary revascularization on survival was investigated using univariable and multivar-
iable Cox’s proportional hazard regression models. The multivariable model was per-
formed using known prognostic factors, including cardiac risk factors and stress SPECT 
results. The risk of a variable was expressed as a hazard ratio (HR) with a corresponding 
95% confidence interval (95% CI). P < .05 was considered statistically significant.
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Table 1. Clinical characteristics of 538 patients with reversible perfusion defects
Value (%)
All
(N=538)
Early 
revascularization
(N=76)
No early 
revascularization
(N=462) P-value
   Age 59.8±11 59.8±9 59.8±11 0.96
  Male gender 395 (73) 64 (84) 331 (72) 0.02
   BMI 26.8±4.4 26.9±3.4 26.9±4.5 0.99
Cardiac risk factors
   Smoking 158 (29) 23 (30) 135 (29) 0.85
   Hypertension 215 (40) 28 (37) 187 (40) 0.55
   Hypercholesterolemia 188 (35) 31 (41) 157 (34) 0.25
   Heart failure 82 (15) 9 (12) 73 (16) 0.37
   Diabetes mellitus 84 (16) 11 (14) 73 (16) 0.77
   Previous revascularization 161 (30) 34 (45) 127 (27) 0.002
   Previous MI 223 (41) 37 (49) 186 (40) 0.17
Medications
   ACE-inhibitors 156 (29) 22 (38) 134 (29) 0.99
   Beta blockers 243 (45) 53 (70) 191 (41) <0.001
   Calcium-channel blockers 209 (39) 43 (57) 166 (36) <0.001
   Diuretics 116 (22) 10 (13) 106 (23) 0.06
   Nitrates 188 (35) 32 (42) 156 (34) 0.16
Stress type
   Exercise bicycle 220 (41) 42 (55) 178 (39) 0.01
   Dobutamine 318 (59) 34 (45) 284 (61) 0.01
SPECT parameters
   Number of abnormal segments 2.2±1.5 2.5±1.2 2.1±1.1 0.005
   Low ischemia burden* 348 (65) 38 (50) 310 (67) 0.004
   Moderate to high ischemia burden* 190 (35) 38 (50) 152 (33) 0.004
Values are expressed as means ± SD or numbers  (%). BMI = body mass index. MI = myocardial infarction. 
ACE = angiotensin-converting-enzyme. SPECT = single-photon emission computed tomography.  
*Low ischemia burden = 1 or 2 abnormal segments. Moderate to high ischemia burden  =  ≥3 abnormal segments. 
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RESULTS
Patient characteristics 
The 538 patients with myocardial ischemia on stress SPECT are characterized in Table 1. 
Mean age and mean body mass index (BMI) were 59.8±11 years and 26.8±4.4 respec-
tively. A total of 395 (73%) patients were men. Regarding stress testing, 220 patients 
(41%) underwent exercise bicycle stress and 318 patients (59%) underwent dobutamine 
stress. During the stress test, there was a significant increase in heart rate (73±15 –134± 
29 bpm, P<0.001) and systolic blood pressure (138±22 – 164±33 mmHg, P<0.001) from 
rest to peak stress. Typical angina occurred in 150 patients (28%), whereas 176 patients 
(33%) exhibited ST-segment changes.
All patients had myocardial ischemia (defined as reversible or partially reversible per-
fusion defect) on stress SPECT. Fixed defects were observed in 81 (15%) patients. Both 
fixed and reversible defects were present in 344 (64%) patients. A total of 348 patients 
(65%) had low ischemia burden and 190 patients (35%) had moderate to high ischemia 
burden. A total of 76 (14%) patients underwent early revascularization (≤90 days after 
the stress SPECT); PCI was performed in 53 (70%) patients and CABG was performed 
in 27 (36%) patients. A total of 4 patients (5%) underwent both PCI and CABG. The re-
maining 462 patients with myocardial ischemia on stress SPECT were treated only with 
pharmacologic therapy. Among the 76 patients who underwent early revasculariza-
tion, mean number of abnormal segments was 2.5±1.2 compared to 2.1±1.1 in patients 
Figure 1. Kaplan-Meier curves for all-cause mortality according to strata of early coronary revas-
cularization.
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without early revascularization (p=0.005).  Patient groups were comparable according 
to age, BMI, smoking, hypertension, hypercholesterolemia, heart failure, diabetes mel-
litus and previous MI. Comparison of the patient groups shows that the patients who 
underwent early coronary revascularization were more frequent men, had more prior 
revascularization and had more moderate to high ischemia burden. These factors may 
have contributed to referring for early coronary revascularization. 
Figure 3. Kaplan-Meier curves for all-cause mortality according to strata of the extent of ischemia 
(low ischemia burden versus moderate to high ischemia burden) and early coronary revasculari-
zation (revasc versus no revasc).
Figure 2. Kaplan Meier curves for cardiac mortality according to strata of early coronary revascu-
larization.
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Long-term outcomes
During a median follow-up of 12 years (range 4-17), a total of 283 (53%) patients died 
(all-cause mortality) of whom 125 (44%) were due to cardiac causes. Kaplan-Meier 
survival curves are demonstrated in Figures 1-5. Survival curves showed that patients 
with myocardial ischemia on stress SPECT who underwent early revascularization had a 
lower risk for all-cause mortality (event-free survival: 88 vs 72% at 5 years, 79 vs 55% at 
10 years, 65 vs 44% at 15 years; overall p<0.001, Figure 1) and cardiac mortality (event-
free survival: 93 vs 82% at 5 years, 88 vs 76% at 10 years, 83 vs 72% at 15 years; overall 
p=0.03, Figure 2). As Figures 3 and 4 shows, this lower risk was not caused by the 348 
patients with low ischemia burden (all-cause mortality, p=0.10, Figure 3, and cardiac 
mortality, p=0.32, Figure 4). In contrast, in the 190 patients with moderate to high is-
chemia burden early revascularization was associated with better long-term outcomes 
compared to patients without early revascularization (all-cause mortality, p<0.001, Fig-
ure 3; cardiac mortality, p=0.03, Figure 4). 
Patients who were able to perform exercise bicycle testing had a better prognosis as 
compared with the patients who underwent dobutamine stress testing. In patients who 
underwent early revascularization, all-cause mortality was significantly higher in the 
dobutamine group than in the exercise group (Figure 5). 
Figure 4. Kaplan-Meier curves for cardiac mortality according to strata of the extent of ischemia 
(low ischemia burden versus moderate to high ischemia burden) and early coronary revasculari-
zation (revasc versus no revasc).
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Figure 5. Kaplan-Meier survival curves for the endpoint of all-cause mortality in patients who 
underwent early revascularization stratified to stress type (exercise test versus dobutamine stress 
test).
Univariable and multivariable predictors of outcome
Univariable and multivariable predictors of long-term outcome are presented in Table 
2 and 3. Univariable predictors of all-cause mortality were age, male gender, hyperten-
sion, diabetes mellitus, hypercholesterolemia, heart failure, prior MI, and number of ab-
normal segments on SPECT (Table 2). Univariable predictors of cardiac mortality were 
age, hypertension, diabetes mellitus, heart failure, previous MI and number of abnormal 
segments on SPECT (Table 3). The univariable analysis also demonstrated that early re-
vascularization was inversely related to both endpoints of interest. 
The results of the multivariable analysis are shown in Table 2 and 3. Age, male gen-
der, hypertension, diabetes mellitus, hypercholesterolemia, smoking, heart failure were 
associated with all-cause mortality (Table 2). Multivariable predictors of cardiac mortal-
ity were age, diabetes mellitus and heart failure (Table 3).The multivariable Cox regres-
sion model revealed that early revascularization had a beneficial effect on both all-cause 
mortality (HR 0.47, 95% CI 0.31-0.72) and cardiac mortality (HR 0.51, 95% CI 0.28-0.93).
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Table 2. Univariable and multivariable predictors of all-cause mortality
Variable Univariable Multivariable
HR 95% CI HR 95% CI
Age* 1.06 1.04-1.07 1.07 1.05-1.08
Male gender 1.34 1.09-1.77 1.63 1.21-2.20
Hypertension 1.57 1.24-1.98 1.32 1.03-1.70
Diabetes mellitus 2.47 1.87-3.27 2.48 1.83-3.36
Hypercholesterolemia 0.67 0.52-0.87 0.72 0.56-0.94
Smoking 1.04 0.80-1.34 1.59 1.21-2.09
Heart failure 2.34 1.79-3.18 1.59 1.17-2.17
Previous revascularization 1.08 0.84-1.38 1.11 0.84-1.45
Previous MI 1.46 1.15-1.84 1.15 0.88-1.49
# Abnormal segments on SPECT 1.13 1.02-1.24 1.06 0.95-1.18
Early revascularization 0.46 0.30-0.69 0.47 0.31-0.72
*per unit increment. #number. MI = myocardial infarction. SPECT = single-photon emission computed tomography. 
Table 3. Univariable and multivariable predictors of cardiac mortality
Variable Univariable Multivariable
HR 95% CI HR 95% CI
Age* 1.06 1.04-1.07 1.06 1.04-1.08
Male gender 1.29 085-1.97 1.52 0.97-2.38
Hypertension 1.60 1.12-1.27 1.23 0.84-1.79
Diabetes mellitus 3.14 2.13-4.62 3.03 1.98-4.64
Hypercholesterolemia 0.70 0.48-1.03 0.76 0.52-1.14
Smoking 0.96 0.65-1.42 1.47 0.97-2.23
Heart failure 2.99 2.01-4.45 1.88 1.22-2.90
Previous revascularization 1.19 0.82-1.73 1.19 0.80-1.77
Previous MI 1.69 1.19-2.41 1.28 0.86-1.89
# Abnormal  segments on SPECT 1.20 1.04-1.39 1.09 0.93-1.28
Early revascularization 0.52 0.29-0.95 0.51 0.28-0.93
*per unit increment. #number. MI = myocardial infarction. SPECT = single-photon emission computed tomography. 
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DISCUSSION
The present study evaluated the impact of early revascularization (≤90 days after stress 
SPECT) on long-term outcome in patients with myocardial ischemia on stress SPECT. Of 
the 538 patients, 30% of patients had previous revascularization and 41% had previous 
MI. During a median follow-up of 12 years,  a total of 283 (53%) patients died (all-cause 
mortality) of whom 125 (44%) were due to cardiac causes. Kaplan-Meier survival curves 
showed that early revascularization (either PCI or CABG) after an ischemic stress SPECT 
was beneficial on both all-cause mortality and cardiac mortality. In  patients with low 
ischemia burden on stress SPECT (defined as <3 ischemic segments) early revascular-
ization was not associated with better long-term outcomes whereas in patients with 
moderate to severe ischemia burden (defined as ≥3 ischemic segments) early revas-
cularization was associated with better long-term outcomes. The multivariable model 
demonstrated that early revascularization was associated with a 53% reduction in all-
cause mortality and a 49% reduction in cardiac mortality. Regarding the type of stress 
test, patients with early revascularization who performed a dobutamine stress test had 
higher all-cause mortality compared to patients who performed exercise bicycle stress 
testing. This finding is in accordance with a previous report from our center.11 The in-
ability to perform exercise testing is a negative prognostic marker in patients with CAD. 
In recent years there has been a considerable interest concerning treatment strategies 
in patients with stable CAD resulting in a wealth of published literature. Both revascular-
ization (PCI and/or CABG) and optimal medical therapy are treatment options in these 
patients. SPECT MPI play a central role in this regard. To date, information on long-term 
outcomes after revascularization in relation to the ischemia burden on stress SPECT is 
relatively scarce. Previous studies have examined the short-term to medium-term out-
comes after revascularization in patients with ischemia on SPECT. Hachamovitch et al.3 
studied >10.000 patients without previous MI and without previous revascularization 
who underwent stress SPECT. The study population was divided in patients who were 
treated medically and patients who underwent early revascularization and was followed 
during a mean follow-up of 1.9 years. In patients with moderate to severe ischemia 
(>10% myocardial ischemia) revascularization was associated with improved survival 
in comparison to medical therapy. Sorajja et al.12 evaluated 826 asymptomatic diabetic 
patients without known CAD who underwent exercise, adenosine or dobutamine stress 
SPECT. SPECT images were classified as low-, intermediate-, and high-risk. A total of 261 
patients (32%) had a high-risk SPECT (defined as a summed stress score ≤47, based on: 
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the lower the score the higher the radioisotope uptake). During a mean follow-up of 
5.7±3.3 years CABG was associated with better survival in patients with moderate to se-
vere ischemia. The current study differs from these previous studies for several reasons. 
First, the current study evaluated a high-risk patient group (30% had previous revascu-
larization and  41% had previous MI versus 0% in the studies of Hachamovitch et al. and 
Sorajja et al. Second, this study showed higher event rates. This may be explained by 
the high prevalence of cardiac history indicating a higher risk status in contrast to these 
previous studies. Also, during the current long-term follow-up natural progression of 
CAD may have occurred. Third, the mean follow-up duration in these previous studies 
was 1.9 and 5.7 years. In the present long-term follow-up study median follow-up dura-
tion was 12 years. To our knowledge, this is the first study that has examined the impact 
of early revascularization in relation the amount of  ischemia in patients with stable 
CAD for long-term (>10 years) outcome. This study extends the conclusions drawn from 
these previous studies in that early revascularization in patients with moderate to high 
ischemia burden is beneficial during long-term outcome. The current findings are also 
in line with previous data which indicates that a certain amount of ischemia has to be 
present for revascularization to be beneficial.13 
In a nuclear substudy of the COURAGE trial6 a total of 314 patients were enrolled 
who underwent either exercise or vasodilator stress 99mTc-sestamibi SPECT. Moderate 
to severe ischemia on SPECT was defined as ≥10% myocardium. The authors found that 
the magnitude of residual ischemia was proportional to the risk of all-cause mortality. 
However, as the authors noted, these findings are based on underpowered data due to 
the small proportion of enrolled patients.6 More recently, a second nuclear substudy of 
the COURAGE trial was performed.7 Of the 1381 patients who underwent SPECT, 699 
patients were treated medically and 682 patients received medical treatment and PCI. 
Patients were followed for a median follow-up of 4.6 years. The extent of ischemia was 
not associated with adverse events; the event rates in both mild ischemia and moder-
ate-severe ischemia were similar according to treatment options (medical treatment or 
medical treatment combined with PCI). In the current long-term follow-up study early 
revascularization was associated with lower all-cause mortality and cardiac mortality. 
This study has several limitations. First, the decision to perform coronary revascu-
larization was made by the treating physician, this could have influenced the current 
results. Further randomized controlled trials are needed to further study the impact of 
ischemia burden and early revascularization on long-term outcomes. Second, at time 
of data collection, medications were underused in view of the current treatment guide-
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lines, maybe because the beneficial effect of these medications was not yet fully under-
stood.15 Third, there were some imbalances in baseline characteristics (more patients in 
the early revascularization group were men and had previous revascularization). This 
could have influenced the outcome. 
CONCLUSION
Patients with myocardial ischemia on stress SPECT who underwent early revasculariza-
tion had a  lower all-cause mortality and cardiac mortality during long-term follow-up 
as compared to patients who received pharmacological therapy alone. This difference 
in long-term outcomes was mainly caused by the survival benefit of early revasculari-
zation in the patients with a moderate to high ischemia burden. In  patients with low 
ischemia burden early coronary revascularization had no beneficial impact on long-
term outcomes as compared to a treatment strategy based on pharmacological therapy 
alone.
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Since the 70s of the last century both myocardial perfusion imaging (MPI) using single-
photon emission computed tomography (SPECT, introduced in 1970) and dobutamine 
stress echocardiography (DSE, introduced in 1979) have played an important role in the 
diagnosis of coronary artery disease (CAD).1,2 In the last decades, stress imaging has not 
only been used for diagnosing CAD, it also has emerged as a noninvasive tool providing 
risk stratification and prognostic information. Risk stratification is based on the concept 
that patients with normal stress test results could be spared invasive angiographic as-
sessment, because a normal test result defines patients at low-risk (typically <1% per 
year of follow-up) for cardiac events.4 On the other hand, patients with abnormal stress 
test results are candidates for invasive coronary angiography and intervention because 
they have a greater risk of cardiac events. However, risk after a normal stress test result 
varies along with the temporal characteristics of the patients, for example the presence 
of known CAD, use of pharmacologic stress and the presence of diabetes mellitus.5 This 
so called warranty period is defined as the duration of time whereby the patient’s risk 
alters significantly from that observed during the early portion of follow-up. Figure 1 
shows the cumulative survival curves of patients with normal versus abnormal DSE. The 
vertical line illustrate that the curves diverge until 7 years. After that point, the curves 
start to run parallel indicating a ‘warranty period’ of 7 years. 
Figure 1. Survival curves of patients with normal versus abnormal DSE. The vertical line illustrate 
that the curves start to run parallel at approximately 7 years.
Multiple studies, to date, have demonstrated the prognostic value of DSE and stress 
SPECT MPI in several patient populations, including obese patients6, elderly patients7, 
diabetic patients8,9 and patients with limited exercise capacity.10,11 In the currently avail-
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able literature patients were followed for short – and medium term follow-up. Data on 
the (very) long-term outcome after noninvasive cardiac stress imaging are lacking. 
This thesis focused on the long-term prognostic value of cardiac stress imaging, more 
precisely on DSE and SPECT MPI in patients with known or suspected CAD. The prog-
nostic value of both imaging modalities was studied in various patient groups, which 
are commonly encountered in with daily practice. The studies that forms this thesis can 
be divided in three main topics: 
A)  Duration of low risk after a normal cardiac exercise stress test,
B)   Prediction of long-term outcome in patients considered at increased risk of adverse 
events, 
C)  Impact of early coronary revascularization on long-term outcomes. 
PART A: Duration of low risk after a normal cardiac exercise stress test
A normal stress SPECT MPI is associated with a low risk of cardiac events irrespective of 
other features including known CAD. In a pooled analysis of 19 studies including a total 
of 39.173 patients the hard cardiac event rate was 0.6% per year for patients with a nor-
mal SPECT MPI.12 However, even in the presence of a normal SPECT MPI a temporal risk 
occurs which increases the cardiac event rate to 2%.5 The duration of the low-risk period 
after a normal SPECT MPI is not clear. In Chapter 2 of this thesis the long-term outcome 
is described of 233 patients who underwent bicycle 99mTc-sestamibi SPECT MPI and had 
normal myocardial perfusion at exercise and at stress. We found relatively low cardiac 
event rates during the long-term follow-up of 15 years, particularly in the first 5 years. 
Age, male gender and diabetes mellitus were predictors of cardiac events in patients 
with known or  suspected CAD. Follow-up should be more intense in these patients.
Exercise electrocardiography (ECG) and exercise SPECT MPI are well established 
methods for the evaluation of patients with known or suspected CAD. The long-term 
impact of SPECT MPI in patients with a normal exercise ECG test is not known. In Chap-
ter 3 it is shown that approximately 50% of patients with normal exercise ECG tests had 
an abnormal SPECT MPI. A total of 20% of patients had reversible perfusion defects 
indicating myocardial ischemia. Current guidelines recommend exercise ECG testing for 
evaluation of known or suspected CAD.13 Our data show that even in patients with nor-
mal exercise ECG, improved risk stratification can be obtained using SPECT MPI. 
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PART B: Prediction of long-term outcome in patients considered at increased risk 
of adverse events
The short- to medium-term prognostic value of both DSE and SPECT MPI has been firmly 
established and both techniques can be used to identify low-risk and high-risk patient 
groups.4 This is important for guiding therapy (medical therapy, revascularization) and 
better patient outcomes. Part B of this thesis contains studies evaluating the long-term 
prognostic value of cardiac stress imaging in patients considered at increased risk of 
cardiac events. In Chapter 4, in a large patient cohort of 638 patients of whom 46% had 
known CAD, the results showed that exercise SPECT MPI has an incremental prognostic 
value over clinical and exercise test parameters during a long-term follow-up period 
of 11 years. Furthermore, patients with an abnormal SPECT MPI have a significantly 
increased risk of cardiac events compared to patients with a normal SPECT MPI. The 
long-term prognostic value of SPECT MPI in high-risk patients (obese patients, heart 
transplant recipients, diabetic patients, patients unable to perform a stress test) may 
be impaired due to the underlying cardiovascular risk. Accordingly, in Chapter 5 the 
results of the long-term outcome after stress SPECT MPI are presented in a total of 267 
obese patients. Up to a 6-year period after testing, stress 99mTc-tetrofosmin SPECT MPI 
does hold its value for the prediction of all-cause mortality and cardiac events in these 
patients. After 6 years repeated testing may be considered in obese patients depending 
on the patient’s symptoms and clinical status.
The guidelines of the International Society for Heart and Lung Transplantation 
(ISHLT) state that SPECT MPI may be useful for diagnosing cardiac allograft vasculo-
pathy (CAV) in heart transplant recipients.14 CAV limits the long-term success of heart 
transplantation. The long-term prognostic role of noninvasive SPECT MPI in heart 
transplant recipients remains unclear. In a total of 166 heart transplant recipients, it is 
demonstrated in Chapter 6 that this technique provides valuable prognostic informa-
tion. Heart transplant recipients with a normal stress 99mTc-tetrofosmin SPECT MPI have 
a significantly better prognosis as compared with those with an abnormal study, up to 
5 years after initial testing. 
SPECT MPI after submaximal exercise stress may underestimate the extent of is-
chaemia. Therefore, patients unable or limited to exercise should be risk stratified using 
SPECT MPI or echocardiography coupled with pharmacologic stress. Both vasodilators 
(adenosine, dipyridamole) and dobutamine are feasible stressors. The latter is used in 
studies described in this thesis. In Chapter 7 the 11-year prognostic value of dobuta-
mine stress SPECT MPI is assessed using 99mTc-sestamibi as a tracer in 473 patients with 
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limited exercise capacity. A total of 61% of the patients died (all-cause mortality) giving 
an annualized event rate of 5.6%/year. The incremental prognostic value of dobutamine 
stress SPECT MPI over clinical data was maintained during the very long-term follow-up 
period. An abnormal SPECT MPI was associated with an increased risk of major adverse 
cardiac events (hazard ratio 1.53, CI 1.02-2.30) incremental to age, male gender, cardiac 
risk factors and stress test results. Subsequently, in Chapter 8, the long-term outcome 
after dobutamine stress 99mTc-tetrofosmin SPECT MPI is described in 247 elderly patients 
(>65 years, mean age 71 years) unable to perform an exercise test. During the median 
follow-up of 14 years, not only the presence of an abnormal SPECT MPI, but also the 
extent and severity of the perfusion defect (as expressed as the summed stress score) 
provided optimal risk stratification. 
Due to its low cost and simplicity, surface 12-lead electrocardiography (ECG) is a 
valuable diagnostic tool. These features also make ECG an attractive option for cardiac 
risk stratification. Recent studies have established the prognostic value of QRS duration 
at ECG in the general population and in groups of lower risk patients on a short term. 
In Chapter 9, the long-term (8 year) prognostic value of QRS duration is evaluated in 
512 patients with known or suspected CAD referred for SPECT MPI for the evaluation 
of myocardial ischemia. QRS duration ≥120ms was a strong predictor of cardiac mor-
tality (hazard ratio 1.95, CI 1.36-2.78) and cardiac mortality or non-fatal MI (hazard ratio 
1.69, CI 1.21-2.36) even after adjustment for clinical variables and SPECT MPI results. 
An abnormal MPI is associated with an increased risk of cardiac mortality and cardiac 
mortality or non-fatal MI.
The worldwide prevalence of diabetes mellitus is increasing and CAD is a major 
cause of mortality and morbidity is these patients.15 In diabetic patients, both SPECT 
MPI and DSE have shown an incremental value in predicting all-cause mortality and 
hard cardiac events at short- and intermediate term follow-up. However, it is not known 
whether this incremental value is maintained at long-term follow-up. We therefore as-
sessed the long-term outcome after SPECT MPI (8 years) and DSE (13 years) in diabetic 
patients with limited exercise capacity in Chapter 10 and Chapter 11 respectively. 
Up to 4-years after testing, there was a significantly better prognosis of patients with 
a normal SPECT MPI compared to those with an abnormal study, described in Chap-
ter 10. The Cox proportional hazard regression model showed that an abnormal SPECT 
MPI, and a reversible perfusion defect were predictors of cardiac mortality and hard 
cardiac events. Comparably, as described in Chapter 11, the prognostic value of DSE 
was optimal up to approximately 7 years after the initial test. The most powerful echoc-
ardiographic predictor of outcome was peak wall motion score index (pWMSI), with 
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left ventricular ejection fraction (LVEF) at rest coming up second. Multivariate analysis 
showed that pWMSI and LVEF were independent predictors of long-term outcome. We 
also found that patients with LVEF≥50% and peak WMSI=1 had a favorable prognosis, 
whereas patients with LVEF<50% and pWMSI>1 had an adverse long-term prognosis. 
Patients with LVEF≥50% and pWMSI>1 and those with LVEF<50% and peak WMSI<1 
had an intermediate prognosis. Importantly, the prognosis in diabetic patients is related 
not only to the extent of stress induced ischemia but also to LV function at rest. Overall, 
patients with diabetes mellitus with limited exercise capacity indicate a high-risk pa-
tient group. This characteristic may have influenced the risk of cardiac events, thereby 
limiting the long-term prognostic value of SPECT MPI and DSE. So, a warranty period 
exists of both SPECT MPI and DSE in patients with diabetes. 
Currently, it is not known whether the prognostic value of DSE in these patients is 
preserved at very long-term (>10 years) follow-up. In Chapter 12 the very long-term 
outcome after DSE in a large (n=3381) high-risk patient group is investigated. Forty-five 
percent of the patients had known CAD. During a mean follow-up of 13 years there 
were 1.725 deaths (51%), of which 1.128 (33% of total study cohort) were attributed to 
cardiac causes. Patients with a normal DSE had a significantly better survival in com-
parison with patients with an abnormal DSE (44% vs 35% at 15 years; p<0.001). WMSI 
during stress predicted both all-cause mortality and cardiac mortality. Interestingly, the 
survival curve of all-cause mortality diverges up to approximately 7 years after DSE indi-
cating that the test seems not to have further discriminating value after this time period. 
This in line with the observations described in Chapter 11. 
The research described in Chapter 13 reported on the comparison between DSE 
and dobutamine 99mTc-sestamibi SPECT MPI. We studied 301 patients with known or 
suspected CAD who underwent both noninvasive imaging modalities. During a mean 
follow-up of 14 years, 172 (57%) deaths and 118 (39%) cardiac events occurred. Age, 
previous MI and the presence of heart failure were the major determinants of long-term 
prognosis. Multivariable analysis revealed that both an abnormal DSE and an abnormal 
SPECT MPI (agreement was 82%, kappa=0.62) had an incremental prognostic value over 
clinical and stress test variables. Both techniques can be used interchangeably to clas-
sify patients as low or high-risk of subsequent cardiac events. 
PART C: Impact of early coronary revascularization on long-term outcomes
In patients with acute coronary syndrome, it has been shown that coronary revascu-
larization substantially reduces mortality.16 Patients with stable CAD can be treated by 
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medical therapy or coronary revascularization. The ESC guidelines on the management 
of stable CAD recommends percutaneous coronary intervention (PCI) in patients with 
single-vessel disease or in patients in which coronary artery bypass graft surgery (CABG) 
may be contra-indicated (e.g. prior CABG, severe lung disease). In patients with recur-
rent in-stent restenosis or multivessel disease with left anterior descending artery (LAD) 
involvement CABG is the preferred revascularization method. However, the jury is still 
out concerning the impact of early coronary revascularization in patients with stable 
CAD.17 Information on the impact of coronary revascularization on long-term outcome 
in patients with myocardial ischemia at DSE or SPECT MPI is lacking. Chapter 14 evalu-
ated the impact of early coronary revascularization on long-term mortality in patients 
with stress-induced ischemia at DSE. Early coronary revascularization was defined as 
PCI or CABG ≤90 days after DSE. During a median follow-up of 10 years, 52% of the 905 
patients died, of which 51% due to cardiac causes. Our findings show that early revascu-
larization (PCI or CABG) after an ischemic DSE had a beneficial effect on all-cause mor-
tality and cardiac mortality, adjusted for clinical characteristics and DSE results. Impor-
tantly, both in patients with a mild to moderately abnormal DSE (peak WMSI≤1.7) and 
in patients with a markedly abnormal DSE (peak WMSI>1.7), early revascularization was 
associated with better long-term outcomes. The multivariable model showed that early 
revascularization had a beneficial effect on all-cause mortality (hazard ratio 0.60, 95% CI 
0.46-0.79) and cardiac mortality (hazard ratio 0.49, 95% CI 0.34-0.72) during long-term 
follow-up. 
Stress SPECT MPI is a reliable tool to assess the ischemia burden, and may be used 
to identify coronary revascularization candidates.18 In Chapter 15 we further examined 
the impact of early coronary revascularization on long-term outcomes in 538 patients 
with myocardial ischemia on exercise bicycle or dobutamine stress SPECT MPI (defined 
as the presence of a reversible or partially reversible perfusion defect). A low ischemia 
burden was defined as the presence of reversible perfusion abnormalities in <3 seg-
ments, whereas a moderate to high ischemia burden was defined as ≥3 ischemic seg-
ments on SPECT MPI. During a median follow-up of 12 years, it was shown that patients 
with myocardial ischemia on stress SPECT MPI who underwent early revascularization 
(n=76) had a lower all-cause mortality (hazard ratio 0.47, 95% CI 0.31-0.72) and cardiac 
mortality (hazard ratio 0.51, 95% CI 0.28-0.93) as compared to patients who received 
pharmacological therapy alone. This difference in long-term outcomes was mainly 
caused by the survival benefit of early revascularization in the patients with moderate 
to high ischemia burden.
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Clinical implications
The unique contribution of the current thesis is based on the (very) long-term prog-
nostic value of cardiac stress imaging. The studies performed in this thesis have several 
potential implications for daily clinical practice. 
First, clinicians should be aware that patients with a normal exercise SPECT MPI have 
a favorable prognosis even at long-term (15-year) follow-up. Consequently, in these pa-
tients a watchful waiting approach is justified and unnecessary invasive coronary angi-
ography could be avoided. 
Second, several clinical (e.g. age, male gender, diabetes, history of CAD) and exer-
cise test parameters (peak exercise heart rate, ST segment changes) can identify pa-
tients with increased risk of cardiac events who have normal exercise SPECT MPI and 
follow-up should be closer in these patients. 
Third, approximately 20% of patients with known or suspected CAD and normal ex-
ercise electrocardiographic testing have completely or partially reversible myocardial 
perfusion defects. SPECT MPI provides additional information for the prediction of long-
term cardiovascular outcomes in these patients.
Fourth, the results of this thesis confirms and extends numerous previous studies 
regarding the short- and medium-term value of DSE and SPECT MPI for risk-stratifying 
patients with low – or high risk at cardiac events. Results of both imaging modalities 
demonstrates the clinical importance for assessment of very long-term outcome in the 
way that these test have a valid role in assisting clinicians in determining therapy to 
reduce the likelihood of cardiac events. This applies for obese patients, heart transplant 
recipients, patients with limited exercise capacity, elderly patients, and patients with 
diabetes mellitus. However, depending on the characteristics of the patients a warranty 
period exists. Less intensive management and eliminating the need for follow-up test-
ing would be expected in patients considered at low risk for cardiac events. 
Fifth, the prognosis in diabetic patients is related not only to the extent of stress 
induced ischemia (pWMSI>1 indicates an adverse long-term prognosis) but also to 
the function of the left ventricle (LV) at rest (LVEF<50% indicates an adverse long-term 
prognosis). 
Sixth, DSE and SPECT MPI still have comparable prognostic value even when a fol-
low-up period is extremely long. Prognostic accuracy is superior for both noninvasive 
imaging modalities as compared with clinical variables alone. 
Finally, while waiting for the ongoing randomized results of the ISCHEMIA trial19 the 
decision to revascularize will depend on a thorough risk assessment and the patient’s 
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symptoms.18 Also, as this thesis demonstrates, the extent of ischaemia, as assessed by 
DSE and/or stress SPECT MPI, can be used in guiding therapy. 
Future challenges
With the ageing of the population more patients are referred for diagnostic and prog-
nostic work-up. Noninvasive imaging techniques therefore, will continue to grow with 
advances in pharmacologic stressors and imaging agents. Landmarks leading to the 
current applications of SPECT MPI include the introduction of 99mTechnetium based 
tracers and the use of attenuation correction.20 New ultrafast SPECT cameras have 
evolved resulting in high-quality perfusion imaging. Moreover, half the dose of a radi-
onuclide tracer can be used.21 More recently, other imaging techniques, including CT 
coronary angiography, cardiac magnetic resonance imaging (cMRI) and positron emis-
sion tomography (PET)  have emerged as alternative methods for evaluating myocardial 
perfusion.22,23 This list of novel techniques reflects the need for continuing innovation 
by clinicians involved in the treatment of CAD. With the introduction of gated SPECT 
combined evaluation of myocardial perfusion and left ventricular function can be per-
formed. Future studies are needed to clarify the value of gated SPECT for the evaluation 
of long-term prognosis.
Furthermore, examples of recently developed radiopharmaceuticals for SPECT MPI 
and PET are 18F-flurpiridaz, 13N-ammonia, H
2
15O, 82Rubidium, and 123I-meta-iodo-ben-
zylguanidine (mIBG).24 Also, new combination modalities are used to improve the de-
tection of CAD more quantitatively, including CCTA/SPECT MPI, PET-CT and SPECT-CT. 
These so-called hybrid imaging techniques combine physiologic and anatomic infor-
mation in order to reduce tracer use and costs. Due to advances in technology of SPECT 
MPI,  which simultaneously occur with the introduction of PET imaging, more studies 
are needed to compare these techniques. 
Other challenges for cardiac stress imaging are based on the procedural limitations 
of cardiac stress imaging: the length of the tests and the radiation exposure to the pa-
tients. The average SPECT MPI study exposes the patients to 12-15 mSV 20, while stress 
echocardiography is free of radiation. Regarding the future of stress echocardiography, 
contrast echocardiography, myocardial Doppler imaging and 3D-echocardiography are 
promising relatively new techniques. To date however, due to the lack of a standardized 
technique, stress echocardiography and stress SPECT MPI are still the most commonly 
used and widely available techniques in the evaluation and management of patients 
with known or suspected CAD. 
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Inleiding
Ondanks betere diagnostiek en behandeling blijven coronaire hartziekten (ziekten 
van de kransslagaders) de belangrijkste doodsoorzaak in veel Westerse landen. Door 
vergrijzing worden er meer patiënten verwezen voor het diagnosticeren en inschatten 
van de prognose van coronaire hartziekten. Voor het op niet-invasieve wijze in beeld 
brengen van coronaire hartziekten kan men gebruikmaken van myocardscintigrafie en 
echografie. Door een patiënt zich te laten inspannen op een loopband of met een fiets 
(een stress test) kunnen veranderingen van de hartspier uitgelokt worden die duiden op 
zuurstofgebrek van de hartspier (ischemie). Myocard perfusie scintigrafie middels single-
photon emission computed tomography (SPECT) meet de doorstroming (perfusie) van 
het hartspierweefsel (myocard) in rust en tijdens inspanning. Stress echocardiografie 
visualiseert wandbewegingsstoornissen van het hart. SPECT en dobutamine stress 
echocardiografie (DSE) worden gebruikt om myocardischemie op te sporen tijdens of na 
inspanning. Bij patiënten die om welke reden dan ook geen inspanning kunnen leveren, 
kan medicatie worden toegediend om stress van het hart na te bootsen. Veelgebruikte 
medicijnen voor dit doel zijn dipyridamol, adenosine en dobutamine. 
Cardiaal stress onderzoek
Cardiaal stress onderzoek speelt een belangrijke rol bij het stellen van de diagnose en de 
bepaling van de prognose van coronaire hartziekten. Patiënten met een normaal stress 
onderzoek hebben een laag risico (<1% per jaar) op cardiale dood of een hartinfarct; 
een invasief coronair angiogram kan daarom worden vermeden. Echter, patiënten met 
een afwijkend stress onderzoek hebben een verhoogd risico op overlijden en het krijgen 
van een hartinfarct. Bij deze patiënten kan de prognose worden verbeterd door een 
coronairangiogram te verrichten en vervolgens, afhankelijk van de bevindingen, een 
percutane coronaire interventie (dotterbehandeling meestal met stent-implantatie) of 
coronaire bypass operatie te doen. 
Het risico van de patiënt op overlijden of een hartinfarct kan na een normaal stress 
onderzoek in de loop van de tijd toenemen, bijvoorbeeld vanwege progressie van al 
bekende coronaire hartziekte of de aanwezigheid van diabetes mellitus. Er is een zekere 
‘geldigheidsduur’ van DSE en SPECT. In de eerste periode na DSE of SPECT is een goede 
inschatting van de prognose mogelijk, daarna kan het risico van de patiënt veranderen. 
De prognostische waarde van cardiaal stress onderzoek is onderzocht voor de korte – en 
middellange termijn. Lange-termijn follow-up data ontbreken echter in de literatuur. 
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In dit proefschrift wordt de lange-termijn prognostische waarde van cardiaal stress 
onderzoek beschreven in verschillende patiëntengroepen. De beschreven studies 
worden onderverdeeld in 3 hoofdonderwerpen:
A)   De duur van een laag risico op overlijden of een hartinfarct na een normaal cardiaal 
stress onderzoek
B)   Het voorspellen van de lange-termijn prognose bij patiënten met een verhoogd risico 
op overlijden of een hartinfarct.
C)   De lange-termijn invloed van vroege coronaire revascularisatie op de prognose. 
De duur van de laag risico periode na een normaal cardiaal stress onderzoek
Patiënten met een normaal cardiaal stress onderzoek hebben in de eerste jaren na 
het onderzoek een goede prognose. Na verloop van tijd stijgt de kans op een cardiaal 
event (zoals sterfte door een cardiovasculaire oorzaak of hartinfarct), ondanks de 
normale stress SPECT. De duur van een laag risico op cardiale events na een normale 
SPECT was vooralsnog onbekend. In Hoofdstuk 2 worden de lange-termijn uitkomsten 
gepresenteerd van 233 patiënten die een inspannings SPECT ondergingen. Gedurende 
de lange follow-up periode van 15 jaar overleed 18% van de patiënten. Met name in 
de eerste 5 jaar van de follow-up periode hebben patiënten met een normale SPECT 
een gunstige prognose. Factoren zoals leeftijd, mannelijk geslacht en diabetes mellitus 
waren voorspellers voor een cardiaal event. Patiënten met deze eigenschappen moeten 
dan ook intensiever vervolgd worden. In Hoofdstuk 3 werd onderzocht wat de waarde 
is van SPECT voor het voorspellen van lange-termijn uitkomsten bij patiënten met een 
normaal elektrocardiogram (ECG). In de onderzochte groep van 650 patiënten had 50% 
een afwijkende SPECT en 20% van de patiënten had een volledig of gedeeltelijk reversibel 
perfusie defect. SPECT heeft een toegevoegde prognostische waarde bij patiënten die 
een normaal ECG in rust hebben en bekend zijn met coronairziekte of een vermoeden 
daarop. 
Het voorspellen van lange-termijn betekenis in patiënten met een verhoogd risico 
op cardiale events
Zowel SPECT als DSE worden gebruikt om patiënten te identificeren die een laag 
of hoog risico hebben op cardiale events. Dit is van belang om patiënten de juiste 
behandeling te kunnen bieden (medicatie en/of revascularisatie). Uit het onderzoek in 
Hoofdstuk 4 blijkt dat SPECT toegevoegde prognostische waarde heeft gedurende een 
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vervolg periode van 11 jaar. Patiënten met een afwijkende SPECT hebben een slechtere 
prognose dan patiënten met een normale SPECT. Er zijn belangrijke risicofactoren voor 
coronaire hartziekten zoals, obesitas, diabetes mellitus, status na harttransplantatie en 
het hebben van een beperkte inspanningscapaciteit. De prognostische waarde van 
SPECT bij patiënten met deze risicofactoren kan beperkt zijn. In Hoofdstuk 5 wordt de 
prognostische waarde van inspannings SPECT beschreven in 261 obesitas patiënten, 
die werden vervolgd gedurende 12 jaar. Obesitas patiënten met een normale SPECT 
hebben een gunstige overleving gedurende de eerste 6 jaar na de SPECT. Invasieve 
onderzoeken kunnen daarom worden vermeden bij deze patiënten. Inspannings SPECT 
levert waardevolle prognostische informatie bij obesitas patiënten tot 6 jaar na de SPECT 
scan. Coronaire hartziekten zijn een veelvoorkomende doodsoorzaak bij patiënten die 
een harttransplantatie hebben ondergaan. SPECT is een nuttige techniek om coronaire 
hartziekten te evalueren in deze patiëntengroep. Hoofdstuk 6 beschrijft de rol van 
inspannings SPECT bij 166 patiënten met een harttransplantatie. Inspannings SPECT 
levert prognostische waarde tot 5 jaar na de SPECT scan. 
Stress SPECT zal de hoeveelheid ischemie onderschatten als patiënten geen of 
een beperkte inspanningscapaciteit hebben. Daarom wordt in deze patiëntengroep 
inspanning nagebootst met medicijnen die de zuurstofvraag van het hart verhogen. In de 
studies beschreven in dit proefschrift is gebruik gemaakt van dobutamine. In Hoofdstuk 
7 is onderzocht wat de prognostische waarde is van dobutamine SPECT in een groep 
van 473 patiënten met een beperkte inspanningscapaciteit. Een afwijkende SPECT was 
een onafhankelijke lange-termijn voorspeller voor het gecombineerde eindpunt van 
cardiale dood, hartinfarct of coronaire revascularisatie. Een afwijkende SPECT bood 
een toegevoegde waarde voor het voorspellen van de lange termijn prognose, naast 
de klinische gegevens en de resultaten van de dobutamine inspanningstest. Vervolgens 
werd in Hoofdstuk 8 de waarde van dobutamine SPECT onderzocht bij 247 patiënten 
van 65 jaar of ouder met een gemiddelde leeftijd van 71 jaar. Tijdens de lange-termijn 
follow-up van 14 jaar was zowel een afwijkende SPECT als de mate en ernst van de 
perfusiedefecten voorspellend voor cardiale events. Deze parameters kunnen gebruikt 
worden om patiënten ouder dan 65 jaar te stratificeren in een laag en hoog risico op 
cardiale events. 
Het maken van een ECG is goedkoop, eenvoudig en waardevol in de diagnostiek 
van patiënten met coronaire hartziekten. Daarnaast maken deze eigenschappen het 
ECG tot een aantrekkelijk onderzoek voor risico stratificatie van patiënten. Hoofdstuk 
9 beschrijft de resultaten van het onderzoek naar de prognostische waarde van de QRS 
duur op het ECG bij 512 patiënten met bekende coronaire hartziekten of een vermoeden 
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daarop. Gedurende de lange-termijn follow-up van gemiddeld 9 jaar bleek dat een QRS 
duur van ≥120 ms een onafhankelijke voorspeller was van cardiale dood en hartinfarct. 
Deze studie toont aan dat zowel de QRS duur als de resultaten van de SPECT gebruikt 
kunnen worden voor optimale risicostratificatie van patiënten met coronaire hartziekten 
of een vermoeden daarop. 
Naast de al genoemde risicofactoren is diabetes mellitus een belangrijke risicofactor 
voor coronaire hartziekten. Hoofdstuk 10 beschrijft de lange-termijn (8 jaar) uitkomsten 
van dobutamine SPECT bij ruim 200 patiënten met diabetes mellitus en een verminderde 
inspanningscapaciteit. Patiënten met een normale dobutamine SPECT hadden een 
significant betere overleving dan patiënten met een afwijkende dobutamine SPECT 
tot 4 jaar na de scan. Na die periode had SPECT geen toegevoegde waarde meer. 
Een afwijkende SPECT en de aanwezigheid van reversibele perfusiedefecten waren 
belangrijke voorspellers voor cardiale dood. In Hoofdstuk 11 worden de resultaten 
beschreven van het onderzoek naar de lange-termijn uitkomsten van DSE bij patiënten 
met diabetes mellitus. In totaal werden 396 patiënten met diabetes mellitus gevolgd 
gedurende 13 jaar. DSE had prognostische waarde tot circa 7 jaar. De sterkste voorspellers 
voor totale mortaliteit, cardiale dood en hartinfarct waren de wall motion score index 
tijdens maximale stress (pWMSI) en de linker ventrikel ejectie fractie (LVEF). Patiënten 
met een LVEF ≥50% en een peak WMSI=1 hadden een gunstige prognose gedurende 
follow-up, terwijl patiënten met een LVEF<50% en een pWMSI>1 een slechtere prognose 
hadden. Ook bleek uit dit onderzoek dat de prognose van patiënten met diabetes mellitus 
gerelateerd was aan zowel de hoeveelheid ischemie geïnduceerd tijdens inspanning als 
aan de functie van de linker ventrikel in rust. Patiënten met diabetes mellitus en een 
verminderde inspanningscapaciteit vormen een hoog-risico patiënten groep. Dit is de 
reden waarom de prognostische waarde van SPECT en DSE bij patiënten met diabetes 
mellitus beperkt is. Er is dus een beperkte geldigheidsduur voor beide technieken bij 
patiënten met diabetes mellitus. 
Hoofdstuk 12 beschrijft de lange-termijn uitkomsten na DSE in een grote groep van 
3381 patiënten, waarvan 45% van de patiënten bekend was met coronaire hartziekten. 
Patiënten met een normale DSE hadden een significant betere overleving dan patiënten 
met een afwijkende DSE (de overleving na 15 jaar was 44% versus 35%). De WMSI tijdens 
stress was voorspellend voor de totale mortaliteit en cardiale dood. Na een follow-up 
periode van 7 jaar bleek dat er geen verschil meer was tussen de overlevingscurves. Dit 
komt overeen met de resultaten van Hoofdstuk 11. 
Vervolgens is in Hoofdstuk 13 de lange-termijn prognostische waarde van 
dobutamine SPECT vergeleken met DSE. In totaal 301 patiënten ondergingen zowel 
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SPECT als DSE en werden vervolgd voor een periode van 14 jaar. Leeftijd, een hartinfarct 
in het verleden en de aanwezigheid van hartfalen waren voorspellers voor de lange-
termijn prognose. Een multivariabele analyse toonde dat beide niet-invasieve technieken 
toegevoegde waarde hadden naast de klinische variabelen en de variabelen van de 
stress test. Beide technieken kunnen dan ook gebruikt worden om patiënten in te delen 
in een laag of hoog risico groep op het krijgen van cardiale events. 
De lange-termijn invloed van vroege coronaire revascularisatie op de prognose
Coronaire revascularisatie bij patiënten met een acuut coronair syndroom leidt tot een 
reductie in mortaliteit. Patiënten met stabiele coronaire hartziekte kunnen zowel met 
medicatie als met coronaire revascularisatie (dotterbehandeling meestal met stent-
implantatie of coronaire bypass operatie) behandeld worden. Het is nog niet geheel 
duidelijk wat de invloed van vroege coronaire revascularisatie is bij patiënten met 
stabiele coronaire hartziekte. In Hoofdstuk 14 wordt beschreven wat de 10-jaars invloed 
is van vroege (≤90 dagen na de DSE) coronaire revascularisatie bij 905 patiënten met 
ischemie op DSE. De resultaten suggereren dat vroege revascularisatie een gunstig 
effect heeft op totale mortaliteit en cardiale dood in deze patiënten groep. Dit gold voor 
zowel patiënten met een matig afwijkende DSE (gedefinieerd als een pWMSI≤1.7) als 
voor patiënten met een ernstig afwijkende DSE (gedefinieerd als een pWMSI>1.7). Ten 
slotte beschrijft Hoofdstuk 15 de invloed van vroege coronaire revascularisatie op totale 
mortaliteit en cardiale dood bij 538 patiënten met ischemie op SPECT. Matige ischemie 
was gedefinieerd als reversibele perfusiedefecten in minder dan 3 segmenten. Ernstige 
ischemie was gedefinieerd als reversibele perfusiedefecten in meer dan 3 segmenten. 
Tijdens de 12-jaar follow-up bleek dat patiënten die vroege revascularisatie ondergingen 
een betere overleving hadden en dat er minder cardiale dood optrad. Dit verschil werd 
met name veroorzaakt door het gunstige effect van vroege coronaire revascularisatie bij 
patiënten met een ernstig afwijkende DSE. 
Conclusie – klinische toepassingen
De lange-termijn studies beschreven in dit proefschrift hebben verschillende 
toepassingen voor de dagelijkse klinische praktijk. 
 Patiënten met een normale inspannings SPECT hebben een gunstige prognose, 
ook op langere termijn. Een conservatieve behandeling is dan ook gerechtvaardigd. Zo 
kunnen invasieve onderzoeken worden vermeden.  
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 Daarnaast kunnen verschillende klinische parameters, zoals leeftijd, mannelijk 
geslacht en diabetes mellitus, worden gebruikt om patiënten te identificeren die 
een verhoogd risico hebben op overlijden, een hartinfarct of het ondergaan van een 
coronaire revascularisatie. Patiënten met deze risicofactoren dienen intensiever vervolgd 
te worden. 
 Ten derde heeft ongeveer 20% van de patiënten met bekende coronaire hartziekten 
of een vermoeden daarop én een normaal inspannings ECG reversibele perfusiedefecten 
met SPECT. Een SPECT onderzoek kan bij bepaalde patiënten aanvullende informatie 
geven over de prognose, zelfs als het inspannings ECG normaal is.
 Ten vierde, de lange-termijn resultaten van dit proefschrift bevestigen eerdere 
studies met betrekking tot de waarde van DSE en SPECT voor risico stratificatie van 
patiënten met een laag of hoog risico op cardiale events. Beide niet-invasieve testen 
kunnen artsen helpen bij het bepalen van een behandeling om het risico op overlijden 
of een hartinfarct te verminderen bij patiënten met obesitas, diabetes mellitus of 
met een harttransplantatie en oudere patiënten of patiënten met een verminderde 
inspanningscapaciteit. 
 Ten vijfde, de lange-termijn prognose van patiënten met diabetes mellitus is 
gerelateerd aan zowel de hoeveelheid ischemie geïnduceerd tijdens inspanning als aan 
de functie van de linker ventrikel in rust. 
 Ten zesde, DSE en SPECT hebben een vergelijkbare prognostische waarde voor 
de zeer lange-termijn. De prognostische waarde van beide afbeeldingstechnieken 
is nauwkeuriger dan klinische variabelen alleen (zoals leeftijd, geslacht, cardiale 
risicofactoren). 
 Ten slotte, zal de beslissing om patiënten wel of niet te revasculariseren afhangen van 
het risicoprofiel en de symptomatologie. De mate van ischemie, vastgesteld met DSE of 
SPECT, kan gebruikt worden bij de keuze van de juiste therapie.    
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Promoveren, in welke fase van je carrière moet die research episode eigenlijk vallen? 
Sommigen promoveren al vóór hun co-schappen, anderen promoveren na hun 
specialistenopleiding. Kan het anders? Jazeker, maar promoveren tijdens je werk als 
arts is alleen mogelijk met veel hulp en steun. Aan het einde van mijn proefschrift wil ik 
daarom graag een aantal mensen in het bijzonder bedanken in de wetenschap dat God 
het was die mij de kracht en gezondheid gaf om dit werk te voltooien. 
Prof. dr. Felix Zijlstra. Prof. Zijlstra, op de vraag ‘Wilt u mijn promotor zijn?’ hoefde u niet 
lang na te denken. Dank voor het feit dat u mijn promotor wil zijn. De begeleiding en de 
verkregen vrijheid in het onderzoek waardeer ik zeer. 
Dr. Arend F.L. Schinkel. Beste Arend, dankzij Ron en jou heb ik de kans gekregen om 
op een unieke manier wetenschappelijk onderzoek te doen en te promoveren. Jij 
leerde mij artikelen schrijven en interpreteren. Je pasklare antwoorden op mijn (soms 
verbijsterende) vragen hebben mij verrast en waren altijd nuttig. Dank voor je altijd 
snelle beoordeling van de manuscripten, daardoor hield ik de vaart erin. Jouw kunst om 
de wetenschap te vertalen naar de klinische werkvloer is uitmuntend en zal mij altijd 
bijblijven. Het maakte voor jou niet uit als ik je vrijdagavond nog opbelde...!
Dr. Ron T. van Domburg. Beste Ron, je hebt mij de eerste beginselen van ‘onderzoek 
doen’ bijgebracht. Je stimuleerde mij tot zelfontplooiing. Dit proefschrift is dan ook in 
belangrijke mate door jou tot stand gekomen. Dank voor je betrokken en enthousiaste 
begeleiding. Ondanks de vele andere (PhD-) studenten die je begeleid hebt, ben ik niks 
tekort gekomen. Geniet van je welverdiende pensioen!
De leden van de kleine commissie, prof. dr. J.W. Deckers, dr. O. Kamp en prof. dr. E.J.G. 
Sijbrands, dank ik voor de bereidheid om mijn proefschrift te lezen en te beoordelen. 
Dank voor de prettige en leerzame contacten. Prof. dr. Eric Sijbrands, door u ben ik dit 
onderzoek in feite begonnen, dank u wel!
Dr. Roelf Valkema (nucleair geneeskundige) ben ik zeer dankbaar voor de samenwerking. 
Jan-Kees van den Berge, Roy Huurman, Rebecca Korbee, Stefan Roest, Jors van der Sijde 
en Jesse Veenis dank ik voor hun samenwerking wat resulteerde in een aantal mooie 
manuscripten. Veel succes gewenst bij jullie verdere loopbaan. 
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Dank aan alle collega’s uit ‘het hok’ (Ee-218) voor de gezelligheid en jullie interesse 
in mijn onderzoek. Houd de koffietijd erin! Ik wens jullie veel succes met jullie eigen 
onderzoek en/of promotie. Hopelijk zien we elkaar terug als specialist, al zal het dan 
waarschijnlijk in de ‘consultensfeer’ zijn...
Alle collega arts-assistenten interne geneeskunde / cardiologie van het Albert 
Schweitzer ziekenhuis dank ik voor hun interesse in mijn onderzoek.
Lieve pa en ma, ik ben jullie zeer erkentelijk voor alle hulp en steun en jullie stimulerende 
houding tijdens mijn studie geneeskunde, mijn werk als arts, maar ook alles voorafgaand 
aan die periode. Ik hoop dat we binnenkort weer is tijd hebben voor Cruquius. Bedankt!
Mijn schoonouders hebben ook een bijzondere plaats in mijn hart. Ik bewonder het feit 
dat jullie altijd met me meeleven en zelfs mijn onderzoek proberen te doorgronden. 
We delen dezelfde passie: zalm en friet! Ik spreek de wens uit dat wij dat continueren. 
Wellicht Simonis in Charleroi?
Lieve Daniëlle, je was, bent en blijft onmisbaar voor mij. Je hebt mij altijd voor 100% 
gesteund. Ik kreeg van jou de tijd om mijn onderzoek in relatief korte tijd te voltooien. 
Vanaf nu help ik je weer in alle dingen, al gaat het je ook prima alleen af! 
Lieve Loïs, papa’s kleine ‘meissie’, wat ben ik trots op jou! Je plezier in het samen spelen 
is voor mij een stimulans om dat ook te blijven doen. I luf joe. 
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The author of this thesis, Hendrik Johannes Boiten (Henk-Jan), was born on October 
4th 1988 in Schiedam, The Netherlands. Secondary school was the Guido de Brès in 
Rotterdam (part of the Wartburg College), where he graduated in 2007. For one year 
he studied ‘Psychobiology’ at the University of Amsterdam (UvA). He then went on to 
study ‘Medicine’ at the Erasmus University Rotterdam. After receiving his medical de-
gree in the end of 2014 he started as an internal medicine resident (ANIOS) at the Albert 
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